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SYNOPSIS 
Cervical cancer is a chronic inflammatory disease of multifactorial etiology accounting for an 
annual estimated 266,000 deaths worldwide and usually present in sexually active women. In 
sub-Saharan Africa, cervical cancer is the most common cancer among women and the leading 
cause of cancer related deaths in this region. The obvious association of HIV infection and 
cervical cancer has long been established. High incidence and prevalence rate of HIV infection 
has been recorded in many areas with high incidence of cervical cancer suggesting that cervical 
cancer and premalignant cervical lesions may increase transmission and acquisition of HIV 
infection. Seminal plasma (SP) has been shown to initiate inflammatory response within the 
female genital tract. Exposure of neoplastic cervical epithelial cells to SP has been shown to 
promote the growth of cancer cells in vitro and tumors in vivo by activating several pro-
inflammatory pathways. In addition to the regulation of tumor growth, SP-mediated 
inflammatory responses within the female genital tract have been suggested to contribute to the 
transmission of HIV and other sexually transmitted infections (STIs).  
The initial aim of this study was to determine the role of SP in the regulation of pro-
inflammatory pathways in neoplastic cervical epithelial cells. TaqMan 96-well array revealed 
that SP regulates the activation of eicosanoid, toll-like receptor-NFκB, kallikrien-bradykinin-
bradykinin receptor, cytokine, and chemokine signaling pathways to mediate the expression of 
inflammatory mediators in cervical cancer cells. These data highlight the potential of SP to 
exacerbate inflammatory processes within the local cervical cancer microenvironment creating 
conditions favorable for cervical tumor progression. 
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IL-1α is a pleotropic pro-inflammatory cytokine found to be robustly regulated by SP in the 
array. IL-1α expression is up-regulated in several human cancers and has been associated with 
virulent tumor phenotype and poorer prognosis. Hence, I investigated the role of SP in the 
regulation of IL-1α in neoplastic cervical epithelial cells HeLa, neoplastic and normal cervical 
tissue and the molecular mechanism underlying this regulation.  
Quantitative real-time PCR and ELISA confirmed the role of SP in the induction of IL-α 
expression in neoplastic cervical epithelial cells. Using selected receptor antagonists and agonists 
and small molecule chemical inhibitors known to inhibit specific biological pathways, I 
established that SP regulated IL-1α mRNA and protein expression via the activation of 
EP2/EGFR/PI3 kinase-Akt signaling in a HeLa (adenocarcinoma) cell line model system. PGE2 
and EGF were identified as possible ligands responsible for SP-mediated induction of IL-1α in 
these neoplastic cells.  
Furthermore, qRT-PCR confirmed overt expression of IL-1α mRNA in cervical squamous cell 
carcinoma and adenocarcinoma tissue explants, compared with normal cervix. Using 
immunohistochemistry, IL-1α was localized to the neoplastically transformed squamous, 
columnar and glandular epithelium in all cases of squamous cell carcinoma and adenocarcinomas 
explants studied. In addition, SP was found to induce IL-1α expression in normal and cancerous 
cervical tissue explants via similar pathways as obtained in HeLa cells. The SP-mediated 
induction of a pleotropic pro-inflammatory cytokine IL-1α in normal and neoplastic cervical 
epithelial cells suggests that SP may promote cervical inflammation as well as progression of 
cervical cancer in sexually active women. 
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To elucidate the relationship between cervical cancer and HIV, I initially investigated the 
expression of HIV receptor and chemokine co-receptor CD4 and CCR5 in in both normal and 
neoplastic cervical tissues explants by real-time RT-PCR analysis and immunohistochemistry. 
CD4 and CCR5 expression was elevated in cervical cancer tissue compared with normal cervix. 
Ex vivo studies conducted on cervical (normal and neoplastic) tissues and HeLa cells, showed 
that SP significantly increases expression of CD4 and CCR5. Using a panel of chemical 
inhibitors of intracellular signaling and a cyclooxygenase (COX)-1 doxycycline-inducible 
expression system, I found that regulation of CCR5 expression by SP occurred via the epidermal 
growth factor receptor and COX-1-prostaglandin E2 pathway. These data provide a link between 
activation of inflammatory pathways and regulation of HIV receptor expression in cervical 
cancer cells and suggests that repeated exposure of cervical epithelium and neoplastic cervical 
epithelial cells to seminal plasma can impact on HIV susceptibility in women. 
In conclusion, this study reports that repeated exposure of neoplastic cervical epithelium to 
seminal plasma in sexually active women with cervical cancer could exacerbate cervical cancer 
development and result in poorer patient outlook as well as increase susceptibility to HIV 
infection in the cervical cancer milieu. 
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 Introduction 
Cervical cancer; cancer of the cervix uteri is the fourth most common cancer in women and the 
seventh overall, with an estimated 528,000 new cases and 266,000 deaths worldwide in 2012  
[1]. As with liver cancer, a large majority (around 80-85%) of the global burden occurs in the 
less developed regions (Figure 1), where it accounts for almost 12% of all female cancers  [1,2].  
 
Figure 1.1: Cervical cancer estimated incidence and mortality Worldwide in 2012 [2]. 
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In sub-Saharan Africa, cervical cancer is the most common cancer among women, accounting 
for 22.2% of all cancer cases and also the leading cause of cancer related deaths in this region 
[3]. The occurrence of the disease is gradually having a decline trend in the developed countries 
as a result of increased awareness, routine screening and early detection/intervention, while in 
many countries in sub-Saharan Africa incidence rate is on the rise as 60-75% of women affected 
reside in the rural areas [4] where there is poor access to health facilities; malnutrition and co-
morbid conditions e.g. HIV infection [5,6]; poor awareness; late presentation with disease [7]; 
limited facilities for treatment; high rate of loss to follow-up [8]; and failure to complete 
treatment.  
 
1.2 Etiology and risk factors 
The etiology of the disease is multifactorial. However, the single most common risk factor 
attributed to cervical cancer is infection with high risk human papillomavirus (HPV) (type 16 
and 18). HPV DNA is found in 90-99.7% of cervical cancer cases [1] and many of the factors 
that could increase HPV acquisition and promote its oncogenic effect are wide spread in sub-
Saharan Africa. Such factors include; high parity, early marriage, and polygamous marriages 
[9,10]. It has been estimated that the life-time risk of contracting HPV is 80% [11] and 
averagely, it takes about 12-15 years before a persistent HPV infection in the phase of 
premalignant lesion (CIN) leads to cervical cancer [12,13]. Although infection with HPV is 
highly prevalent among sexually active women, only a few of these infected women will develop 
cervical cancer thus suggesting that other co-factors are necessary for the development of 
neoplasia [14]. 
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Other risk factors include low socio-economic status; immunosuppression from co-morbidities 
such as TB, HIV, and herpes simplex virus (type 2) [15]; non-HPV sexually transmitted infection 
(STI) such as; Neisseria gonorrhea [16,17], Chlamydia trachomatis [18,19], and bacterial 
vaginosis [20]. The presence of these STIs in the cervix elicit chronic inflammatory responses 
leading to the release of  free radical and subsequent activation of various inflammatory 
pathways which have been found to play a vital role in disease progression. Similarly, cigarette 
smoking has also been identified as an independent risk factor for the development of cervical 
cancer [21-23] as tobacco-specific carcinogens and polycyclic aromatic hydrocarbons have been 
detected in the cervical epithelium or mucus of smokers [24,25]. These compounds can cause 
malignant transformation by binding and damaging cellular DNA, hence enhancing the effect of 
HPV [1].  
 
1.2.1 HIV; a co-factor in cervical cancer 
In January, 1993, the surveillance case definition of AIDS was expanded to include cervical 
cancer in women infected with human immunodeficiency virus, thus classifying it, Kaposi 
Sarcoma, and Non-Hodgkin Lymphoma as an AIDS-defining disease [26]. This makes HIV an 
important risk factor/co-factor in the development of cervical neoplasia. The role of HIV in the 
development of cervical cancer has been largely attributed to immunosuppression, but recent 
findings suggests a molecular interaction between HIV and HPV playing a vital role in disease 
occurrence and progression [3,27].  
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1.3 Classifications 
Cervical cancer can be classified into three major histological categories as recognized by WHO 
(World health organization) [28] these include; squamous cell carcinoma, adenocarcinoma, and 
other undifferentiated carcinomas.  
 
1.3.1 Squamous cell carcinoma of the cervix 
This is the most common histological type of cervical cancer accounting for approximately 70 - 
80% of all cases [1]. Cervical squamous cell carcinomas have been further classified into; large 
cell keratinizing, large cell non-keratinizing, and small cell carcinomas according to the 
predominant cell type. Large cell non-keratinizing squamous cell carcinomas account for the 
majority of tumors. 
 
1.3.2 Adenocarcinoma of the cervix 
Adenocarcinoma of the cervix represents the second most common histological type accounting 
for approximately 20-25% of tumors [1]. It is derived from the glandular cells of the cervix. Over 
the past decade, there has been an increase in the incidence of adenocarcinoma especially in 
women younger than 35 years of age, attributed to an increase in prevalence of HPV infection 
[29,30]. 
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1.3.3 Other uncommon subtypes: 
1.3.3.1 Verrucous carcinoma of the cervix  
Verrucous carcinoma is a rare subtype of well differentiated squamous cell carcinoma and it has 
been associated with HPV 6. Histological features comprises of well differentiated squamous 
cells with fond-like papillae and minimal stromal invasion. It is a slow growing locally invasive 
tumor [31]. 
 
1.3.3.2 Adenosquamous carcinoma of the cervix  
Adenosquamous carcinoma of the cervix contains an admixture of glandular and malignant 
squamous cells. It accounts for approximately 1-2% of cases [1]. 
 
1.3.3.3 Neuroendocrine (small-cell) carcinoma of the cervix  
Neuroendocrine carcinoma of the cervix is a rare malignancy, representing less than 5% of all 
cases of cervical cancer. It is characterized by frequent and early nodal and distant metastases, 
resulting in a relatively poor prognosis [32].  
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1.3.3.4 Adenoma mallignum of the cervix  
Adenoma mallignum of the cervix is a well differentiated adenocarcinoma that is difficult to 
recognize as malignant condition. It is associated with peutz-jeghers syndrome and account for 
1% of adenocarcinomas [33]. 
 
1.3.3.5 Adenoid cystic carcinoma of the cervix  
Adenoid cystic carcinoma of the cervix is an uncommon variant of adenocarcinoma and occurs 
more commonly in postmenopausal women and multiparous black women in sixth and seventh 
decades of life. However, it is known to develop before age 40 in certain women [34]. 
 
1.3.3.6 Metastatic tumors  
Metastatic tumors within the cervix are uncommon if one excludes endometrial carcinoma, 
which involves the cervix by direct spread. A variety of other neoplasms rarely metastasize to the 
cervix [35]. These include tumor occurring as direct extension from the bladder, and rectum and 
lymphatic or vascular metastasis from distant organs such as ovaries, breast, colon, and kidneys 
[35]. 
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1.4 Clinical presentation 
Abnormal vaginal bleeding is the most common symptom of invasive cancer of the cervix and it 
could present as a blood stained discharge, scant spotting, or frank bleeding [36]. Abnormal 
vaginal discharge is usually purulent, odorous and non-puritic. A positive history of post-coital 
bleeding may occur. Patients can also complain of pelvic pain which is often unilateral and 
radiating to the hip or thigh in advanced cases. Symptoms of systemic illness such as generalized 
weakness, weight loss and anemia can also be present [37]. 
Signs and symptoms of local metastasis may include loss of urine and faeces per-vagina 
indicating fistula formation with the bladder and rectum respectively [1]. 
 
1.5 Diagnosis 
The natural history of cervical cancer as a continuous single disease progressing steadily from 
mild cervical intraepithelial neoplasia (CIN1) to more severe degrees of neoplasia and 
microinvasive lesions (CIN 2 or CIN 3) and finally to invasive carcinoma has been the basis for 
diagnosis [38]. The median age of cervical cancer diagnosis is 47 years [1]. However, disease 
occurrence can begin as early as third decade of life [1] and during pregnancy in predisposed 
women [39]. The primary method for the detection of high-risk HPV is the Papanicolaou-stained 
(Pap) smear [40], which is a screening tool that detects changes in cells of the transformation 
zone of the cervix often caused by HPV. Invasive carcinoma of the cervix may be suspected on 
the analysis of Pap smear or on visualizing a lesion on the cervix. Pap smear reporting 
classification has evolved and been refined over time. The current reporting system is the 
Bethesda System (Table 1) [40,41].  
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Pap smear may in some cases be falsely negative or non-diagnostic, hence any suspected lesion 
on the cervix must be biopsied and examined histologically for neoplastic/dysplastic epithelial 
cells [1]. If biopsy reveals cells suggestive of carcinoma in situ/or micro-invasion, or in the 
setting of a negative colposcopy with significantly abnormal cervical cytology smear cone 
biopsy (conization) should be done to diagnose the presence or absence of invasion. However, 
greater than 90% of early onset diagnosis can be cured. 
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Table 1.1: The Bethesda and CIN Classiﬁcation System for cervical squamous cell dysplasia[40] 
Bethesda System  CIN System Interpretation 
 
Negative for intraepithelial 
lesions or malignancy 
 
Normal 
 
No abnormal cells 
 
ASC 
ASC-US (atypical squamous 
cells of undetermined 
significance) 
  
Squamous cells with 
abnormalities greater than those 
attributed to reactive changes 
but that do not meet the criteria 
for a squamous intraepithelial 
lesion. 
ASC-H (atypical squamous 
cells, cannot exclude HSIL) 
  
 
LSIL (low-grade squamous 
intraepithelial lesion) 
 
CIN 1 
 
Mildly abnormal cells; changes 
are almost always due to HPV 
 
HSIL (high-grade squamous 
intraepithelial lesion) with 
features suspicious for 
invasion (if invasion is 
suspected) 
 
CIN2/3 
 
Moderately to severely 
abnormal squamous cells. 
 
Carcinoma 
 
Invasive squamous cell 
carcinoma 
Invasive glandular cell 
carcinoma (adenocarcinoma) 
 
The possibility of cancer is high 
enough to warrant immediate 
evaluation but does not mean 
that the patient definitely has 
cancer. 
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1.6 Clinical staging 
Once tissue diagnosis of invasive carcinoma has been made, it is important to estimate the extent 
of the disease for both prognostic purposes and treatment planning. The most widely used 
staging system is that of FIGO (International Federation of Gynecology and Obstetrics) staging 
of cervical cancer (Table 2).  Staging is done at the time of primary diagnosis and is determined 
clinically using the size of the cervical tumor and/or its extent of spread to the pelvis [1].   
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Table 1.2: Cervical cancer staging according to FIGO staging system [1]. 
Stage Description 
Stage 0 Carcinoma-in-situ, intraepithelial carcinoma 
Stage I Invasive carcinoma strictly confined to the cervix 
Stage IA Invasive carcinoma identified microscopically 
Stage IA1 Measured invasion of stroma 3 mm or less in 
depth and no wider than 7 mm 
Stage IA2 Measured invasion of stroma more than 3 mm but 
no greater than 5 mm in depth and no wider than 
7 mm 
Stage IB Preclinical lesions greater than stage IA or 
clinical lesion confined to the cervix.  
Stage IB1 Clinical lesions 4 cm or less in size 
Stage IB2 Clinical lesions more than 4 cm in size 
 
Stage II 
 
Carcinoma extending beyond the cervix but not to 
the pelvic sidewall; carcinoma involves vagina 
but not its lower third 
Stage IIA Involvement of upper two-third of the vagina, no 
parametrial involvement 
Stage IIB Obvious parametrial involvement 
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Stage III  
Carcinoma extending onto the pelvic wall; no 
cancer free space between the tumor and pelvic 
sidewall (on rectal examination). Involvement of 
the lower third of the vagina. 
Stage IIIA Involvement of lower third of the vagina; no 
extension to pelvic sidewall  
Stage IIIB Extension to pelvic sidewall and/or 
hydronephrosis or nonfunctioning kidney 
Stage IV  
Carcinoma extends beyond true pelvis or 
clinically involves mucosa of bladder or rectum.  
Stage IVA Spread of tumor to adjacent organs 
Stage IVB Spread of tumor to distant organs 
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1.7 Molecular Pathogenesis 
1.7.1 Papillomaviruses 
The papillomaviruses belong to the family Papovaviridae. A mature virion is about 52-55 nm in 
diameter with a supercoiled circular double stranded DNA (8kb in length) enclosed by an 
icosahedral structure composed of 72 capsomers [42,43]. All the reading frames are on one 
strand of the DNA. The virus infects squamous epithelia (or cells with potential for squamous 
maturation) [43], inducing chronic infections that have no obvious systemic sequellae and rarely 
cause mortality in the infected host, but periodically shed large amounts of infectious virus that 
can be transmitted to naïve individuals [44].  Infection can also give rise to the induction of 
proliferative lesions e.g. skin warts and occasionally neoplasia [43]. They are exclusively species 
specific hence they could be grouped/classified using the host specie i.e. human papilloma virus 
(HPV) infecting only human. Papillomaviruses are also tissue-tropic having tendency to infect 
cutaneous and /or internal squamous mucosal surfaces in their host [43]. 
Papillomaviruses are classified by the host species infected and the degree of DNA sequence 
homology (genotype) within specific viral genes. To date, about 200 HPV types have been 
identified and cloned based on sequencing gene encoding the capsid protein L1 [40,45], of these 
types 16, 18, 31, 35, 39, 45, 51, 52, 56, 58, 66, and 70 have been implicated in most cases of 
cervical cancer [1,40] (Table 3). Furthermore, based on their oncogenic potential and frequency 
of occurrence in neoplastic lesions, they have been classified into; low risk types such as HPV 
6b, 11, 40, 42, 43, and 44 associated with low grade lesions such as cervical intraepithelial 
neoplasia 1 (CIN 1) and cervical condylomas; intermediate (or high in some literatures) risk 
types such as HPV 33, 31, 35, 45, 51, 52, 56, 58, and 59 found infrequently in all grades of CIN 
[46-48]; high risk types HPV 16 and 18 found in 90% of cervical cancer and about 50-80% of 
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CIN 2 and CIN 3 [49-51] (Table 3). HPV 16 is the most prevalent type in squamous cell 
carcinoma while type 18 the most prevalent in adenocarcinoma. The mere presence of HPVs 
alone doesn’t confer neoplasia as the virus can be found in about 3-30% of asymptomatic 
patients [50], thus indicating that other events such as viral persistence and/or altered viral gene 
expression are required to initiate neoplastic process.  
HPV types have different effects on the transition from CIN to cancer and the approximate 
measure of the risk of transition from intraepithelial neoplasia to invasive cancer can be 
calculated using the cancer:CIN prevalence ratio [42].  Studies have shown that HPV 18 is 
associated with a higher cancer:CIN ratio than HPV 16, suggesting that it confers a more 
aggressive neoplastic phenotype than type 16 [52,53].  
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Table 1.3: HPV types and disease association [54,55] 
Disease HPV type 
Plantar warts  1, 2, 4, 63 
Common warts  2, 1, 7, 4, 26, 27, 29, 41, 57, 65, 77, 1, 3, 4, 10, 28 
Flat warts  3, 10, 26, 27, 28, 38, 41, 49, 75, 76 
Other cutaneous lesions (e.g., epidermoid 
cysts, laryngeal carcinoma)  
6, 11, 16, 30, 33, 36, 37, 38, 41, 48, 60, 72, 73 
Epidermodysplasia verruciformis  2, 3, 10, 5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 
24, 25, 36, 37, 38, 47, 50 
Recurrent respiratory papillomatosis  6, 11 
Focal epithelial hyperplasia of Heck  13, 32 
Conjunctival papillomas/carcinomas  6, 11, 16 
Condyloma acuminata (genital warts)  6, 11, 30, 42, 43, 45, 51, 54, 55, 70 
 
Cervical intraepithelial neoplasia 
 
Unspeciﬁed  30, 34, 39, 40, 53, 57, 59, 61, 62, 64, 66, 67, 68, 
69 
Low risk  6, 11, 16, 18, 31, 33, 35, 42, 43, 44, 45, 51, 52, 74 
High risk  16, 18, 6, 11, 31, 34, 33, 35, 39, 42, 44, 45, 51, 
52, 56, 58, 66 
Cervical carcinoma  16, 18, 31, 45, 33, 35, 39, 51, 52, 56, 58, 66, 68, 
70 
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1.7.2 Transmission and immune evasion 
 HPV infectious cycle begins when the cervical epithelium is exposed to virus present in the 
saliva, seminal fluid or skin of infected partner during coitus. The virus enters the body through 
mild abrasion or micro-trauma to the cervico-vaginal epithelium by  first binding to the heparin 
sulfate proteoglycans (HSPGs) on the basal membrane exposed after tissue disruption/abrasion 
[56] and proceed to infect primitive basal keratinocytes (Figure 2) [57], with high level 
expression of viral proteins and viral assembling confined to the upper layers of the stratum 
spinosum and granulosum of the epithelia [58] (Figure 2).  
Post transmission the virus remains confined to the epithelia mucosa where it does not come in 
contact with the bloodstream hence evading the innate immune system. The ability of the virus to 
evade immune detection and immune-invasion has been considered to play a vital role in viral 
persistence [43]. For the most part of its infectious cycle, there is no local release of pro-
inflammatory cytokines that are important for dendritic cell (DC) activation and migration, and 
the essential signals required to activate immune response is also absent in the infected epithelia. 
Even though there is no viraemia, viral-induced cytolysis, or cell death, infected keratinocytes 
are expected to activate the antiviral defense system, the type 1 interferons (IFNs). The type 1 
INFs (IFNα and IFNβ) possess anti-proliferative, anti-angiogenic, antiviral and immune-
stimulatory properties acting as a bridge between innate and adaptive immunity activating 
immature DCs [59]. The virus is capable of actively inducing mechanism that de-regulate the 
interferon pathway via down regulation of pattern recognition receptors such as Toll-like 
receptor 9 (TLR-9), hence enabling infection to proceed undetected [43]. Since these receptors 
augment innate and adaptive responses to pathogens by activating the antigen presenting cells 
and phagocytes [60,61].  
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Similarly, the high risk HPV (16 and 18) viral oncoprotein E6 and E7 also directly interact with 
components of the IFN signaling pathway [62]. Type 16 E7 inhibit IFNα-mediated signal 
transduction by binding to IFN regulatory factor (P48/IRF-9), this prevents translocation to the 
nucleus, thus inhibiting the formation of the IFN-stimulated gene factor 3 (ISGF-3) transcription 
complex that binds IFN-specific response element (ISRE) in the nucleus [63]. It also impedes 
intermediate IFN-mediated signaling by forming a complex with IRF-1, inhibiting IRF-1 
mediated activation of IFNβ promoter and recruiting histone deacetylase to the promoter, in so 
doing preventing transcription [64]. Type 18 E7 oncoprotein on the other hand reduces the 
expression of IRF-1 target gene e.g. monocyte chemotactic protein 1 (MCP-1), transporter 
associated with antigen processing 1 (TAP1) and IFNβ by inhibiting the transactivation of IRF-1 
[65]. E6 can bind to IRF-3, inhibiting its transactivating function, thereby preventing IFNα 
mRNA transcription [66], it can also inhibit phosphorylation of Tyk2, STAT (signal transducer 
and activator of transcription) 1 and 2, impairing JAK (Janus kinase)/STAT activation, and 
therefore inhibiting specific IFNα-mediated signal transduction  [67].  
In addition, studies have shown that HPV type 16 generally alters the expression of three groups 
of gene which are; cell-cycle signaling genes, IFN-response genes and NF-κB (nuclear factor 
kappa B) - stimulated genes [68-70]. It is therefore evident that the viral oncoprotein E6 and E7 
play a fundamental role in host resistance to infection and immune function by direct alteration 
of various genes and pathway complexes required for immune detection and invasion. 
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Figure 1.2: Schematic presentation of the infectious cycle of HPV showing strong E6 and E7 expression 
in differentiated epithelial cells. Infectious cycle begins when the virus present in the saliva, seminal fluid 
or skin of infected partner during coitus. The virus enters the body through mild abrasion or microtauma 
to the cervico-vaginal epithelium and proceeds to infect primitive basal keratinocytes, targeting stem 
cells. Daughter cells of epithelial stem cells divide along the basement membrane and then mature 
vertically through the epithelium without further division (right side). After the introduction of HPV into 
the stem cells in the basal layer of the epithelium, expression of viral non-structural proteins occurs. 
Under the regulation of these proteins, the dividing-cell population expands vertically and epithelial cell 
differentiation is delayed and is less complete. Viral proteins are expressed sequentially with 
differentiation, as shown and mature virions are produced only in the most superficial layers of the 
epithelium. Intraepithelial antigen-presenting cells (APCs) are depleted in the HPV-infected epithelium 
[57]. 
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1.7.3 Genome Integration and Oncogene expression 
Within the primitive basal cells, the viral oncogenes are incorporated into the host’s DNA, where 
they utilize the host’s DNA replication machinery to bring about viral DNA replication. This 
round of DNA replication process is independent of the cell cycle and help to amplify the viral 
copy to about 50-100copies/cell [43]. This is then followed by a phase of plasmid maintenance 
during which there is minimal viral gene expression. At this stage the, expression of the viral 
oncogene (especially E6 and E7) is also under strict control with their transcript barely detectable 
[43].    
However, as the infected cells mature and enter the differentiation stage, there is massive rapid 
viral DNA replication with associated up-regulation of viral gene expression. This brings the 
number of viral copy to about 1000 copies/cell with abundant expression of the early genes (E6 
and E7) and expression of the late genes from the late promoter [71]. As these cells mature they 
migrate vertically towards the epidermal layer. On getting to the superficial epidermal layers, 
they then undergo programmed cell death (apoptosis) which results in the release of viral 
particles. The whole replication cycle is said to take about 3weeks which coincide with the time 
taken by keratinocyte to mature, differentiate and desquamate [43]. There exist no blood-borne 
phase of infection as infectivity is completely intra-epithelial, however, some of the replicating 
virus may be exposed to the immune system [43]. On detection, the immune (innate and 
adaptive) systems initiate inflammatory responses against the virus, thus eradicating it in 
majority of infected cases [20,72]. However, in about 15-20% of cases this inflammatory 
response fails to clear the virus [73,74], hence leading to persistent infection, which together 
with inadequate resolution or exacerbation of activation of inflammatory pathways can promote 
malignant progression [43,75]. 
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1.7.4 HPV oncogenes and cervical tumorigenesis 
The viral genome is made up of 3 domains; a non-coding upstream regulatory region (URR) of 
about 1kb, an early region containing open reading frames (ORFs) E6, E7, E1, E2, E4,  and E5 
and a late region encoding the major and minor caspid proteins (L1 and L2) (Figure 3) [43]. 
Once infection ensue, the E6 and E7 early genes are actively transcribed to express the E6 and 
E7 oncoproteins, both of which are highly implicated in neoplastic transformation [71]. Although 
E6 and E7 oncogenes appears to be the major HPV oncogenes involved in neoplastic change, 
recent studies have demonstrated a role for the E5 oncogene in tumorigenesis and immune cell 
modulation [76] and regulation of late viral functions together with E4 oncogene. E1 and E2 
oncogenes encode replication factors and are thought to play a role in HPV resistance by 
allowing episomal copies of the virus to be maintained in the nucleus and partitioned into 
daughter cells during mitosis [77]. Many of the observations of the roles of HPV oncogenes have 
been derived using in vitro model systems of HPV-containing cell lines where specific 
oncogenes have been ablated by RNA interference, or HPV negative cells that have been 
transfected with cDNA constructs containing specific oncogenes. These studies have shown that 
both oncoproteins target different molecular pathways in the cell to promote neoplastic state. E6 
oncoprotein binds to P53  protein and targets it for ubiquitin-dependent degradation, while the 
E7 binds to the family members of the retinoblastoma protein (Rb) and disrupts the complex 
between Rb and the E2F transcription factor family (Table 4) [78].  
These effects on P53 and Rb tend to cause an alteration in the cell cycle as both proteins are 
negative growth regulators that control transit from G0/G1 to S phase [42].  
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Similarly, P53 is also involved in DNA response to damage, by inducing either growth arrest or 
cell death by apoptosis. Hence, HPV mediated loss of Rb and P53 function facilitates 
immortalization of the cells and triggers the early steps in malignant transformation by disrupting 
cell cycle control [43,78]. Resulting into uncontrolled replication and a build-up of damaged 
DNA - ideal conditions for cancer development. 
Animal studies using transgenic mouse models of cervical cancer have highlighted more 
specifically the contribution of individual oncogenes to tumorigenesis and have shown that the 
E7 proteins induces high-grade cervical  dysplasia and invasive tumors, whereas the E6 proteins 
induces low-grade cervical dysplasia. Furthermore, they have highlighted that both oncogenes 
work in synergy to promote cervical cancer progression, since co-expression of E6 and E7 
proteins produce larger and more extensive tumor compared to E7 alone [79].  
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Figure 1.3: Genome organization of high risk HPV 16 [43].  
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Table 1.4: High risk HPV ORFs and their role in tumorigenesis [43]. 
ORF Role in tumorigenesis 
 
E6 
 
Binds to P53  protein and targets it for ubiquitin-dependent degradation 
 
E7 
 
Binds to the family members of the retinoblastoma protein (Rb) and disrupts the complex 
between Rb and the E2F transcription factor family 
 
E1 
 
ATP binding protein essential for viral DNA replication 
 
E2 
 
Viral transcription factor; binds to E1 to facilitate initiation of vital DNA replication 
important in genome encapsidation.  
 
E5 
 
Possess weak transforming activity, but contributes to up-regulation of growth factor 
receptor 
 
E4 
 
Interacts with cytoskeletal proteins, allows viral assembly. 
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1.8 The role of inflammation and inflammatory pathways in tumorigenesis 
Inflammation is a complex process involving a coordinate effort by the body to maintain 
homeostasis in the face of insult by disease pathogens (e.g. bacterial, viral or fungi) or by injury. 
It involves a host of resident and recruited immune cell types working together to promote the 
removal of the insult or injury and initiate tissue repair [80]. When successful, these results in the 
restoration of tissue homeostasis, a process termed resolution [81-83].  
Rudolf Virchow in 1863 demonstrated the presence of leukocytes in neoplastic tissues and made 
a link between inflammation and cancer (Table 5). Virchow proposed that the origin of cancer at 
sites of chronic inflammation is reflected by the lymphoreticular infiltrate at such site [72]. Over 
the past decades, our knowledge of the inflammatory microenvironment of malignant tissues has 
evolved to support Virchow’s hypothesis. Hence, the alliance between cancer and inflammation 
is beginning to have an impact on mode of treatment and cancer prevention. Approximately 15-
20% of the global cancer burden is attributable to infectious agents [84] and inflammation is an 
essential element of these chronic infections. 
Similarly, chronic inflammatory responses mediated by certain chemicals and autoimmune 
diseases have also been associated with increased risk of neoplastic changes and ultimately 
invasive malignancy [85,86]. 
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Table 1.5: Association between specific cancers and infectious agent/inflammatory stimulus [72] 
Malignancy Infectious agent/inflammatory stimulus 
 
Cancer of the bladder 
 
Schistosomia hematobium (Schistosomiasis) 
 
Bronchial cancer 
 
Silica (silicosis), asbestos (asbestosis), 
cigarette smoke. 
 
Cervical cancer 
 
Papillomavirus (Human papilloma virus) 
 
Colorectal cancer 
 
Inflammatory bowel disease 
 
Esophageal cancer 
 
Barrett’s metaplasia 
 
Gastric cancer 
 
Helicobacter pylori  (gastritis) 
 
Hepatocellular cancer 
 
Hepatitis virus (B and C) 
 
Kaposi’s sarcoma 
 
Human herpes virus type 8 
 
MALT lymphoma 
 
Helicobacter pylori 
 
Mesothelioma 
 
Asbestos 
 
Ovarian cancer 
 
Pelvic inflammatory disease, talc, tissue 
remodeling. 
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1.8.1 Inflammatory cell component of tumors  
The inflammatory microenvironment of tumors (including cancer of the cervix) is characterized 
by the presence of vast population of different host immune cells in the stroma and tumor areas 
at any given time – each capable of synthesizing cytokines or other factors which can alter the 
fate of the immune populations within the tumor. Leukocytes are recruited into the tissue in 
response to cytokines and chemokines released by tumor cells and are resident both in the stroma 
and in the tumor itself [87].  
 
1.8.1.1 Polymorphonuclear leukocytes (PMN’s or neutrophils) 
Polymorphonuclear leukocytes (PMN’s or neutrophils) are the first immune cell types to be 
recruited to sites of inflammation, followed by monocytes which are derived from haemopoietic 
progenitor cells [88]. When in the tissue, monocytes then differentiate into either macrophages or 
dendritic cells (called Langerhans cells in the epidermis). Langerhans cells generally constitute 
the first defense against pathogens. Recently tumor associated neutrophils have been described 
that are capable of polarizing the phenotype of other immune cells and altering the cellular 
composition of the tumor microenvironment [89]. Here PMN’s are thought to exist in either an 
N1state, capable of killing tumor cells by producing and releasing cytotoxic compounds, or an 
N2 state capable of promoting tumor growth by modulating the cytokine/chemokine 
environment in the tumor [89].  
 
1.8.1.2 Macrophages 
A significant proportion of the immune infiltrate in tumors is comprised of tumor-associated 
macrophages (TAMs). These are derived from circulating monocyte precursors via the release of 
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monocyte chemotactic protein (MCP) chemokines [75]. Although TAMs are a heterogeneous 
cell population, early stage tumors generally have type 1 macrophages (M1). These produce pro-
inflammatory cytokines and chemokines, such as CXCL10 and CXCL19 to recruit Th1, Th17 
and natural killer (NK) cells [90]. In more advanced tumors, TAMs polarize towards a type 2 
(M2) state to encourage Th2 differentiation and the production of potent angiogenic factors such 
as VEGF to facilitate tissue remodeling  which is thought to promote tumorigenesis [91].  
 
1.8.1.3 Dendritic cells (DC) 
DCs play a crucial role in the activation of antigenic-specific immunity and the maintenance of 
tolerance, thus helping to provide a link between innate and adaptive immune systems. However, 
tumor-associated dendritic cells (TADCs) typically have an immature phenotype with defective 
ability to stimulate T cells [92], making them poor inducers of effective response to tumor 
antigens.   
 
1.8.1.4 Lymphocytes 
Natural killer cells (NK) are quite rare to find in the tumor microenvironment [87]. The 
predominant T-cell populations possess a “memory” phenotype. In cervical cancer these cells 
have been discovered to produce interleukins (IL) 4 and 5 [93] which are associated with the T-
helper type 2 (Th2) cells. Polarized Th2 responses are generally ineffective against tumors and 
viruses. Similarly, T-cell receptor signaling has also been found to be defective in tumor-
infiltrating T cells (TIL) [94]. 
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1.9 Pro-inflammatory cytokines 
The cytokine and chemoattractive cytokine (chemokine) networks vary in many tumor tissues, 
compared with normal tissue [95,96]. It has been discovered that the cytokine complex of many 
tumors is loaded with pro-inflammatory cytokines, chemokines and growth factors but 
commonly lacks specific cytokines required for immune sustaining responses [95]. These 
inflammatory cytokines and chemokines that can be produced by the neoplastic cells themselves 
and/or tumor-associated leukocytes, and platelets have been found to contribute immensely to 
tumorigenesis and malignant progression. The high level of hypoxia found in the tumor cells 
have been discovered to be responsible for the induction of many of these cytokines and 
chemokines [97]. A good example of some of the most important cytokine found in tumor 
microenvironment are; tumor necrosis factor (TNF), interleukin 1 (IL-1), interleukin 6 (IL-6) and 
chemokines.  
 
1.9.1 Tumor necrosis factor (TNF) 
Tumor necrosis factor (TNF) is a major cytokine involved in inflammation and tissue 
remodeling. It stimulates fibroblast growth and angiogenesis as well as the production of MCP-1 
(monocyte chemotactic protein 1), which  regulates the infiltration of macrophages and 
lymphocytes [75]. It has been found to play an essential role in several cancer models, and a 
critical mediator of inflammation in autoimmune disease in both humans and mice, acting 
primarily via the induction of NF-κB [98,99]. Similarly, the direct evidence to demonstrate the 
role of TNF in malignancy comes from the observation that mice lacking the TNF gene do not 
develop skin carcinogenesis [100]. 
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1.9.2 Interleukin 1 (IL-1)  
IL-1 represent a term used for two polypeptides (IL-1α and IL-1β) that possess a wide range of 
inflammatory properties [101]. It has been found to stimulate tumor growth, development and 
metastases. IL-1 also plays a role in leukocyte adherence to the vascular endothelium to promote 
extravasation of the vasculature and tumor infiltration [75]. In addition, IL-1 can activate NF-κB 
in a manner similar to TNF [102]. 
 
1.9.3 Interleukin 6 (IL-6) 
IL-6 is a key cytokine that promotes cancer cell proliferation while also inhibiting their apoptosis 
via the activation of signal transducer and activator of transcription 3 (STAT 3) [103,104]. IL-6 
acts as an angiogenic factor and has also been implicated in the same processes as TNF [102]. 
Additionally, IL-6 promotes the activation of the coagulation cascade, differentiation of B cells 
and T cell activation [105].  
 
1.9.4 Chemokines  
 Inflammatory cytokines are also major inducers of chemokines in many resident and recruited 
cell types. Chemokines represent a group of small chemotactic protein (approximately 8-11 kDa 
in size) [106], which are grouped on the basis of the arrangement of the two N-terminal cysteine 
residues and are designated as CXC, CC, C, and CX3C depending on whether the first two 
cysteine residues have one or more amino acid between them (CX..C) or are adjacent to one 
another (CC) [106]. The CXC and CC families are the most numerous of all known chemokines. 
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They interact with cell-surface G protein coupled receptors [106] and to date, of the 50 
chemokines discovered only about 18 chemokine receptors have been described [107].  
Chemokines are renowned for their ability to stimulate directional movement of virtually all 
classes of leukocytes and in addition stimulate the affinity of integrins on leukocytes for 
endothelial receptors such as intracellular adhesion molecule 1 and 2 and vascular adhesion 
molecule -1 (VCAM-1) to facilitate diapedesis into the inflamed/cancerous tissue [108]. CXC 
chemokines are generally active on neutrophils and lymphocytes, whereas CC chemokines act on 
monocytes, dendritic cells, lymphocytes and natural killer (NK) cells, but not neutrophils [72]. 
Similarly, the receptors for these chemokines can be found mainly on the infiltrating leukocytes 
and the tumor cells [72]. 
 
2.1 Molecular role of inflammatory cytokines/chemokines in tumorigenesis 
Inflammatory cytokines and chemokines augment tumorigenesis by influencing growth and 
development, proliferation, mutation, and movement of both the neoplastic and stroma cells [72] 
via a variety of complex molecular mechanism such as: induction of angiogenesis, DNA 
damage, acting as growth factors, and enhancing cell metastasis. 
 
2.1.1 Induction of angiogenesis 
Prolonged and excessive pathological angiogenesis is an important feature of cancer and 
inflammatory diseases that may predispose to cancer [72,109]. Once established tumor cells may 
acquire further characteristic which stimulate new vessel formation and it has been established 
that various signals such as; metabolic stress (e.g. low pH, hypoxia, and hypoglycaemia), 
mechanical stress (e.g. pressure from proliferating cells), genetic mutations (e.g. deletion of 
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tumor-suppressor gene controlling production of angiogenic regulators), and 
immune/inflammatory response [110,111] can trigger neovascularization. Tumor vessels 
development involves various mechanism including; sprouting or intussusceptions from pre-
existing vessels, mobilization of endothelial precursors from the bone marrow [112,113], and by 
growth of tumor cells around existing vessels to form perivascular cuff [114]. It is known that 
there are various molecular players involved in these different mechanisms, and among these are 
vascular endothelial growth factor (VEGF) and angiopoietin (Ang) [114].  
Infiltrating immune cells (such as monocytes, macrophages, mast cells and platelets) secrete an 
array of angiogenic factors such as VEGF, TGF-β1, bFGF, Ang 1, insulin like growth factor 1 
(IGF-1) etc. some of which contribute to tumor angiogenesis [115,116]. Cytokines (e.g. TNF, IL-
1, and IL-6) can stimulate the production of angiogenic factors such as VEGF. Chemokines also 
augment angiogenesis in tumor microenvironment. The N terminus of some CXC chemokines 
contains three amino acid residues [Glu-Leu-Arg (ELR motif)] preceding the first cysteine amino 
acid residue of the primary structure of these cytokines [117,118]. Chemokines containing the 
ELR motif (ELR+) are angiogenic factors and members of this angiogenic CXC chemokines 
include, CXCL1, CXCL 2, CXCL 3, CXCL 5, CXCL 6, CXCL 7 and CXCL 8 [117]. These 
chemokines act directly as chemotactic factor to endothelial cells and can also stimulate 
angiogenesis in vivo [117,119]. Furthermore, CXCL 12 an ELR- CXC chemokine has also been 
discovered to promote angiogenesis by increasing the expression of VEGF.  
 
2.1.2 Acting as growth factors 
Cytokines and chemokines found in tumor microenvironment do not only attract infiltrating cells 
into tumor site but also have the potential to stimulate tumor cell growth, proliferation and 
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survival by acting as autocrine growth factors for neoplastic cells. The best described 
chemokines in this group are the growth-related (GRO) family chemokines (e.g. CXCL 1, CXCL 
2, and CXCL 3) and CXCL 8 [120-122]. Similarly, cytokines (IL-1 and IL-6) have also been 
found to act as growth factors for various tumors such as hematological and gastric malignancies 
[123,124].  
 
2.1.3 DNA damage 
DNA damage is a hallmark of cancers. Inflammatory cytokines (e.g. TNF) induces nitric oxide 
synthase (NO synthase) to produce reactive oxygen in the form of nitric oxide (NO) [125]. This 
NO can then directly oxidise DNA to cause mutagenic changes and damage to some DNA repair 
proteins [125]. Cytokines may also disrupt genome integrity by inhibiting cytochrome p450 or 
glutathione S-transferase isoenzymes [72]. 
Furthermore, inflammatory cytokines can induce DNA damage by causing functional 
inactivation of the tumor-suppressor protein p53.  
 
2.1.4 Enhancing cell metastasis and invasion 
Inflammatory cytokines and chemokines influence various stages in the process of metastasis. 
Cytokines and CC chemokines promote tumor cell invasion and metastasis by inducing the 
production of proteases which are required for cell metastasis [72]. IL-1 and TNF have been 
shown to augment the expression of adhesion molecules on endothelial cell [86,126]. Recent 
findings have suggested that the chemokine receptor CCR7 and ligand CCL21 involved in the 
emigration of activated DC to lymph nodes are likely involved in nodal metastasis [106]. 
Similarly, activation of the chemokine receptor CXCR4 by its ligands CXCL12 enhances 
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metastatic properties by rapidly increasing the affinity of the β1 integrin on B16 cells for 
VCAM-1 [127]. Furthermore, the chemokine complex CXCR4/CXCL12 activates several 
migratory, proliferative, and survival signaling pathways, including the mitogen-activated 
protein kinase pathway, phosphatidylinositol-3 kinase (PI-3K)-Akt pathway and possibly certain 
Janus tyrosine kinases 2 and 3 [128].  
 
3.1 Inflammatory pathways 
3.1.1 Cyclooxygenase-Prostaglandin (COX-PG) pathway 
The inflammatory cyclooxygenase (COX)-prostaglandin (PG) axis is a central pathway 
regulating inflammation and cancer [129,130]. There are two COX enzyme isoforms in humans, 
namely COX-1 and COX-2 [131]. COX-1 is found to be constitutively expressed in health in a 
wide range of cells and tissues where it mediate various physiological functions [132], while 
COX-2 is normally absent in healthy tissues but is rapidly induced in response to inflammatory 
cytokines, oncogenes, hormones and tumor promoters [133]. However, studies have shown that 
both COX enzymes and/or their products may function in promoting and maintaining neoplastic 
conditions [28]. Initially thought to be induced by HPV E6 and E7 oncogenes, following 
infection by high risk HPV [134], the mechanisms by which COX enzymes promote cervical 
tumorigenesis are complex. The enzymes act via a cell-autonomous pattern to promote 
conversion of premalignant cells to malignancy. COX enzymes can augment malignant cell 
progression by inducing genome instability via reactive oxygen (ROS) and lipid peroxidase 
induced DNA mutations [129]. Furthermore, COX enzymes have also been shown to initiate 
oncogenic signaling networks and transcription factors leading to deregulation of oncoproteins or 
tumor suppressor genes [135,136]. 
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 COX enzymes catalyze the enzymatic conversion of arachidonic acid (AA) after its release from 
the membrane glycerophospholipids by the enzymes phospholipase A2 (PLA2) to PGG2, which is 
subsequently reduced to an unstable endoperoxide intermediate prostaglandin H2 (PGH2) (Figure 
4). PGH2 is then metabolized by specific PG synthases to produce five structurally related 
bioactive lipid molecules including PGE2, PGI2, PGD2, PGF2α and TxA2 [137-139] (Figure 4). 
COX derived PGE2 is the major prostaglandin produced in most human solid tumors including 
cancer of the cervix [28] and recent findings have indicated that COX derived PGE2 and its 
signaling pathways is a key mediator of inflammatory responses, tumor growth and metastasis 
[28,140]. Similarly, PGF2α have also been discovered to play a vital role in tumorigenesis. Sales 
et al. (2008) revealed that PGF2α acting through its receptor (FP receptor) promotes adhesion and 
migration of endometrial cancer cells while TxA2 has been reported to promote angiogenesis 
[141,142]. 
    
 
 
 
 
 
 
 
Figure 1.4: Diagram showing overview of prostaglandins (PG) synthesis. COX-1 and COX-2 
both catalyzes the oxygenation and reduction of arachidonic acid (AA) after its release from 
glycerophospholipids to the intermediate form prostaglandin H2 (PGH2) which is then converted 
by prostaglandin or thromboxane synthase (PG or Tx synthase) to respective PG metabolites 
[140]. 
 
Arachidonic 
PGH2 
PGI2 PGD2 PGE2 TXA2 PGF2α 
COX-1 COX-2 
PG or Tx synthase 
 35 
 
3.1.1.1 PGE2 regulation 
Cellular level of PGE2 is relatively dependent on the COX/PGE synthase biosynthesis and 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) degradation [140]. The two cytosolic 
(GSTM2-2 and GSTM3-3) and microsomal (mPGES1 and mPGES2) PGE2 synthases can also 
catalyze the conversion of PGH2 to PGE2 [143-145]. The prostaglandin degrading enzyme 15-
PGDH catalyzes the oxidation of the 15 (S)-hydroxyl group of PGE2 converting it to a 
biologically inactive 15-keto PGE2 form [146]. Hence the loss of 15-PGDH expression is 
suggested to contribute to tumor progression [140]. 
 
3.1.1.2 PGE2 receptors 
PGE2 initiate its tumorigenic effects by binding to its cognate receptors. Four major subtypes of 
PGE2 receptors have been described and identified (EP1, EP2, EP3, EP4) [147]. These receptors 
are G-protein-coupled seven-transmembrane-domain receptors which belong to the rhodopsin 
superfamily of serpentine receptors [148]. EP1 receptor couples to Gq to stimulate phospholipase 
C activation, calcium mobilization, and subsequent protein kinase C activation [149]. EP2 and 
EP4 subtypes couples to Gs which in turn activates adenylcyclase, thus stimulating intracellular 
cAMP production [149], while EP3 receptor couples to Gi which lowers intracellular cAMP via 
the inhibition of adenylcyclase [149]. However, there are splice variants of EP3 that can couple 
to Gq, Gs or G12 [149].  
The biological role of PGE2 and its cognate receptor mediated signaling in tumorigenesis has 
been further substantiated by studies showing the impairment of tumor growth, angiogenesis, 
invasion, and metastasis in EP receptor knockout animals [150-152].  
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3.1.1.3 PGE2-EP signaling and cancer progression 
Profound evidence has shown that PGE2 promotes tumor progression by stimulating EP receptor 
signaling. This subsequently enhances cellular growth and proliferation, angiogenesis, invasion 
and metastasis, and suppression of immune response [140].  
 
3.1.1.3.1 PGE2-EP signaling in tumor growth/proliferation 
PGE2 mediates tumor growth/proliferation by a complex circuit of signaling pathways that are 
found to be cell-type and cell content-dependent [129]. Activation of the EP2 and EP4 receptors 
subsequently leads to the downstream activation of Ras/Raf-1/ERK pathway which play an 
important regulatory role in the proliferative response of several tumor cells to PGE2 [153-155]. 
Binding of PGE2 to EP2 transactivates epidermal growth factor receptor (EGFR) resulting in 
ERK activation and subsequent stimulation of cellular growth [156]. In addition, PGE2 has been 
found to also activate ERK via EP1-dependent activation of protein kinase C (PKC) [157]. 
 
3.1.1.3.2 PGE2-EP signaling in tumor angiogenesis 
Studies have shown that COX enzymes significantly influence tumor angiogenesis by inducing 
the release of VEGF and PGE2 [158,159]. PGE2 can stimulate angiogenesis directly by 
influencing endothelial cell response or indirectly by the induction of growth factor release 
[160,161]. Binding of PGE2 to endothelial EP2 and EP4 receptors leads to the activation of NF-
κB and AKT while its interaction with tumor cell surface EP2/EP4 receptors induces the 
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production of VEGF and plasminogen activator receptor (uPAR); both signaling events leading 
to tumor  angiogenesis [162]. 
 
3.1.1.3.3 PGE2-EP signaling in tumor invasion/metastasis 
The AKT/PI3-kinase pathways have been discovered to play a central role in the transmission of 
PGE2 pro-migratory signal to neoplastic cells [129].  PGE2-AKT activation transactivates EGFR 
in a manner dependent on p60src [163]. In addition to its metastatic properties, PGE2 signaling 
also augments tumor cell invasion by inducing extracellular matrix degradation, adhesion of 
tumor cells to extracellular matrix, and adhesion of cells to the vascular bed. These events are 
mediated by EP4 receptor ligation leading to the up-regulation of CD44 expression and increased 
metalloprotease -2 (MMP-2) activity [157,164-166]. 
 
3.1.1.3.4 PGE2-EP signaling in tumor immune suppression 
PGE2 mediates its immunosuppressive effects via various mechanisms such as suppression of T 
cell function, stimulation of T regulatory cell function, inhibition of dendritic cell activation, and 
polarization of activated macrophages [167-169]. PGE2 has been shown to down-regulate Th1 
cytokines such as TNFα, IFNγ, and IL-2 [170] and up-regulate Th2 cytokines such as IL-4, IL-6, 
and IL-10 (immunosuppressive cytokines) [171,172]. Furthermore, recent findings have also 
shown that PGE2-EP2 dependent signaling can stimulate accumulation of myeloid-derived 
suppressor cells in tumor microenvironment [173]. However, the downstream signaling events 
that mediate these PGE2 immunosuppressive effects are poorly understood.  
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3.1.2 Epidermal growth factor receptor (EGFR) pathway 
Several groups of growth factor receptors have been discovered to play a vital role in 
pathogenesis and progression of different carcinoma types and among these is the Epidermal 
growth factor receptor (EGFR) [174,175]. EGFR; a receptor tyrosine kinase (RTK) belongs to 
the ErbB family of receptors [176] that encompasses four related receptors namely; EGFR 
(ErbB1/HER1), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4) [177-179]. These receptors 
possess an extracellular ligand binding domain, a single hydrophobic transmembrane segment 
and an intracellular protein tyrosine kinase containing a regulatory carboxyl terminal segment. 
Activation of the receptor leads to recruitment and phosphorylation of several downstream 
intracellular substrates, hence leading to cellular signaling and other tumor promoting cellular 
activities [176].    
 
3.1.2.1 Receptor activation and signaling 
The ErbB receptor ligands, EGF-related growth factors are a family of small polypeptide ligands 
which are homologous to their specific ErbB receptor. They have been classified in to three 
major groups [179,180] which include; group 1[EGF, transforming growth factor α (TGF-α) and 
amphiregulin (AR)] which bind specifically to EGFR; group 2 [beta cellulin (BTC), heparin-
binding growth factor (HB-EGF) and epiregulin (EPR)] which possess dual specificity by 
binding to both EGFR and ErbB4; group 3 [neuregulins (NRGs)] which is subdivided into NRG-
1 and NRG-2 (binds to ErbB3 and ErbB4) and NRG-3 and NRG-4 (binds to ErbB4 only) [181-
184]. 
However, none of the EGF family peptides have been found to bind to ErbB2. These peptides 
(EGF) can be found freely in the serum where they are being synthesized as inactive membrane 
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anchored precursors that must be cleaved and released by the metalloproteinases to give rise to 
the matured and active form of growth factor [185].  
Upon binding of its cognate ligands to the extracellular domain, EGFR stimulate the formation 
of receptor homo or hetero dimers leading to the activation of the intrinsic receptor tyrosine 
kinase and autophosphorylation of specific tyrosine residues within its cytoplasmic domain 
[176,186]. These phosphotyrosine residues, then serves as a nucleation sites for proteins 
containing Src homology 2 (SH2) and phosphotyrosine binding (PTB) domains, the recruitment 
of which leads to activation of various intracellular signaling pathways [187]. 
 
3.1.2.2 EGFR and cancer progression. 
The roles of EGFR and EGF-family of peptide growth factor-driven signaling in human 
tumorigenesis have long been established [187]. This receptor and its associated ligand-binding 
peptides are often over-expressed in human carcinomas thus giving rise to a more clinically 
aggressive tumor variant [176,187] and several in vivo and in vitro studies have also 
demonstrated that these proteins can initiate cellular transformation [188-190]. Furthermore, the 
role of EGFR in autonomous proliferation of various carcinoma cells have also been formally 
demonstrated and blockade of EGFR significantly inhibits the in vitro and in vivo growth of 
several human derived cancer cell lines of various histological type [180].   
 
3.1.2.2.1 EGFR signaling in tumor proliferation 
One of the major downstream signaling routes for EGFR is via the Ras/Raf/MEK/MAP kinase 
pathway [191]. EGFR activate the Ras/Raf/MEK/MAP kinase via the growth factor receptor 
bound protein-2 (Grb2) or SH2-containing collagen-related proteins (Shc) [192,193]. Ras 
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activation leads to a multistep phosphorylation cascade that causes the activation of MAKs, 
ERK1, and ERK2 [194]. These (ERK1 and ERK2) then regulate the transcription of molecules 
that are linked to cell proliferation, survival and transformation [194]. 
 
3.1.2.2.2 EGFR signaling in tumor invasion/motility 
Another important downstream signaling target for EGFR is the PI3K/AKT pathway [195,196]. 
AKT phosphorylation tranduces signals that activate a cascade of responses which include cell 
growth and proliferation, survival and motility [195]. Furthermore, EGFR can also signal via the 
stress-activated protein kinase pathway, involving protein kinase C (PKC) and JAK/STAT. 
Activation of these pathways translate in the nucleus to initiate cellular responses such as cell 
division, motility, invasion, adhesion, and cellular repair [179]. 
 
3.1.3 Phosphatidylinositol 3 kinase-AKT (PI3K-AKT) pathway 
The phosphatidylinositol 3 kinases (PI3Ks) belongs to a family of lipid kinase that is 
distinguished by their ability to phoshorylate the inositol ring 3’-OH group of membrane inositol 
phospholipids to generate the second messenger phosphatidylinositol-3,4,5-trisphosphate (PI-
3,4,5-P3) [197]. They have been grouped into three classical subfamilies according to their 
structure and substrate specificity [198] and these include:  
 
3.1.3.1 Class I kinases  
Members of class I are activated by cell surface receptors and have been divided into two 
subclasses (Ia and Ib) based on their mechanism of activation and associated adaptors [197,199]. 
The primary lipid generated in vivo by the members of class I kinases is phosphatidylinositol 
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(PtdIns)-3,4,5-trisphosphate (PI-3,4,5-P3) and phosphatidylinositol-3,4-bisphosphate (PI-3,4-P2), 
using phosphatidylinositol-4,5-bisphospahte (PI-4,5-P2) as a substrate [200,201]. Class Ia PI3Ks 
consist of heterodimers of a p110 catalytic and a p85 regulatory/adaptor subunits [198,202] and 
they are activated by receptors with protein tyrosine kinase activity (RTK) while the class Ib are 
made up of heterodimers of a p110γ catalytic and p101 regulatory subunits and are activated by 
G-protein coupled receptors. The class I kinases (especially class Ia) are the most extensively 
investigated class of all the PI3Ks. 
 
3.1.3.2 Class II Kinases  
This class is made up of three distinct isoforms that are ubiquitously expressed. They are 
characterized into PIK3C2α, PIK3C2β, and PIK3C2γ (liver specific) on the basis of the presence 
of a C2 domain on the extreme C-terminus [203]. They are devoid of adaptor/regulatory subunits 
and use PtdIns(4)P and PtdIns as their principal substrates. In contrast to the class I which in the 
resting state are cytoplasmic, the class II PI3Ks are predominantly membrane-bound  [199] 
where they play a suggestive role in membrane trafficking and receptor internalization [198]. 
Members of this class can also be activated by RTKs, integrins and cytokine receptors however, 
their effector response to these activators are poorly understood [204].  
 
3.1.3.3 Class III kinases  
Members of this class are heterodimeric enzymes with catalytic (Vps34) and regulatory (p150) 
subunits. They utilize PtdIns as their primary substrate and are implicated in the regulation of 
mammalian target of rapamycin (mTOR) activity, protein trafficking through the lysosomes, and 
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the regulation of autophagy response to cellular stress, thus indicating their importance in 
controlling cellular growth and survival [198]. 
 
3.1.3.4 Protein kinase B (AKT) 
The downstream signaling of the PI3Ks is mediated most importantly via the serine/threonine 
kinase AKT (protein kinase B or PKB). AKT was initially characterized as the human 
homologue to v-akt (a viral oncogene known to cause a type of leukaemia in mice) from 
transforming retrovirus AKT8 [205,206]. Three isoforms of the human PKB/AKT family have 
been identified, they are named PKBα (AKT 1), PKBβ (AKT 2), and PKBγ (AKT 3) [207]. 
Although these isoforms are products of different genes, they are highly homologous to each 
other at the amino acid level [208,209]. Genes encoding these isoforms are differentially 
distributed in the tissues, with PKBα (AKT 1) and PKBβ (AKT 2) having a wider distribution 
than the PKBγ (AKT 3) isoform. Each isoform is composed of a pleckstrin homology (PH) 
domain (with approximately 100 amino acids at the N-terminal), a central kinase domain 
analogous to those of PKA and PKC [210,211], and a hydrophobic C-terminus containing a 
second regulatory site. The kinase domain and the C-terminus of the PKBα (AKT 1) contain 
threonine (Thr308) and serine (Ser473) residues respectively. The interaction of the PH domain 
with PI-3,4,5-P3 initiate conformational changes resulting in the exposure of these sites (Thr308 
and Ser473) for phosphorylation, an action essential for maximal AKT activation [212].  
The PI3K/AKT pathway is known to play a fundamental role in the regulation of various cellular 
functions such as cell growth, survival and movement [208,213]. However, recent findings have 
shown that this pathway play a major role in tumorigenesis, as well as the tumor’s potential 
response to cancer treatment [197].   
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3.1.3.5 PI3k-AKT Pathway activation and signaling 
Activation of RTKs (e.g. EGFR, VEGFR, interleukin receptors, integrin receptors) by growth 
factors causes the activated receptor to interact with one or two SH2 domains in the 
phosphotyrosine adaptor unit, and localize PI3K to the plasma membrane. Similarly, intracellular 
proteins such as protein kinase C (PKC), SHP1, Rac, Rho, and Src can also activate PI3K in the 
cell [200]. Activated PI3K phosphorylates PI-4,5-P2 to produce PI-3,4,5-P3, and the lipid 
phosphatase PTEN (phosphatase and tensin homolog deleted on chromosome 10) directly 
opposes the activity of PI3K by dephosphorylating PIP3 into PIP2, thus acting as the central 
negative regulator of PI3K [214]. PI-3,4,5-P3 mediates its cellular effect by binding to a subset of 
proteins containing pleckstrin homology (PH), FYVE, Phox (PX), C1, and C2 domains, thus 
activating these downstream targets [203]. Proteins containing PH domains include Tec family 
tyrosine kinase; guanine nucleotide exchange factors (GEF) for Rac; adenosine diphosphate 
(ADP)-ribosylating factor 6 (ARF6); GTPase –activating proteins (GAPs); and AKT (PKB) 
which represent principal mediators for PI3K class Ia-induced signaling [200-202]. 
Association of the PH domain of AKT with PI-3,4,5-P3 leads to its recruitment to the plasma 
membrane where it is been phosphorylated at the kinase domain (Thr 308 in Akt 1) by 
phosphoinositide-dependent kinase 1(PKD 1) [201,215]. Additional phosphorylation by PDK2 at 
the C-terminal domain (Ser 473 in Akt 1) is essential for full activation of AKT [200,216]. Post 
activation, AKT reverts to the cytoplasm and the nucleus where it phosphorylates a number of 
downstream targets involved in various cellular functions.  
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3.1.3.6 PI3K-AKT signaling and cancer progression 
Carcinogenesis is a complex process arising as a result of imbalance between cell division/ 
growth and programmed cell death (apoptosis). In this context, various signaling pathways 
involved in the regulation of cellular processes such as cell growth, differentiation, and 
development undergo oncogenic changes more than any other molecule. Studies have shown that 
components of the PI3K-AKT signaling pathways are frequently altered in human cancers [197] 
with amplification and over expression of the gene encoding PI3K (PIK3C) being described in 
ovarian, cervical, gastric, and breast cancers [217,218]. Similarly, various studies have also 
demonstrated akt amplification in human cancers [219,220]. This deregulation/amplification of 
components of the PI3K-AKT signaling pathway exerts a key role in tumor growth, survival, 
metastasis, and angiongenesis. Inhibition of signaling molecules in this pathway has been shown 
to strongly reduce tumor growth and angiogenesis in animal model experiment [203].  
 
3.1.3.6.1 PI3K-AKT signaling in tumor angiogenesis 
Angiogenesis is an essential process in tumorigenesis that can be triggered by growth factors, 
genetic alterations, and mutation of tumor suppressor gene such as p53. The angiogenic process 
in tumors can occur via sprouting of new vessels from preexisting blood vessels or via protrusion 
of interstitial tissue columns into vascular lumen [109]. 
PI3K-AKT signaling has been found to augment tumor angiogenesis by regulating the 
expression of VEGF and hypoxia–inducible factor 1 (HIF-1) via the activation of p70S6K1 and 
HDM2. In addition, this pathway can also promote tumor angiogenesis through the activation of 
reactive oxygen species (e.g. eNOS) [221,222]. 
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3.1.3.6.2 PI3K-AKT signaling in tumor cell proliferation 
PI3K-AKT signaling augment tumor cell proliferation by modulating the functions of numerous 
cellular substrates involved in the regulation of cell proliferation. A good example of these 
substrates include glycogen synthase kinase-3 (GSK-3) [223,224], membrane translocation of 
glucose transporter-4 (GLUT4) [223], cyclin-dependent kinase inhibitors, p21/Waf1/Cip1and 
p27/Kip2 [216,225-228], mammalian target of rapamycin (mTOR) [229,230] and tuberous 
sclerosis complex 2(TSC2) [231]. 
PI3K-AKT inhibits GSK 3 activity by direct phosphorylation of the serine residue in the N-
terminal regulatory domain of insulin-activated PI3K [232]. GSK 3 inhibition prevents the 
phosphorylation of β-catenin, thus impeding its degradation and facilitating its translocation into 
the nucleus. In the nucleus, β-catenin combines with various transcription factors such as 
TCF/LEF-1 to induce the expression of Cyclin D1 which induces cell cycle progression by 
regulating Rb hyperphosphorylation and inactivation. Furthermore, PI3K-AKT signaling also 
phosphorylate of p21/Waf1/Cip1 and p27/Kip2, inhibiting their anti-proliferative effects by 
reducing their ability to activate Cyclin D1/Cdk4 complex [233]. 
By increasing the phosphorylation of mTOR, PI3K-AKT signaling enhances protein synthesis an 
essential process required for cell proliferation [234]. In addition this signaling pathway also 
phosphorylate TSC2 complex to inhibit its growth suppressor function.  
 
3.1.3.6.3 PI3K-AKT signaling in tumor cell survival (inhibition of apoptosis)  
PI3K-AKT pathway regulates tumor cell survival by phosphorylating downstream substrates that 
directly or indirectly control the apoptotic machinery. The pathway inactivates the pro-apoptotic 
factors Bad and pro-caspase 9; activates the transcription of NF-κB regulated anti-apoptotic 
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genes via the activation of Ikappa B kinase (IKK); inactivates Forkhead family transcription 
factors (AFX, FKHR, and FKHRL1) thereby inhibiting the expression of pro-apoptotic gene 
such Fas lingand (FasL), Bim, and IGFBP-1 [197,208,235].  
 
3.1.3.6.4 PI3K-AKT signaling in tumor cell metastasis 
The PI3k-AKT signaling contributes to tumor invasiveness and metastasis by inhibiting anoikis 
and stimulating MMPs secretion. 
 
4.1 Regulation of cervical inflammation, inflammatory pathways, and tumorigenesis by 
HPV oncogenes 
Inflammation involves extensive tissue remodeling events which are orchestrated by complex 
networks of cytokines, chemokines and bioactive lipids. These work across multiple cellular 
compartments to elicit their function. The classic hallmarks of inflammation are the recruitment 
of immune cells into the tissue and alteration of vascular function to allow for immune cell 
extravasation. This alteration in permeability causes edema and the redness generally associated 
with tissue inflammation. Several reports have correlated inflammatory cell infiltrate with HPV-
induced high grade lesions. Infiltrating lymphocytes are thought to contribute to tumor growth 
and spread as well as immunosuppression, generally associated with malignant diseases [72]. 
Although the precise mechanism whereby HPV oncogenes regulate tissue remodeling events is 
unclear, HPV infections have been shown to promote the release of inflammatory mediators and 
cytokines from keratinocytes to alter the immune response and promote the infiltration of 
macrophages, lymphocytes and NK cells [236]. Changes in the vasculature to facilitate immune 
extravasation and angiogenesis require tissue remodeling of the extracellular matrix, a process 
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facilitated by MMP’s [237]. Several studies have correlated HPV E6 and E7 transcription with 
MMP transcription [238,239] and genes in cervical epithelial cells involved in tissue 
differentiation and remodeling [240]. In addition, transfection studies have shown that E7 
oncoprotein forms a complex with and down-regulates leukocyte elastase inhibitor [241]. This 
would facilitate the activation of neutrophils and promote neutrophil influx into the tissue. 
Furthermore, transgenic mouse models where the early region genes from HPV16 are expressed 
under the control of the human keratin 14 promoter have shown that macrophage recruitment to 
HPV-associated lesions occurs via the release of the chemokine CCL2 and interaction with its 
receptor CCR2 present on macrophages [242].   
Once resident in the tissue, inflammatory cells are known to produce vast amounts of reactive 
oxygen species and nitric oxide which have been shown to induce DNA damage [243] and to 
contribute towards the progression of the disease in high grade cervical lesions [243]. 
Furthermore nitric oxide has been shown to induce transcription of E6 and E7 oncogenes in 
cervical epithelial cells [244], which can further enhance inflammation via an auto-amplifying 
positive feedback loop via activation of COX-2 and other parallel inflammatory pathways. 
Similarly,  studies by Subbaramaiah and Dannenberg and Oh and colleagues have now emerged 
to show that in neoplastic cervical epithelial cells, HPV 16 E5, E6 and E7 oncogenes can induce 
the inflammatory COX-PG axis, by elevating expression of the immediate early oncogene COX-
2 and the E-series prostaglandin receptors, EP2 and EP4 [76,245,246]. And several studies have 
also emerged from in vitro and in vivo model systems employing cell lines and rodents to 
demonstrate that prostaglandins, produced as a consequence of elevated COX enzyme 
expression, can promote extensive tissue remodeling within tumors by evoking all the classical 
hallmarks of cancer, namely: cellular proliferation, angiogenesis, inhibition of apoptosis and 
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alteration in vascular permeability to allow immune cell extravasation from the vasculature 
[80,247] as discussed above.  
 
5.1 HIV, cervical cancer and inflammation 
The human immunodeficiency virus (HIV); the only etiological factor attributed to the Acquired 
Immunodeficiency Syndrome (AIDS) belongs to the genus Lentivirus within the family 
Retroviridae [248]. About 33 million people harbor this virus worldwide [249] with high 
epidemic rates in sub-Saharan Africa.  Mature HIV virion is spherical (approximate diameter of 
100-120nm), with a genome of two copies of identical (9.2kb) single-stranded positive sense 
RNA molecule encoding the characteristic retrovirus proteins; Gag, pol, and Env [250]. HIV is 
divided into two main sub types HIV-1 and HIV-2. HIV-1 is further subtyped into phylo-
genetically related clades; types A-K [251].  
Transmission is via unprotected sexual intercourse, intravenous drug use, blood transfusion or 
infection with blood-derived products. To initiate infection, virus attaches to cellular surfaces via 
an interaction between the gp120 viral envelope protein and a receptor complex present on the 
host cell consisting of the CD4 receptor and G protein-coupled receptor (GPCR) co-receptor, 
usually CCR5 or CXCR4 [250]. Most primary HIV-1 variants are restricted to the use of CCR5 
and CXCR4 [252,253], however they have been shown to use alternative receptors in vitro. HIV-
2 variants are capable of infecting a wider range of cells expressing different co-receptors such 
as GPR15 and CXCR6 in addition to CCR5 and CXCR4 [254]. This leads to fusion between the 
viral and cellular membranes and ultimate release of the viral core into the cell cytoplasm [250]. 
Once inside the host cell the virus is reversed transcribed to full length double stranded DNA by 
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the reverse transcriptase enzyme and is integrated into the host genome [255]. The hallmark of 
infection is characterized by progressive depletion of CD4+ and CD8+ helper T-cells leading to 
an immunodeficiency state, paving the way for opportunistic infection and ultimately mortality 
[256].  
 
5.1.1 The interplay between HIV and HPV and their role in cervical cancer 
The interplay between HPV and HIV is complex; however their synergistic role in exacerbating 
pathology of the cervix has been well documented. For example, epidemiological studies have 
shown that women that are co-infected by HPV and HIV have an estimated 41 fold increase in 
the risk of developing neoplastic cervical lesions [257] and HIV infected immune-compromised 
women have been shown to have a higher prevalence of HPV-induced lesions [258]. 
Furthermore, studies in sub-Saharan women, where 67% of the population are living with 
HIV/AIDS have shown that women with HIV develop cervical cancer at an earlier age than 
women who are HIV negative [5,259,260].  
Although the precise mechanisms predisposing women infected with HPV to HIV infection are 
unclear, there is compounding evidence that clearance of HPV infection from the female genital 
tract elicits an enormous cell-mediated immune response characterized by gross infiltration of 
lymphocytes and macrophages into the epithelium [261], which can enhance the risk of HIV 
infecting immune cells in the cervix in these women after unprotected sexual contact.  
Central to the role of HIV in cervical cancer is its ability to ablate the systemic immune response 
to infection, including HPV infection. This can facilitate inadequate clearance of HPV in 
infected individuals, enhancing HPV persistence or re-infection, and increases the likelihood that 
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precancerous lesions will develop into cancer. To this end, HIV may modify HPV related 
carcinogenesis by altering the expression of inflammatory components (cytokines) in the cervix 
and diminution of local cervical cellular immunity, thus altering HPV regulation [249]. For 
example, HIV tat gene  has been shown to increase the expression of HPV E1 and L1 genes, 
hence causing up-regulation of the HPV replication [262,263].  Furthermore, HIV-1 tat protein is 
capable of transactivating HPV16 transcription [264].  
 
5.1.2 The role of HIV in regulating inflammation and its potential contribution to cervical 
cancer. 
Systemic expression of several pro-inflammatory cytokines has been reported to be a major 
feature in HIV infection. The virus causes immune dysregulation leading to increase in the 
production of pro-inflammatory cytokines such as; TNFα, IL-1, and IL-6 which are detected in 
the plasma and lymph node of infected patient [265]. This link between HIV and production of 
pro-inflammatory cytokine was suggested by the observation that the virus and/or its surface 
glycoprotein gp120 can induce in vitro secretion of TNF, IL-1 and IL-6 by monocytes isolated 
from uninfected individuals [266-268].  Other studies also detected high levels of IL-1α, IL-1β, 
IL-6, and TNF in the serum and cerebrospinal fluid of sero-positive individuals [269,270]. Often 
associated with the production of these cytokines is the elevated secretion of CC-chemokines 
such as macrophage inflammatory protein (MIP)-1α, MIP-1β, and RANTES [271,272]. These 
pro-inflammatory cytokines expressed as soluble factors or membrane binding molecules and are 
directly or indirectly involved in HIV entry and T cell apoptosis [256]. These cytokines have 
been found to be abundant in microenvironment of several tumors including cervical cancer (as 
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discussed above) where they are secreted by the tumor cells, endothelial cells and/or infiltrating 
activated immune cells where they act as endogenous tumor promoter by stimulating the 
production of transcription factors (e.g. NF-кB, AP-1), proliferative and angiogenic proteins (e.g. 
VEGF, MMPs) and adhesion molecules (e.g. E-selectin, VCAM), thus enhancing tumor growth 
and mediating tumor metastasis [273]. TNF, a major mediator of inflammation, can be detected 
in various human neoplasias where it is implicated in the induction of MCP-1 which can 
modulate the infiltration of immune cells in to the tumor microenvironment. 
In addition to regulation of immune cell infiltrate, alteration in the expression profile of HIV 
receptors on cells within the cervico-vaginal region could impact on HIV acquisition and 
cervical cancer progression. The epithelial surface of the female reproductive tract expresses all 
the receptors necessary for HIV infection including CD4, CCR5 and CXCR4 [274]. Maher and 
colleagues have recently shown that HIV virions can bind the external surface of cervical 
epithelium and penetrate beneath the epithelial surface [275]. Thus, it is plausible that epithelial 
cells lining the cervico-vaginal interface could be the first cells to come into contact with HIV 
and might play a role in the replication of the virus and transmission to leukocytes present in the 
submucosa.  
Expression of some of the HIV receptors on uterine epithelial cells display a temporal variation 
in expression during the menstrual cycle, indicating that they are hormonally regulated [274]. 
This could alter susceptibility to infection depending on the phase of the menstrual cycle. 
Chemokine receptors such as CXCR4 are elevated in cervical cancer and play a role in lymph 
node metastasis during advanced stage disease [276]. These receptors can also be hijacked by 
HIV for entry in such women. CXCR4 expression can be regulated by HPV oncogenes [277] and 
prostaglandins [278] in the female genital tract. These observations suggest that HPV infection 
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and inflammation can drive expression of HIV co-receptors on epithelial cells. It is unknown 
whether the inflammatory milieu of cervical cancer can also alter expression of HIV receptors on 
immune cells in the tumor periphery. It is plausible that in women with HPV infection or 
localized cervico-vaginal inflammation, alterations in HIV receptor expression could allow more 
virus to bind the epithelium and elevate the amount of virus present locally in the genital tract 
following intercourse. In women with cervical cancers or inflammatory cell infiltrate into the 
cervix, this could enhance susceptibility to infection.  
 
6.1 Seminal plasma, cervical cancer, HIV and inflammation 
Seminal plasma (SP) is the major constituent of the male ejaculate. It is  a complex organic fluid 
comprising of secretions of the cowper’s and littre glands (5%), prostate (15-30%), and the 
seminal vesicles (65-70%) [279]. Secretions from each of these reproductive organs are 
biochemically distinct, and on mixing as occurs at ejaculation, gives rise to the complex 
biochemical nature of the SP. Also called “Seminal Fluid”, this endogenous fluid has been 
conventionally viewed as a nutritive, protective and transport medium for the mammalian 
spermatozoa [280]. However, recent studies both in rodents and humans have shown that SP 
contains signaling molecules which can bind to cognate epithelial receptors in the female 
reproductive tract to trigger inflammatory gene expression, thus causing modifications in cellular 
structure and composition in a sequence that resembles inflammatory response [280].  
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6.1.1 Role of seminal plasma in regulating cervical inflammation and its potential 
contribution to cervical cancer. 
In mammals, the most evident physiological effects of insemination is a prompt and dramatic 
influx of inflammatory cells into the site of semen deposition [280]. These cellular changes, 
studied in detail in mice [281-283] was discovered to be mediated by SP as opposed to sperm 
[283] and is initiated when endogenous molecules present in SP interact with cervical and uterine 
epithelial cells to induce a surge in cytokines and chemokines synthesis [283]. These pro-
inflammatory mediators stimulate the extravasation and infiltration of cervical sub-epithelial 
stroma by immune cells. Similarly, in humans coitus elicits immune cell (neutrophils, 
macrophages, dendritic cells, and lymphocytes) recruitment into the superficial epithelial and 
deep stroma tissues of the female reproductive tract [284]. In sexually active women, the degree 
at which SP normally activates the secretion of these pro-inflammatory components in any 
compartment of the female reproductive tract is poorly understood. However, exposure of the 
cervix to SP during coitus has been shown to elicit substantial changes in the leukocyte 
populations within the cervix, initiating a reaction reminiscent of inflammatory response with 
effects that penetrate through the stratified epithelial layer and deep into the stroma of the 
ectocervix [285]. The role of SP in mediating leukocyte influx in the cervix was supported when 
no inflammatory response was seen in the absence of coitus or with condom-protected coitus 
[285]. SP regulated the cervical leukocyte influx via the activation of pro-inflammatory 
cytokines and chemokines [286]. Similarly, in vitro studies have shown that SP induce the 
expression of inflammatory enzyme (COX-1 and COX-2), interleukin (IL) 6, 11 and chemokines 
CXCL1 and CXCL8 in cervical adenocarcinoma cells [287].  
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The influx of immune cells expands inducible regulatory T cell population, hence promoting 
immune tolerance there by preparing the reproductive tract for conception [285,288,289]. More 
broadly, the inflammatory response initiated by SP would be expected to impact on all 
physiological and pathophysiological events regulated by cervical leukocytes.  
 
6.1.2 Role of seminal plasma in regulating HIV infection and its potential contribution to 
cervical cancer 
 In 1993, cervical cancer was classified as one of the AIDS-defining diseases in women infected 
with HIV [26]. This highlighted HIV as an important risk factor/co-factor in the development of 
invasive cervical neoplasia and highlighted cervical cancer as an infectious disease [27].  
Since the beginning of the AIDS pandemic, greater than 35 million deaths have been reported in 
both adults and children worldwide [290]. It has been well documented that unprotected hetero 
or homo sexual intercourse is the major route of HIV infection with infected seminal plasma 
being the major transmission vector [291-293]. Post deposition of HIV on the recipient mucosa, 
infectious virus must cross the mucosal epithelium to interact with CD4+ T lymphocytes, 
macrophages, and dendritic cells (DCs). These immune cells express the receptor CD4 and co-
receptors CXCR4 or CCR5 which are required for HIV infection [292-295]. The exact molecular 
mechanisms through which HIV traverse the mucosal barriers and establish infection are poorly 
defined. The virions may transcytose through the genital epithelium [292,295] or pass through 
exposed genital lesions [296-298]. In addition, post coital epithelial microabrasions found in the 
vagina of most healthy women after consensual intercourse is suggested to constitute a frequent 
scenario for sexual transmission [299].  
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Beyond its role as a carrier for delivery of HIV during receptive vaginal or anal intercourse, SP 
has been suggested to play a more major role in HIV transmission. This is supported by studies 
which provided insight into the SP-mediated effects on both the virus and the mucosal HIV entry 
sites. A novel mechanism by which SP could enhance sexual transmission of HIV was 
demonstrated by Munch et al. (2007) [300]. To identify natural agents that might play a role in 
sexual transmission of HIV, Munch and colleagues screened a complex peptide/protein library 
derived from human SP for novel inhibitors and enhancers of HIV infection. They found that 
naturally occurring fragments of the prostatic acidic phosphatase (PAP) drastically enhance HIV 
infection [300].  
Functional and structural analyses shows that PAP forms amyloid fibrils termed semen-derived 
enhancer of virus infection (SEVI) which markedly increased HIV infection. SEVI capture HIV 
and strongly heighten the number of productively infected cells by promoting the attachment and 
fusion of the virus to the cell surface. SEVI was shown to increase the infection by R5-, X4- and 
dual tropic HIV-1 clones in peripheral blood mononuclear cells (PBMCs), DCs and macrophages 
in vitro. In an in vivo experiment to demonstrate the enhancing effect mediated by SEVI, using 
hCD4/hCCR5-transgenic rats challenged with HIV-1 or SEVI-treated HIV-1 by tail vein 
injection. Munch and colleagues discovered that pre-treatment of HIV with SEVI resulted in a 5-
fold increase in the number of HIV cDNA copies found in the splenocyte extracts from infected 
rats [300]. Taken together, the increase in HIV infectivity when treated with SEVI in vitro, 
suggests that it might favor sexual transmission of HIV. This however, has been shown to be 
highly dependent on the individual semen donor and correlates with the level of SEVI [301]. 
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In addition, it has been suggested that SP-mediated inflammatory responses within the female 
genital tracts may contribute to the transmission of HIV and other STIs (sexually transmitted 
infections) through two major mechanisms; a) by disrupting the epithelial barrier, and b) by 
inducing the local recruitment of CD4+ target cells favoring the dissemination of HIV infection 
[284,302,303].  
Other proposed mechanisms of SP-mediated HIV transmission include; the role of spermatozoa 
in efficient transmission of HIV to dendritic cells [304], neutralization of the acidic pH of the 
vaginal fluid [305], and SP-mediated immunomodulation and suppression of both innate and 
adaptive immune response against HIV [306]. However, the detailed cellular and molecular 
mechanism by which SP can influence inflammatory pathways to regulate inflammation and 
HIV transmission in cervical cancer, which may play a major role in tumor progression, is yet to 
be studied.   
 
6.1.3 Seminal plasma prostaglandins: potent pro-inflammatory factor 
Seminal plasma is known to contain an enormous diversity of  antigenically  distinct molecules  
that  include  cytokines,  angiogenic  factors,  prostaglandins,  proteases,  signal transduction  
molecules,  protein  kinases,  transporter  proteins,  structural  molecules and immune response 
proteins [307]. However, it is the highly expressed levels of prostaglandins found in human SP 
[308]  that have attracted much interest of late. 
Prostaglandins (PGs) are lipid autacoids that mediate both homeostatic functions and pathogenic 
mechanisms, including inflammatory response within the human body [309]. These potent pro-
inflammatory lipids are generated from arachidonate by the action of cyclooxygenase enzymes, 
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and their biosynthesis is blocked by non-steroidal anti-inflammatory drugs. Of the PGs present in 
SP, PGE2 has been identified as one of the predominant types detected [310,311]. 
Over the years, studies have shown that overt expression of PGE2 and its signaling is found in 
numerous disorders including cervical cancer [28,312] and women infected with HIV and HPV 
[134,313]. It has been shown that PGE2 potentiates the chronic inflammatory response seen in 
these diseases, leading to greater tumorigenesis (cervical cancer) [28] and enhanced viral 
replication (HIV infection) [314]. 
Similarly, recent study by Joseph et al. (2012) identified PGE2 present abundantly in SP as the 
main constituent responsible for SP-mediated inflammatory effects in vaginal cells [315]. It is 
therefore very likely that SP-PGE2 can influence inflammatory pathways to regulate 
inflammation and HIV transmission in cervical cancer. This is more evident as studies have 
shown that cervical cancer has up-regulated expression of PG receptors [28]. 
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7.1 Statement of the problem 
Presently there are more than 273,000 deaths occurring worldwide each year from cervical 
cancer thus accounting for 9% of total cancer deaths in women [316]. 
Mortality from cervical cancer is high in sub-Saharan Africa with a mortality rate of 35/100,000 
women in East Africa, 23/100,000 in Southern Africa, and 24/100,000 in Western Africa as 
opposed to 2/100,000 in North America and 4/100,000 in Western Europe [317,318].  
As previously mentioned infection with HPV (especially type 16) account for 50% of cases [10] 
and inflammation plays a major role in the pathogenesis of this disease. Seminal plasma has been 
shown to regulate the expression of inflammatory genes and initiate inflammatory processes and 
components in both normal and neoplastic human cervical epithelium in sexually active women 
[285,287]. 
Hence a complete and detailed understanding of the role and molecular mechanism by which 
seminal plasma regulates the expression of arrays of inflammatory genes to augment cervical 
tumorigenesis, alter susceptibility of women with cervical neoplasms to HIV infection and 
increase the development of AIDS related cervical cancer in sexually active women will serve as 
lead in developing new modalities for clinical intervention and treatment. 
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8.1 Hypothesis 
We hypothesize that in sexually active women, repeated exposure of cervical epithelial cells to 
seminal plasma can regulate inflammatory pathways. In women with neoplastic cervical lesions, 
hyperactivation of inflammatory pathways could potentially enhance tumorigenesis and regulate 
pathways involved in HIV infection and AIDS-related cancer progression. 
 
9.1 Aim 
This study investigates the inflammatory and tumorigenic pathways regulated by SP in cervical 
epithelial cells and the molecular pathways underlying this regulation.  
 
10.1 Specific objectives  
1. To investigate the role of seminal plasma (SP) in regulating the expression of 
inflammatory genes in cervical adenocarcinoma cell in vitro. 
2. To elucidate the various inflammatory pathways involved in SP induction of a pleotropic 
pro-inflammatory cytokine IL-1α and the molecular mechanisms underlying their action.  
3. To investigate the inflammatory pathways and role of SP in HIV susceptibility in women 
and the mechanisms underlying this. 
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CHAPTER 2 
 
GENERAL MATERIALS AND METHODS 
 
2.1 Ethics statement 
Ethics approval for this study was obtained from the University of Cape Town Human Research 
Ethics Committee (HREC/REF: 067/2011). Written informed consent was obtained from all 
subjects before sample collection. 
 
2.2 Chemicals and Reagents 
All chemicals used for this study were of molecular biology grade, and were purchased from 
Merck Chemicals (PTY) Limited (Gauteng, South Africa) or Sigma Chemical Company (Cape 
Town, South Africa). Cell culture media, penicillin-streptomycin, and fetal-calf serum were 
purchased from Highveld Biological (PTY) Limited (Cape Town, South Africa). Bovine serum 
albumin (BSA), phosphate buffered saline (PBS), and Trizol® were all   purchased from Sigma 
Chemical Company (Cape Town, South Africa). The chemical inhibitors: AG1478, epidermal 
growth factor receptor (EGFR) kinase inhibitor; LY294002, phosphoinositide-3-kinase (PI3K) 
inhibitor; SC560, cyclooxygenae-1 (COX-1) inhibitor; NS398, cyclooxygenase-2 (COX-2) 
inhibitor; SN50, nuclear factor kappa B (NFκB) inhibitor; and PD98059, extracellular signal-
regulated kinases 1/2 kinase (ERK1/2) inhibitor were purchased from Calbiochem (Merck, 
Darmstadt, Germany). Prostaglandin E2, Butaprost, PGE2 receptor antagonist (AH6809), and 
human recombinant epidermal growth factor (EGF) were purchased from Sigma Chemical 
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Company (Cape Town, South Africa). Quantikine® Human IL-1α ELISA kit was purchased from 
R&D Systems, Minneapolis, USA.  Polyclonal goat anti-IL-1α (sc-1253), β-actin (sc-1616), 
CCR5 (CKR5; sc-6128), CD4 (sc-19641), COX-1 (sc-1752), and biotin conjugated secondary 
donkey anti-goat IgG antibody (sc-2042) were purchased from Santa Cruz Biotechnology. 
Streptavidin-biotin peroxidase complex and 3.3’-diaminobenzidine were all purchased from 
Dako North America Incorporation, USA. Total PKB (AKT) (9272s) and phosphorylated PKB 
(S473) antibodies were purchased from Cell Signaling Technology. Pierce® BCA Protein Assay 
Kit and SuperSignal® West Pico Chemiluminescent Substrates were purchased from 
ThermoScientific, Rockford, USA and PVDF membrane was purchased from GE Healthcare, 
Amersham, United Kingdom.   
 
2.3 Semen donors and preparation 
Semen was collected from healthy male volunteers attending the Andrology Laboratory of the 
Reproductive Medicine unit at Groote Schuur Hospital, Cape Town, South Africa. All donors 
had at least 72 hours of total sexual abstinence (self-reported) prior to ejaculation. Ejaculates 
were collected in sterile specimen jars following a voluntary self-masturbation. Parameters such 
as sample volume, sperm number, sperm concentration, peroxidase-positive leukocytes, pH and 
viscosity were noted and compared with the 2010 WHO (World Health Organization) reference 
values for human semen characteristics [319]. Samples with below average parameters were 
excluded from the study. All samples were processed within 30 minutes of collection. The 
individual ejaculates were transported to the laboratory. Seminal plasma (SP; the cell free 
supernatant of the ejaculate) was isolated from ejaculate by centrifugation at 15000 g for 20 
 62 
 
minutes. Ejaculates from 10 individual volunteers were pooled and then aliquoted (200μL) and 
stored at -80 0C until required. Individual ejaculates were analyzed for their ability to regulate 
expression of target genes before being pooled to minimize experimental variability. Prior to use 
seminal plasma was thawed on ice and diluted in sterile filtered serum free medium to use at a 
concentration of 1:50. SP has been shown to exert no toxic effect on HeLa cell viability up to 
and including concentration used in this study [287,320]. 
 
2.4 Cervical specimen  
2.4.1 Cytobrush Sample 
Cervical specimens were collected from women attending the Gynecology (Colposcopy) 
outpatient Clinic at Groote Schuur Hospital, Cape Town, South Africa. Specimens were obtained 
by cytobrush as described by Musey and colleagues [321]. Briefly, the cytobrush was inserted 
within the cervical os and gently rotated one 360 degree turn. The cytobrush was smeared onto a 
microscope slide for diagnosis and then placed into a 15ml collection tube containing serum free 
Dulbecco’s modified Eagle’s medium nutrient mixture F-12 (DMEM) (Highveld Biological 
(PTY) Limited, Cape Town, RSA) with Glutamax-1and 1% penicillin-streptomycin. The tubes 
were immediately placed on ice and transported to the laboratory. The cells were dislodged from 
the cytobrushes by gentle agitation and each sample divided into two aliquots and was treated 
with vehicle (PBS) or 1:50 dilution of seminal plasma in serum free DMEM for 24 hours. After 
which, cells were pelleted by centrifugation at 1500 rpm and RNA extracted using Trizol 
(Sigma) following the manufacture’s guidelines and reverse transcribed. 
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2.4.2 Cervical Tissue Explant 
Cervical cancer tissue specimens were obtained at the time of surgery or biopsy from patients 
attending the Gynecologic Oncology Clinic at Groote Schuur Hospital (Cape Town) and who 
had previously been diagnosed with pre or invasive carcinoma of the cervix. Diagnostic cytology 
report was defined according to the Bethesda System for reporting cervical cytology [322] while 
pathological staging was defined according to the revised International Federation of 
Gynecology and Obstetrics (FIGO) staging for carcinoma of the cervix [323] upon physical 
examination. Punch biopsies were taken from the lesion by an experienced gynecologist with a 
special interest in gynecology oncology. Samples were immediately transported in PBS on ice to 
the laboratory where they were divided into experiment and control and then serum starved 
overnight prior to stimulation with seminal plasma. Histologically normal cervical tissues were 
collected from women undergoing Wertheim’s hysterectomy for benign gynecological 
malignancies at Groote Schuur Hospital (Cape Town). Cervical (approximately 3 X 4mm) tissue 
samples collected at the time of surgery were immediately transported in PBS on ice to the 
laboratory where they were chopped into smaller pieces and divided into experiment and control 
before being serum starved overnight prior to SP stimulation.  
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2.5 Cell Line 
2.5.1 HeLa S3 
HeLa-S3 (HeLa) authenticated and verified as cervical adenocarcinoma cells positive for HPV-
18 sequence with normal levels of pRB (retinoblastoma) and low levels of p53 tumor suppressor, 
were purchased from BioWhittaker (Berkshire, UK). 
 
2.6 Cell Culture 
Cells were routinely maintained in DMEM nutrient mixture F-12 with Glutamax-1 and 
pyroxidine supplemented with 10% fetal bovine serum (FBS) (Highveld Biological (PTY) 
Limited, Cape Town, RSA)  and 1% penicillin-streptomycin (500 IU/ml penicillin and 500 
μg/ml streptomycin) at 37 0C and 5% CO2. The medium was stored at 4 
0C, and was warmed to 
37 0C before use. Monolayer cultures of HeLa cells were grown in 125 cm2 tissue culture (TC) 
flasks and kept in a humidified incubator (37 0C , 95% relative humidity and 5% CO2). Cellular-
growth was monitored every 48 hours using an inverted fluorescent microscope and cells were 
passaged when confluent. To passage, cells were removed from the incubator and the media 
aspirated using sterilized Pasteur pipette attached to a pump. The cells were then washed twice in 
pre heated (37 0C) phosphate buffered saline (PBS) and dissociated from the TC flask with 5ml 
1x trypsin-EDTA, and the flask placed back in the incubator for 5 min at 37°C. TC flask was 
then removed from the incubator and viewed under an inverted fluorescent microscope to 
confirm cell detachment after which excess trypsin-EDTA was aspirated and complete media 
added. The cells were then transferred into a new culture flask with complete medium at a ratio 
of 1 in 10 with a new passage number being recorded on each flask or seeded onto culture dishes 
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for experimentation or frozen down for later use. Early passage cells were frozen down for later 
use by re-suspending the trypsinized cells (~1×106 cells/ml) in FBS containing 5-10% DMSO 
and transferred into small sterile cryogenic vials. The vials containing cell aliquots (1ml each) 
were placed upright in a -80 0C freezer and later transferred to liquid nitrogen for long term 
storage. 
 
2.7 Cellular Investigations 
2.7.1 Cell treatment with seminal plasma 
HeLa S3 cells were seeded in complete medium at density of 2x105 cells in 3 cm diameter tissue 
culture dishes and allowed to attach and grow overnight. The following day, the complete 
medium was aspirated and cells were serum starved by incubating in serum free medium 
(Dulbecco’s modified Eagle’s medium nutrient mixture F-12 (DMEM) with Glutamax-1 
enriched with 1% penicillin-streptomycin (500 IU/ml penicillin and 500 μg/ml streptomycin) 
without FBS) for 24 hours. Cells were then treated with serum free media containing SP at a 
final dilution of 1:50 or serum free media with PBS as control for 4, 8, 16 and 24 hours. SP at 
this concentration has been shown to not affect cell viability [324]. The cells were then harvested 
after 4, 8, 16 and 24 hours using 1ml Trizol® (Sigma). In parallel, untreated wild type HeLa cell 
(positive control) was lysed in 1 ml of Trizol® (Sigma) and used as a reference control in each 
Real Time quantitative RT-PCR reaction. Samples were stored at -80°C until further use.  
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2.7.2 Treatment with chemical inhibitors  
HeLa S3 cells at a density of 2x105 were seeded in 6 well tissue culture plates and allowed to 
attach and grow overnight in a humidified incubator  (at 37°C  and 5% CO2(v/v)). The next day, 
the complete medium was aspirated and the cells washed twice with PBS. The cells were then 
serum starved for 24 hours. After 24 hours, the serum free medium was then aspirated and cells 
pre-incubated with aforementioned chemical inhibitors (CalBiochem, Merck) at 37°C (Table 2.1) 
for 1 hour. The medium containing inhibitors was then aspirated and replaced with fresh serum 
free medium containing the inhibitors or vehicle (H2O or DMSO) in the presence or absence of 
SP (1:50 dilution). The samples were incubated for 4, 8 or 16 hours. Post incubation the medium 
was  aspirated and cells harvested with 1ml Trizol® (Sigma) and RNA extracted following the 
manufacture’s guidelines and reverse transcribed as described previously [312]. The 
concentrations of the chemical inhibitors were determined empirically by titration as described 
[325-327]. 
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Table 2.1:  Inhibitors, the enzyme or molecule inhibited and concentration used [326,328,329] 
 
Compound Enzyme/molecule Inhibited Concentration used 
 
EGTA 
 
Ca2+ chelator 
 
1.5mM 
 
NS-398 
 
COX-2 
 
8-10µM 
 
SC-560 
 
COX-1 
 
10-15µM 
 
PD-98089 
 
ERK 
 
50µM 
 
AG-1478 
 
EGFR 
 
100-200nM 
 
SN50 
 
NFκB 
 
100µg/mL 
 
LY-294002 
 
PI3K 
 
25µM 
 
 
2.8 RNA extraction 
Throughout the RNA extraction,  a ribonuclease (RNase) free environment was maintained by 
wiping all the surfaces with RNase-ZAP® (Sigma) and  by  using double distilled deionized 
water that was pretreated with  0.01%  diethylpyrocarbonate (DEPC; Sigma). RNA was 
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extracted from cell samples using Trizol® (Sigma) following the manufacturer’s protocol. 
Briefly, lysed cells in 1 ml of Trizol® (Sigma) were retrieved from -80 0C and thawed on ice after 
which 100µL  BCP (1 bromo-2 chloropropane)  (Merck) was added to each sample. The mixture 
was shaken vigorously for 15 seconds and incubated at room temperature for 10 minutes. 
Samples were then centrifuged for 15 minutes at 15,000 rpm at 4°C. The top colorless aqueous 
phase containing RNA was carefully transferred into a clean tube. The RNA was pelleted by the 
addition of 0.5mL of isopropanol (Merck) per 1ml of Trizol®, mixed thoroughly and allowed to 
stand for 10 minutes at room temperature. The samples were centrifuged at 15000 rpm for 10 
minutes at 4°C. The isopropanol was then discarded and the resultant RNA pellet was washed 
with 75% (v/v) ethanol by centrifugation at 15000 rpm for 5 minutes at 4°C. The supernatant 
was then discarded and the pellet was air dried for 30 minutes. The pellet was re-suspended in 
nuclease free or 0.01% DEPC (Sigma Aldrich, UK) treated water and heated to 55°C for 2 
minutes to remove any tertiary RNA structure. RNA quality and concentration was determined 
by Thermo Scientific NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, 
Wilmington, USA). The RNA was diluted using nuclease free or DEPC treated water to a final 
concentration of 200ng/µL and was stored at -80°C until future use. 
 
2.9 Reverse transcription (cDNA synthesis) 
The diluted RNA samples were thawed on ice and  reverse transcribed to cDNA using reverse 
transcription reagent mix (Table 2.2) containing; MgCl2  (5.5.mmol/L),  (Applied Biosystems), 
10x Reverse transcription buffer (1mmol/L), (Applied Biosystems), deoxynucleoside 
triphosphate (dNTP) mix (0.5mmol/L), (Applied Biosystems),  RNase inhibitor (0.4 IU/μL) 
(Applied Biosystems), Random Primers  (1.5μmol/L), (Invitrogen), oligo-dT (1.25 μmol/L), 
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(Applied Biosystems), and  MultiScribe™ Reverse Transcriptase enzyme  (1.25 IU/μL) (Applied 
Biosystems). The mix was aliquoted into individual polymerase chain reaction (PCR) tubes 
(9μL/tube) and template RNA was added (1 μL/tube of 200ng/μL RNA). A reaction mix devoid 
of the reverse transcriptase enzyme was included as control for any genomic DNA 
contamination. The reverse transcription reaction was performed on a GeneAmp® 2700 
(Applied Biosytems) PCR machine under the following cycling conditions:  10 min annealing at 
25°C, 45 min reverse transcription at 48°C and then denaturation at 95°C for 5min. Thereafter 
cDNA samples were stored at 4° C. 
 
 
 
Table 2.2: Reverse transcription reaction mix; components and concentrations 
 
Component                                   Stock concentration Final reaction concentration 
MgCl2 25mM 5.5mmol/L 
RT-PCR Reaction Buffer 10× 1mmol/L (1×) 
dNTP 10mM 0.5mmol/L 
RNase inhibitor 20IU/μL 0.4 IU/μL 
Random Primers 3μg/μL 1.5μmol/L 
Oligo-dT 50μM 1.25 μmol/L 
Reverse Transcriptase enzyme 50U/μL 1.25 IU/μL 
RNA 200ng/μL 200ng 
 
 
 
 
 
 70 
 
 
2.10 Quantitative real time Polymerase Chain Reaction (RT-PCR) 
The advent of quantitative real-time PCR (qRT-PCR) has dramatically changed the field of 
measuring gene expression [330]. qRT-PCR is the technique of collecting data throughout the 
PCR process as it occurs, thus combining amplification and detection into a single step. This is 
achieved using a variety of different fluorescent chemistries that correlate PCR product 
concentration to fluorescence intensity [331]. qRT-PCR reactions are characterized by the point 
in time (or PCR cycle) where the target amplification is first detected. This value is usually 
referred to as cycle threshold (Ct), the time at which fluorescence intensity is greater than 
background fluorescence [332]. 
 
 
2.10.1 Primer design 
All primer pairs used in this study for target genes excluding were designed using PRIMER 
express program (Perkin Elmer, PE Biosystems, Warrington UK) or Primer3 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) or ApE- A Plasmid Editor v1.17 software 
(Wayne Davis, University of Utah, USA) and synthesized at the Molecular and Cellular Biology 
synthetic DNA laboratory (University of Cape Town, RSA). At least one primer of each pair 
spanned an exon-exon junction to prevent amplification of genomic DNA during the PCR 
reaction.  The specificity of the designed primers was checked by blasting the sequence using a 
BLAST program (http://www.ncbi.nlm.nih.gov/BLAST/).  
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2.10.2 Quantitative real-time PCR detection Chemistries 
In this study, SYBR® Green dye was mainly used to detect PCR products while the TaqMan® 
was used at the beginning of the study to validate SYBR® Green dye experiments. Both reactions 
were carried out on Sequence Detection Systems (SDS) instruments. SYBR Green dye chemistry 
uses the SYBR Green dye to detect polymerase chain reaction (PCR) products by binding to 
double-stranded DNA formed during PCR (Figure 2.1). As the double-stranded PCR product 
accumulates during cycling, more dye can bind and emit fluorescence. Thus, the fluorescence 
intensity is directly proportional to synthesized dsDNA concentration [333]. TaqMan® 
chemistry, also known as 5′ nuclease assay, uses fluorogenic probes to detect PCR product 
accumulation during PCR (Figure 2.1). The sequence-specific probe is labeled with a reporter 
dye on the 5′ end and a quencher dye on the 3′ end [334], which allows the quencher to reduce 
the reporter fluorescence intensity by fluorescence resonance energy transfer (FRET) when the 
probe is intact [335]. FRET reduces fluorescence intensity in hydrolysis probes and increases 
intensity in hybridization probes. When annealed to the target sequence, the bound and quenched 
probe will be degraded by the DNA polymerase’s 5′ nuclease ability during the extension step of 
the PCR. Probe degradation allows for separation of the reporter from the quencher dye, 
resulting in increased fluorescence emission [332,334] (Figure 2.1). 
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Figure 2.1: Comparison of SYBR® Green dye and TaqMan® qRT-PCR detection chemistries 
(http://www.lifetechnologies.com). 
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2.10.3 SYBR Green quantitative real-time PCR reaction 
Quantitative real-time PCR was performed on the samples using a SYBR Green 2x SensiMixTM 
SYBR No-ROX One Step Kit (Bioline, UK). Briefly, a master mix (Table 2.3) containing 1x 
SensiMixTM SYBR No-ROX, 250nM Forward Primer, 250nM Reverse primer and distilled H20 
was prepared, after which 1μL of cDNA and 9uL of master mix (10μL total reaction volume) 
were aliquoted in duplicate in each well of the PCR plate (48 wells (Illumina) or 96 wells 
WHT/WHT Hard Shell® (Biorad). An RT negative, no template control (containing water) and 
the reference positive control were also added in duplicate. To normalize the gene of interest, a 
reaction mix containing glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or human 
cyclophilin A (HCYPA) primers and corresponding cDNA samples was included in the 
experiment to serve as an internal reference control. These genes (GAPDH and HCYPA) were 
the two most stable genes of all five reference genes (Eukaryotic translation elongation factor 1 
alpha 1 (EEF1A1), actin, β-actin, GAPDH and HCYPA) analyzed for HeLa S3 and cervical 
tissue when their average expression stability value M was calculated using geNorm in qbase+ 
2.5.1 software (Biogazelle, Belgium). The wells were sealed using plate covers and the qRT-
PCR was performed using the following parameters; a holding step of 15 minutes at 95°C 
followed by 40 cycles  polymerase activation  at 95°C for 15  seconds and 60°C extension  for 
60minutes using the Eco™ Real time PCR system (Illumina™) or CFX96™ qRT-PCR detection 
system (BioRad, South Africa). A melt curve was also performed at 95°C for 15 seconds, 55°C 
for15 seconds and 95°C for 15 seconds to confirm the purity of the PCR products (Figure 2.2).  
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Figure 2.2: Typical melt curve analysis following SYBR green real time qRT-PCR reaction 
showing two distinct peaks of GAPDH (Green) and IL-1α (blue). 
 
 
 
 
Table 2.3: Real time RT-PCR reaction mix (SYBR Green); components and concentrations 
 
 
Reagents Stock concentration Final reaction concentration 
Syber Green 2x SensiMixTM 2× 1× 
Forward Primer 25μM 250nM 
Reverse primer 25μM 250nM 
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2.10.4 TaqMan quantitative real-time PCR reaction 
To validate the results obtained from the SYBR Green qRT-PCR, a Taqman qRT-PCR was also 
performed for IL-1α, using TaqMan® 2x universal PCR master mix (Applied Biosystems) (Table 
2.4). Briefly, a master mix containing 1x TaqMan® 2x universal PCR master mix, 300nM 
Forward primer, 300nM Reverse primer, 200nM  probe  (Primer design, UK), and 18.75nM 
ribosomal18s primers (Primer design, UK) was made. The final reaction mix (9ul of master mix 
and 1ul of cDNA) was aliquoted in duplicate into 96 well plates (Biorad). The wells were sealed 
using plate covers and the qRT-PCR was performed using the following parameters; a holding 
step of 15 minutes at 95°C followed by 40 cycles  polymerase activation  at 95°C for 15 seconds 
and 60°C extension for 60minutes using CFX96™ RT-PCR detection system (BioRad,UK). 
PCR primers and probe for IL-1α was designed using PRIMER express program (Perkin Elmer, 
PE Biosystems, Warrington UK). The probe had a fluorescent reporter dye, Carboxyfluorescein 
(FAM™) dye  attached to the 5’ end and was used to measure the fluorescence of the samples 
and an internal control 18s (VIC™) dye was included in the wells.  Each of the reporters was 
quenched by tetramethylrhodamine (TAMRA™) dye at the 3´end.  
 
Table 2.4: Real-time RT-PCR reaction mix (TaqMan); components and concentrations 
 
Reagents Stock concentration Final reaction concentration 
2× TaqMan mix 2× 1× 
Forward Primer 25μM 300nM 
Reverse primer 25μM 300nM 
Ribosomal 18s primers 1.25μM 18.75nM 
Target gene probe 5μM 200nM 
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2.10.5 Calculation of relative mRNA expression using the comparative Ct method 
The comparative Ct method is a mathematical model that calculates changes in gene expression 
as a relative fold difference between an experimental and calibrator sample [330]. In this study, 
the ΔΔCt method, also known as the Livak method [336] was used to determine relative mRNA 
expression of genes assayed. This method normalizes the expression of the target genes relative 
to a single reference gene and expressed relative to the reference sample [336]. Calculations 
adapted from Livak et al. (2001) are summarized below; 
ΔCt = Average Ct (target assay) - Average Ct (Reference assay) 
ΔΔCt = ΔCt (Test sample) - ΔCt (Reference sample) 
Relative quantification (RQ) = 2-ΔΔCt 
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Table 2.5: Primers and probes used for qRT-PCR 
Target gene  Sequence ( 5'-3') 
 
HCYP-A 
 
Forward primers 
 
 
CCCACCGTGTTCTTCGACAT 
 
 Reverse primers CCAGTGCTCAGAGCACGAAA 
GAPDH Forward primers AATGATTCATAGGGCTTCAG 
 Reverse primers ACAGTCAGCCGCATCTTC 
18s Forward primers CGGCTACCACATCCAAGGAA 
 Reverse primers GCTGGAATTACCGCGGCT 
 Probe (VIC) TGCTGGCACCAGACTTGCCCTC 
IL-1α Forward primers TGTATGTGACTGCCCAAGATGAA 
 Reverse primers CTACCTGTGATGGTTTTGGGTATC 
 Probe (FAM) CAGGCATCTCCTTCAGCAAGCACTGGTTG 
IL-1RI Forward primers TGGTGACTCCCTCCTGAGAAG 
 Reverse primers CAGCCTCCAGAGAAGAAATCAG 
IL-8 Forward primers CTGGCCGTGGCTCTCTTG 
 Reverse primers TTAGCACTCCTTGGCAAAACTG 
IL-12α Forward primers CGGTCATCTGCCGCAAA 
 
 Reverse primers TGCCCATTCGCTCCAAGA 
 
COX-1  Forward primers TGTTCGGTGTCCAGTTCCAATA 
 
 Reverse primers ACCTTGAAGGAGTCAGGCATGAG 
PTGFR Forward primers GCAGCTGCGCTTCTTTCAA 
 Reverse primers CACTGTCATGAAGATTACTGAAAAAAATAC 
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PTGIR 
 
Forward primers 
 
 
GCCCTCCCCCTCTACCAA 
 Reverse primers TTTTCCAATAACTGTGGTTTTTGT G 
CXCR4  Forward primers CAGTGGCCGACCTCCTCTT 
 
 Reverse primers CAGTTTGCCACGGCATCA 
CD4  Forward primers CTAAGCTCCAGATGGGCAAG 
 
 Reverse primers CACCACCAGGTTCACTTCCT 
CCR5  Forward primers AGCTATGCAGGTGACAGAGACTCTT 
 
 Reverse primers TCCCCGACAAAGGCATAGAT 
CCR2b  Forward primers TGCCTGACTCACACTCAAGG 
 
 Reverse primers GGCTTCTCAGCAACTGAACC 
CXCR6  Forward primers GGTTCTTCTTGCCACTGCTC 
 
 Reverse primers CATGAGGTTGAAGGGCATCT 
GPR1  Forward primers TTCTGCCCCTGTACATCTCC 
 
 Reverse primers AGAAGCCAAAAGCCAGATGA 
 
 
2.11 Protein extraction from cells 
For protein experiment, total protein was extracted from HeLa cells. Briefly, HeLa cells were 
seeded at a density of 5×105 cells in a 3cm TC dishes and cultured in complete media (2mL) 
overnight. The cells were lysed on ice by an addition of lysis buffer  (Table 2.6) (150mM NaCl, 
1% Triton X-100 (Sigma), 10mM Tris-HCL pH 7.4,  1mM  EDTA, 0.1% sodium diodecyl 
sulfphate (SDS), and containing cOmplete™, EDTA free protease inhibitor cocktail tablet 
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(chymotrypsin, thermolysin, papain, pronase,  pancreatic extract and trypsin  inhibitors)  
(Roche)) and cells scraped off with cell scraper (Griener Bio-One, Germany). The insoluble 
material was pelleted by centrifugation at 14000 rpm for 15 minutes at 4°C and the clarified 
lysate was transferred to a new tube and kept at -20 0C for further protein quantification.   
 
Table 2.6: Components of protein extraction buffer 
 
Reagents Concentration 
NaCl 150mM 
Triton X-100 1% 
Tris-HCl pH 7.4 10mM 
EDTA 1mM 
SDS 0.1% 
 
 
2.12 Protein quantification 
Protein concentrations were determined by using the Pierce® BCA Protein Assay Kit (Thermo 
scientific, Rockford, USA) as  directed by the manufacturer’s instructions. Bovine serum 
albumin (BSA) was used as a protein standard and diluted from 2000μg/mL to 0μg/mL in 100μL 
of distilled water in tubes. Aliquots of 25μL of standards or samples were loaded into a 96-well 
plate (in triplicate) followed by the addition of 200μL of working reagent (WR) (50 parts of 
BCA™ Reagent A with 1 part of BCATM Reagent B [50:1, Reagent A:B]) and plate was mixed 
thoroughly on a plate shaker for 30 seconds.  Thereafter, plate was covered and incubated at 37 
0C for 30 minutes followed by cooling at RT for 15 seconds. Absorbance was then measured at 
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wavelength of 595nm on Anthos Microplate Reader (Columbia Bioscience Inc, USA). A 
standard curve was plotted using the program Graphpad Prism® 5.0 and the unknown protein 
concentrations were determined from the standard curve. 
2.13 SDS-PAGE gel 
Protein samples were re-suspended in 1× SDS protein sample loading buffer (Table 2.7), loaded 
in 6% stacking (SDS-PAGE) gel and separated on a 15% sodium diodecylsulfphate poly 
acrylamide (SDS-PAGE) gel (Table 2.8). The gel is formed by the polymerization of two 
compounds, acrylamide and N,N-methylenebis-acrylamide (Bis) (BioRad). Briefly, a total of 20-
30μg of protein was re-suspended in SDS (1×) protein sample loading buffer (Table 2.7), heated 
at 95°C for 5 minutes to denature the protein and resolved on the 15% SDS–PAGE gel (Table 
2.8) at 100V. The relative sizes of the proteins were determined by a Spectra protein marker 
(Invitrogen). 
Table 2.7: SDS protein sample buffer (reagents and concentration) 
Reagents Concentration 
Glycerol 10% 
Tris-HCl pH 6.8 60mM 
SDS 2% 
Bromophenol blue  0.01% 
Beta-mercaptoethanol 1.25% 
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Table 2.8: SDS-PAGE (reagents, concentration, and volume pipetted) 
Reagents Concentration volume 
 
Separating gel (15%) 
  
Acrylamide (Biorad) 30% 12.5mL 
H2O - 3.65mL 
Tris pH 8.8 1.25M 8.3mL 
SDS 10% 0.25mL 
Ammonium persulfate (APS)  10% 0.3mL 
Tetramethylethylenediamine 
(TEMED) (Thermo Scientific) 
 
- 25μL 
Stacking gel (6%)   
Acrylamide (Biorad) 30%  
H2O - 5.075mL 
Tris pH 6.8 0.375M 4mL 
SDS 10% 0.125mL 
Ammonium persulfate (APS)  10% 0.3mL 
Tetramethylethylenediamine 
(TEMED) (Thermo Scientific) 
 
- 20μL 
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2.14 Western Blot 
The proteins were transferred onto a polyvinylidene difluoride (PVDF) membrane (GE Health 
Care, Amersham, UK) using a Novex® Semi-Dry Blotter (Invitrogen™). Three layers of 
chromatography paper (Lasec, Cape Town, RSA) were soaked briefly in transfer buffer (25mM 
Tris, 192mM glycine, 10% methanol) and stacked onto the anode plate of the Semi Dry blotter. 
The PVDF membrane cut to the dimension of the gel was activated in methanol for 1 minute, 
washed in water and equilibrated in transfer buffer before being stacked onto the 
chromatography paper. The SDS-PAGE gel was removed from the apparatus equilibrated in the 
transfer buffer and placed over the membrane. Additional three layers of wet (soaked in transfer 
buffer) chromatography paper were then placed over the gel and the Semi Dry blotter apparatus 
(Invitrogen™) was covered with the cathode plate, sealed and transferred at 14volts for 90 
minutes. After transfer, the PVDF membrane was washed in 20mL PBS-Tween (1× PBS and 
0.1%Tween-20) for 5 minutes. The membrane was then incubated in 10mL of blocking buffer 
(1× PBS, 0.1% Tween-20 with 5% w/v nonfat dry milk) on a shaker for 30 minutes at RT, after 
which it was washed three times for 10 minutes each with 15mL PBS-Tween followed by an 
overnight incubation with relevant primary antibody at 4 0C with gentle shaking. The following 
day, membrane was washed three times for 10 minutes each with 15mL of PBS-Tween, 
incubated for 1 hour with relevant horseradish peroxidase (HRP)-conjugated secondary antibody 
(1:5000) at RT and washed again three times with 15mL PBS-Tween as described  above. 
Protein detection was by chemiluminescence; membrane was incubated with SuperSignal® West 
Pico Chemiluminescent Substrate (ThermoScientific, Rockford, USA) (1mL of SuperSignal 
West Pico Luminol /Enhancer Solution and 1mL SuperSignal West Pico Stable Peroxide 
Solution) for 5 minutes at RT; excess developing solution was drained, placed in transparent film 
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and proteins viewed with BioSpectrumTM 500 Imaging System (Ultra-Violet Products [UVP] 
Limited, Cambridge, UK). 
 
2.15 Enzyme Linked Immunosorbent Assay (ELISA) 
Secreted IL-1α was measured by ELISA using Quantikine® Human IL-1α ELISA kit (R&D 
Systems, Minneapolis, USA) (Whitehead Scientific, Cape Town, South Africa). HeLa cells were 
seeded at a density of 5×105 in 3cm TC dishes with complete media and allowed to attach and 
grow overnight. The next day, complete media was aspirated, cells washed twice in PBS and 
incubated with serum free media for another 24 hours after which they were incubated for 16 and 
24 hours in the presence of SP (1:50), vehicle (PBS or DMSO)  in the absence/presence of 
chemical inhibitors. After the incubating period, protein was extracted and quantified as 
described above  using the Pierce® BCA Protein Assay Kit (Thermo scientific, Rockford, USA) 
(sections 2.11 and 2.12). The secreted IL-1α protein was determined from the total protein in the 
lysate using Quantikine® Human IL-1α ELISA kit (R&D Systems, Minneapolis, USA) as per the 
manufacturer’s instruction. Five independent experiments were conducted and data expressed as 
fold change over basal where the amount of IL-1α secreted in treated cells (experiment) is 
divided by the amount secreted in their respective controls.  
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2.16 Immunohistochemistry 
Immunohistochemistry was done on archival cervical blocks obtained from the Department of 
Anatomical Pathology, University of Cape Town. Briefly, sections were deparaffinized and 
rehydrated by immersing in xylene twice for 5 minutes, 100% ethanol twice for 5 minute, 95% 
ethanol for 5 minutes, 70% ethanol for 5 minutes, 50% ethanol for 5 minutes and rinsed with 
water. Antigen retrieval was done by pressure cooking for 2 minutes in 0.01M sodium citrate pH 
6. Sections were blocked for endogenous peroxidase by incubating with 3% Hydrogen peroxide 
in methanol on a rocker at RT for 30 minutes and then rinsed with water followed by 1× TBS 
(tris-buffered saline) (50mM Tris-HCl, 150mM NaCl at pH 7.4). Sections were blocked using 
5% normal donkey/goat serum diluted in TBS after which tissue sections were incubated with 
specific polyclonal primary antibodies at 4 0C for 18 hours. After incubation, tissue sections were 
then washed in TBS twice for 5 minutes each followed by incubation with biotinylated 
secondary IgG antibody at dilution of 1:500 at RT for 30 minutes. Tissue sections were then 
further incubated with streptavidin-biotin peroxidase complex (1:50) at RT for 30 minutes. 
Controls were incubated with biotinylated IgG secondary antibody only. Color reaction was 
developed by incubating with 3.3’-diaminobenzidine. Tissue sections were counterstained in 
aqueous hematoxylin, before mounting and coverslipping. Fluorescent images were visualized 
and photographed using a Carl Zeiss laser scanning microscope LSM 510 (Jena, Germany).  
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2.17 Quantification of immunohistochemical stains 
Quantification of immunohistochemical stains was done using image de-convolution (H-
DAB) and thresholding analysis on Fiji software (http://fiji.sc/Fiji) as described by Ruifrok and 
Johnston, 2001 and Viel et al., 2013 [337,338]. Briefly, images were opened on Fiji after which 
background was subtracted to correct for shadow or color effects. Images were then de-
convolved (H-DAB color de-convolution). The resulting blue and brown monochromes were 
converted to grayscale (8bit) thresholded and % area of staining measured in proportion to the 
size of the image /tissue. % DAB stained was calculated as follows; 
 
% DAB stain = % DAB stain         × 100 
                          % DAB + % H stain  
 
2.18 Statistics 
All data in this study were analyzed by t-test or one-way ANOVA using Graph Pad Prism 5.0 
software (GraphPad Software Inc., San Diego, CA). Paired T-tests were conducted on the 
untransformed means of the replicates between SP and control. Unpaired T-tests were performed 
on SP versus SP and inhibitor after conversion to fold increases. One-way ANOVA was used as 
an additional tool to determine the significant difference between various time points in genes 
expression by real-time PCR in response to SP.   
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CHAPTER 3 
REGULATION OF INFLAMMATORY PATHWAYS IN NEOPLASTIC CERVICAL 
EPITHELIAL CELLS BY SEMINAL PLASMA 
3.1 Introduction 
Inflammation is a complex process that involves a host of resident and recruited immune cell 
types working together to promote the removal of insult or injury and initiate tissue repair [80]. 
Many cancers including cancer of the cervix have been shown to develop as a consequence of 
persistent chronic inflammation [339].  
Characteristically regarded as response to tissue injury or pathogenic insult, chronic 
inflammation is typified by alterations to vascular, epithelial, and immune cell function [287]. 
These are coordinated by specific molecular inflammatory pathways involving numerous growth 
factors, cytokines, chemokines, receptors (GPCRs), enzymes, and lipid mediators which 
orchestrate tissue repair mechanism and alteration of endothelial and vascular function to 
promote angiogenesis, vascular permeability, and extravasation of immune cells to the inflamed 
tissue [80]. Over the last decade, numerous experimental studies using gene-disruption and gene 
over-expression systems in cell lines as well as studies on laboratory animals, and tissue explants 
have provided evidence to support the role of inflammation and inflammatory pathways such as 
the COX-PG in cervical cancer pathogenesis and progression [28,312,340-342]. These pro-
inflammatory pathways have been discovered to be induced by various stimuli such as 
endogenous growth factors, cytokines, tumor promoting carcinogens, and lipopolysaccharides 
(LPS) [130]. 
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Human seminal plasma is a complex organic fluid comprising of numerous endogenous 
antigenically distinct molecules [307,343]. Some of which have been implicated in the initiation 
of inflammatory response and activation of specific inflammatory pathways. Furthermore, 
studies have shown that the exposure of the cervical epithelium to seminal plasma as seen during 
unprotected sexual intercourse can further modify the inflammatory milieu of the cervix in 
sexually active women [344-346]. In addition, studies by Sales et al. (2002), Muller et al. (2006), 
and Sutherland et al. (2012) demonstrated the pro-inflammatory role of seminal plasma on 
neoplastic cervical epithelium. These studies reveal that seminal plasma can promote cancer cell 
proliferation by inducing the expression of angiogenic genes and pro-inflammatory 
cytokines/chemokines via the activation of inflammatory pathways including COX-PGs, EGFR-
ERK 1/2, and NF-κB pathways [287,345,346]. 
The discovery of these pathways led to the hypothesis that the human seminal plasma can 
augment cervical tumorigenesis by regulating the expression of a wide range of inflammatory 
pathways that are yet to be identified.   
 
3.2 Aim of the study 
This present study was designed to investigate gene arrays of inflammatory pathways that can be 
regulated by SP in neoplastic cervical epithelial cells, as a model to identify pro-inflammatory 
genes that exacerbate neoplastic cervical inflammation and promote tumorigenesis in response to 
SP.    
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3.3 Materials and Method 
3.3 Cell culture, treatment with seminal plasma and RNA extraction 
HeLa S3 cells were routinely maintained as previously described in section 2.6. HeLa cells were 
seeded in complete medium at density of 2x105 cells in 3 cm diameter tissue culture dishes and 
allowed to attach and grow overnight. The following day, the complete medium was aspirated 
and cells were serum starved by incubating in serum free medium as described in section 2.6 for 
24 hours. Cells were then treated with serum free media containing SP at a dilution of 1:50 or 
serum free media with PBS (control) for 8hrs (n = 5 individual experiment done in duplicate). 
RNA was extracted as described in section 2.8 and reverse transcribed as described in section 
2.9. For the array, the 5 individual experiments were pooled together. 
  
3.3.2 Quantitative real time PCR and Taqman array analysis. 
qRT-PCR was performed to investigate the expression of inflammatory genes and chemokines 
using the TaqMan® Array 96-Well Plate (Human inflammation) and TaqMan® Array 96-Well 
Plate (Human Chemokines) (Applied Biosystems, USA). The reaction was conducted on a Bio-
Rad CFX96TM quantitative RT-PCR machine (Bio-Rad Laboratories Ltd.) under normal 
operating conditions. Relative expression was calculated using the comparative Ct method  (as 
described in section 2.10.5) and arrays were normalized for RNA loading using 18s Ribososmal 
RNA, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Hypoxanthine 
phosphoribosyltransferase 1(HPRT1), and Glucuronidase beta (GUSB) as internal controls. The 
array experiment was conducted once on pooled cDNA samples (n = 5).  
 89 
 
3.3.3 Bioinformatics analysis of genes regulated by seminal plasma 
Approved names and symbols of all genes were obtained from HGNC (HUGO Gene 
Nomenclature Committee) (www.genenames.org/data/hgnc_data). NCBI (The National Center 
for Biotechnology Information) Accession number for all genes was obtained from 
www.ncbi.nlm.nih.gov. Genes were classified into pro and anti-inflammatory based on 
description obtained from OMIM® (Online Mendelian Inheritance in Man®) 
(http://www.omim.org). Gene List Analysis, a web tool from PANTHER (Protein ANalysis 
THrough Evolutionary Relationships) classification system (www.pantherdb.org) was assigned 
to classify seminal plasma regulated genes into molecular functions, biological process, protein 
class and pathways [347,348].  
 
3.3.4 Verification of the TaqMan Array Data 
3.3.4.1 Treatment of Cells with Seminal plasma 
With the aim of validating the temporal expression of SP regulated genes as seen in the TaqMan 
array,  2 × 105 HeLa cells were treated with vehicle (PBS) or SP (1:50) for 4, 8, 16 and 24 hrs as 
described in section 2.7.1. The cells were then harvested using 1ml Trizol® (Sigma) and their 
RNA extracted immediately or stored at -80°C until further use. The experiments were repeated 
individually for n = 5 times.  
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3.3.4.2 Quantitative real time PCR Analysis 
qRT-PCR was performed on an Eco™ Real time PCR system (Illumina™) to detect the 
expression of IL-1α, IL-8, IL-12α, PTGIR, PTGFR, and CXCR4 genes respectively as described 
in section 2.10.3. To normalize the gene of interest, a reaction mix containing glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) primers and corresponding cDNA samples was included in 
the experiment to serve as an internal reference control.  
To further validate/compare the results obtained from the SYBR Green RT-PCR, a TaqMan RT-
PCR was also performed for IL-1α, using TaqMan® on a CFX96™ RT-PCR detection system 
(BioRad, UK) as described in section 2.10.4. The relative mRNA expression was calculated 
using the comparative Ct method (section 2.10.5) and data represented on a bar chart as fold 
above control.  
 
3.3.5 Statistical Analysis   
All data are presented as mean ± SEM. Statistical significant differences were determined by t-
test (non-parametric) using Graph Pad Prism 5.0 software (GraphPad Software Inc., San Diego, 
CA). Paired T-test or Wilcoxon matched pair test were conducted on the untransformed means of 
the replicates between SP and control (*, p < 0.05; **, p < 0.01; ***, p < 0.001). One-way 
ANOVA was used as an additional tool to determine the significant difference between various 
time points of IL-1α, IL-8, IL-12α, PTGIR, PTGFR, and CXCR4 gene expression by real-time 
RT-PCR in response to SP. 
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3.4 RESULTS 
 3.4.1 Seminal plasma regulates the expression of inflammatory pathways in cervical cancer 
cells 
TaqMan® 96 well gene expression array (Human inflammation and Chemokines) was used to 
investigate the role of seminal plasma in the regulation of inflammatory genes/pathways that can 
augment cancer cell progression. Neoplastic cervical epithelial cells (HeLa) were treated with 
PBS (control) or 1:50 dilution of seminal plasma for duration of 8 hours and RNA subjected to 
reverse transcription and TaqMan array analysis. Expression was considered significant based on 
a fold change of 2 fold or more above control as a cut-off point [349]. Of the 181 (3 genes 
duplicated in both plates) genes analyzed, seminal plasma regulated the expression of 95 genes. 
Of these, 44 genes were significantly up-regulated (fold change ≥ 2), 35 genes were down 
regulated (fold change <1), and 16 genes were not significantly up-regulated (fold change ≥1<2). 
86 genes were not detected (ND) (Appendix I). Fold induction of some important pro-
inflammatory genes regulated by seminal plasma are as follows: pro-inflammatory enzyme 
cyclooxygenase-1 (COX-1) (2.43 fold); inflammatory cytokines/chemokines such as IL-6 (fold 
change 4.19), IL-8 (38.93 fold), CXCL1 (GRO-α) (12.37 fold), TNF (26.55 fold) and IL-1α 
(68.56 fold); GPCRs such as Prostaglandin F receptor (PTGFR) (20.21 fold), Prostaglandin I2 
receptor (PTGIR) (7.22 fold); immune cell chemotactic and activating factors such as CCL2 
(monocyte chemotactic and activating factor) (4.43 fold), CCL5 (eosinophil chemotactic 
cytokine) (5.24 fold); and genes involved in the modulating inflammatory responses/ 
transcription factor such as Nuclear factor κ B (NF-κB) (2.32 fold) and TLR2 ( Toll like receptor 
2) (88.47 fold). The list of the genes regulated by seminal plasma, their inflammatory properties 
(i.e. pro or anti-inflammatory) and the fold increase/decrease are mentioned in table 3.1.  
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Table 3.1: List of inflammatory genes regulated by seminal plasma in HeLa cells 
Accession 
number 
Gene 
symbol 
Gene description Inflammatory 
properties 
Fold 
change 
RECEPTORS 
NM_000684 ADRB1 Adrenergic, beta-1-, receptor Pro-inflammatory 1.50 
NM_000024 ADRB2  Adrenergic, beta-2-, receptor Pro-inflammatory 0.64 
NM_000710 BDKRB Bradykinin receptor B1 Pro-inflammatory 22.39* 
NM_000623 BDKRB2 Bradykinin receptor B2 Pro-inflammatory 1.63 
NM_006639 CYSLTR1 Cysteinyl leukotriene receptor 1 Pro-inflammatory 150.14* 
NM_001008540 CXCR4 Chemokine (C-X-C motif) receptor 4 
  
Pro-inflammatory 1.67 
NM_000861 HRH1 Histamine receptor H1 Pro-inflammatory 
(binds to Th1) 
1.39 
NM_000869 HTR3A 5-hydroxytryptamine (serotonin) 
receptor 3A 
Pro-inflammatory 1.82 
NM_000416 IFNGR1 Interferon gamma receptor 1 Pro-inflammatory 1.03 
NM_000877 IL1R1 Interleukin 1 receptor, type I Pro-inflammatory 1.24 
NM_016232 IL1RL1 Interleukin 1 receptor-like 1 Pro-inflammatory 22.65* 
NM_004633 IL1R2 Interleukin 1 receptor, type II Anti-
inflammatory 
(inhibit IL-1 
activity) 
0.20 
NM_000206 IL2RG Interleukin 2 receptor, gamma Pro-inflammatory 
(required for T 
cell maturation) 
0.01 
NM_001143919 LTB4R Leukotriene B4 receptor Pro-inflammatory 4.27* 
NM_000529  MC2R Melanocortin 2 receptor Pro-inflammatory 6.52* 
NM_000176 NR3C1 Nuclear receptor subfamily 3, group C, 
member 1 
Pro-inflammatory 0.84 
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NM_000952 PTAFR Platelet-activating factor receptor Pro-inflammatory 0.09 
NM_000956 PTGER2 Prostaglandin E receptor 2 (subtype 
EP2) 
Pro-inflammatory 0.80 
NM_000959 PTGFR Prostaglandin F receptor (FP) Pro-inflammatory 20.21* 
NM_000960 PTGIR Prostaglandin I2  receptor (IP) Pro-inflammatory 7.22* 
NM_001060 TBXA2R Thromboxane A2 receptor Pro-inflammatory 0.96 
NM_001066 TNFRSF1B Tumor necrosis factor receptor 
superfamily, member 1B 
Pro-inflammatory 2.70* 
NM_001065 TNFRSF1A Tumor necrosis factor receptor 
superfamily, member 1A  
Pro-inflammatory 3.16* 
NM_003264 TLR2 Toll-like receptor 2  Pro-inflammatory 88.47* 
NM_138554 TLR4 Toll-like receptor 4  Pro-inflammatory 1.66 
ENZYMES 
NM_000698 ALOX5 Arachidonate 5-lipoxygenase Pro-inflammatory 0.88 
NM_033292 CASP1 Caspase 1, apoptosis-related cysteine 
peptidase  
Pro-inflammatory 0.66 
NM_001266 CES1 Carboxylesterase 1 
(monocyte/macrophage serine esterase 
1) 
 3.97* 
NM_000860 
  
HPGD  Hydroxyprostaglandin dehydrogenase 
15-(NAD) 
 Anti-
inflammatory 
(degrades PGs) 
0.32 
NM_004972  JAK2 Janus kinase 2  Pro-inflammatory 1.72 
NM_002257 KLK1 Kallikrein-related peptidase 1 Pro-inflammatory 0.64 
NM_001002231 KLK2 Kallikrein-related peptidase 2 Pro-inflammatory 19.59* 
NM_001030047 KLK3 Kallikrein-related peptidase 3 Pro-inflammatory 34.58* 
NM_022046 KLK14 Kallikrein-related peptidase 14 Pro-inflammatory 2.53* 
NM_000892 KLKB1 Kallikrein B, plasma (Fletcher factor) 1 Pro-inflammatory 1.73 
NM_000897 LTC4S Leukotriene C4 synthase Pro-inflammatory 10.03* 
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NM_002745  MAPK1 Mitogen-activated protein kinase 1 Pro-inflammatory 0.72 
NM_001040056 MAPK3 Mitogen-activated protein kinase 3 Pro-inflammatory 0.52 
NM_002750  MAPK8 Mitogen-activated protein kinase 8 Pro-inflammatory 0.83 
NM_001315   MAPK14 Mitogen-activated protein kinase 14 Pro-inflammatory 0.67 
NM_002468 MYD88 Myeloid differentiation primary 
response gene (88)  
Pro-inflammatory 9.41* 
NM_001111307 PDE4A Phosphodiesterase 4A Anti-
inflammatory 
(regulates cellular 
conc. Of cAMP) 
0.52 
NM_002600 PDE4B Phosphodiesterase 4B Anti-
inflammatory  
0.42 
NM_001165899 PDE4D Phosphodiesterase 4D Anti-
inflammatory 
0.52 
NM_000928 PLA2G1B Phospholipase A2, group IB (pancreas) Pro-inflammatory 0.89 
NM_000300 PLA2G2A Phospholipase A2, group IIA Pro-inflammatory 3.00* 
NM_001168357 PLA2G7 Phospholipase A2, group VII  Pro-inflammatory 0.005 
NM_001159322 PLA2G4C Phospholipase A2, group IVC 
(cytosolic, calcium-independent) 
Pro-inflammatory 0.42 
NM_003561 PLA2G10 Phospholipase A2, group X Pro-inflammatory 46.32* 
NM_000932 PLCB3 Phospholipase C, beta 3 
(phosphatidylinositol-specific) 
Pro and Anti-
inflammatory 
0.40 
NM_000933 PLCB4 Phospholipase C, beta 4 Pro-inflammatory 2.82* 
NM_001130964 PLCD1 Phospholipase C, delta 1 Pro-inflammatory 0.21 
NM_182811 PLCG1 Phospholipase C, gamma 1 Pro-inflammatory 29.05* 
NM_002661 PLCG2 Phospholipase C, gamma 2 
(phosphatidylinositol-specific) 
Pro-inflammatory 0.85 
NM_016341 
   
PLCE1 Phospholipase C, epsilon 1 Pro-inflammatory 6.71* 
NM_000962 PTGS1 Prostaglandin-endoperoxide synthase 1  Pro-inflammatory 2.43* 
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NM_000963 PTGS2 Prostaglandin-endoperoxide synthase 2  Pro-inflammatory 0.53 
NM_001061 TBXAS1 Thromboxane A synthase 1  Pro-inflammatory 0.63 
NM_001953 TYMP Thymidine phosphorylase  Pro-inflammatory 3.22* 
LIGANDS 
NM_000700 
   
ANXA1 Annexin A1 Anti-
inflammatory 
(inhibit 
phospholipase 
A2) 
0.15 
NM_005139 
   
ANXA3 Annexin A3 Anti-
inflammatory 
0.29 
NM_001154 
   
ANXA5 Annexin A5 Anti-
inflammatory 
0.00031 
NM_000074 
   
CD40LG CD40 ligand  Pro-inflammatory  18.69* 
NM_013246 
   
CLCF1 Cardiotrophin-like cytokine factor 1 Pro-inflammatory 1.46 
NM_001735  C5 Complement component 5  Pro-inflammatory 2.14* 
NM_002982 CCL2 Chemokine (C-C motif) ligand 2  Pro-inflammatory 4.43* 
NM_002985 CCL5 Chemokine (C-C motif) ligand 5  Pro-inflammatory 5.24* 
NM_052999 CMTM1 CKLF-like  MARVEL transmembrane 
domain containing 1  
Pro-inflammatory 3.15* 
NM_001511 CXCL1 Chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating activity, 
alpha)  
Pro-inflammatory 12.37* 
NM_002089 CXCL2 Chemokine (C-X-C motif) ligand 2  Pro-inflammatory 0.49 
NM_002090 CXCL3 Chemokine (C-X-C motif) ligand 3  Pro-inflammatory 8.19* 
NM_005409 CXCL11 Chemokine (C-X-C motif) ligand 11  Pro-inflammatory 2.47* 
NM_000201 ICAM1 Intercellular adhesion molecule 1 
(CD54) 
Pro-inflammatory 
(mediates 
leukocytes 
adhesion) 
3.82* 
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NM_000632 ITGAM Integrin, alpha M (complement 
component 3 receptor 3 subunit) 
Pro-inflammatory 
(mediates 
leukocytes 
adhesion) 
4.78* 
NM_002211 ITGB1 Integrin, beta 1 (fibronectin receptor, 
beta polypeptide) 
Pro-inflammatory 1.02 
NM_000211 ITGB2 Integrin, beta 2 (complement 
component 3) 
Pro-inflammatory 0.61 
NM_000575 IL1A Interleukin 1, alpha  Pro-inflammatory 68.56* 
NM_017416 IL1RAPL2 Interleukin 1 receptor accessory 
protein-like 2 
Pro-inflammatory 5.64* 
NM_000600 IL6 Interleukin 6 (interferon, beta 2)  Pro-inflammatory 4.19* 
NM_000584 IL8 Interleukin 8  Pro-inflammatory 38.93* 
NM_000882 IL12A Interleukin 12A (natural killer cell 
stimulatory factor 1, cytotoxic 
lymphocyte maturation factor 1, p35)  
Anti-
inflammatory 
2.36* 
NM_002188 IL13 Interleukin 13 Pro-inflammatory 1.39 
NM_001562 IL18 Interleukin 18 (interferon-gamma-
inducing factor)  
Pro-inflammatory 17.84* 
NM_002468 MYD88 Myeloid differentiation primary 
response gene (88)  
Pro-inflammatory 9.41* 
NM_001165412 NFKB1 Nuclear factor of kappa B1 Pro-inflammatory 2.32* 
NM_004787 SLIT2 Slit homolog 2 (Drosophila)  Anti-
inflammatory 
3.63* 
NM_014011 SOCS5 Suppressor of cytokine signaling 5  Anti-
inflammatory 
0.00047 
NM_139276 STAT3 Signal transducer and activator of 
transcription 3  
Pro-inflammatory 0.86 
NM_000594 TNF Tumor necrosis factor (TNF 
superfamily, member 2)  
Pro-inflammatory 26.55* 
NM_001190942 TNFSF10 Tumor necrosis factor (ligand) 
superfamily, member 10  
Pro-inflammatory 1.91 
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NM_001145645 TNFSF13B Tumor necrosis factor (ligand) 
superfamily, member 13b 
Pro-inflammatory 4.83* 
CALCIUM CHANNELS 
NM_000722 CACNA2D1 Calcium channel, voltage-
dependent, alpha 2/delta subunit 1 
 0.73 
NM_000724 CACNB2 Calcium channel, voltage-
dependent, beta 2 subunit 
 0.28 
NM_000726 CACNB4 Calcium channel, voltage- 
dedependent, beta 4 subunit 
 0.51 
 
*, Fold change ≥ 2. 
 
 
 
3.4.2 Ontologies of genes regulated by seminal plasma 
The PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification System 
was designed to classify proteins (and their genes) in order to facilitate high-throughput analysis. 
PANTHER uses the Gene OntologyTM for classifications by molecular function, biological 
process and cellular component. The PANTHER Protein Class ontology was adapted from the 
PANTHER/X molecular function ontology, and includes commonly used classes of protein 
functions, many of which are not covered by GO molecular function. Molecular function is the 
function that a protein performs on its direct molecular targets; e.g. the insulin receptor has 
transmembrane receptor tyrosine protein kinase activity, which means it catalyzes the reaction 
that adds a phosphate group to a tyrosine in another protein (its target). Cellular component is the 
location where the protein performs its molecular function; e.g. the insulin receptor is located in 
the plasma membrane. Biological process covers the biological systems to which a protein 
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contributes; e.g. the insulin receptor is involved in regulation of carbohydrate metabolic process. 
Pathway is similar to biological process, but a pathway also explicitly specifies the relationships 
between the interacting molecules (www.pantherdb.org) (www.geneontology.org). All the 95 
genes regulated by seminal plasma were subjected to PANTHER Gene List Analysis. 
Application of gene ontology annotation for molecular function showed that the top three 
enriched categories were binding activity (receptor or calcium ion binding) 37 genes (38.9%), 
receptor activity (GPCRs, cytokine receptor and TNF receptors) 35 genes (36.8%), and enzyme 
catalytic activity (hydrolases, oxidoreductase or tranferase) 34 genes (35.7%) (Appendix IIA). 
Similarly, application of gene ontology term  “biological processes” revealed that SP-regulated 
genes regulates three major biological processes namely; cellular process (cell adhesion, cell 
communication, cell cycle, cell motion, and cellular component organization) 82 genes (86.3%), 
cell communication (cell-cell signaling and signal transduction) 78 genes (82.1%), and immune 
system processes (immune response and macrophage activation) 67 genes (70.5%) (Appendix 
IIB). Other important biological processes regulated by these genes include apoptosis, cell cycle 
and response to stimulus (Appendix IIB). Further analysis with PANTHER protein classification 
grouped seminal plasma regulated genes into two major classes; receptor (GPCRs and cytokine 
receptors) 31 genes (32.6%) and signaling molecule (cytokines) 28 genes (29.4%) (Appendix 
IIC). PANTHER pathway classification revealed one major enriched pathway for SP-regulated 
genes, which is inflammation mediated by chemokine and cytokine signaling pathway 
(comprising of chemokine signaling, cyclooxygenase and lipooxygenase signaling [Eicosanoid 
signaling], NFκB signaling, cytokine receptor signaling, SOCS5, Janus kinase signaling, and 
interleukin 2 signaling) 29 genes (30.5%) (Appendix IID). 
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3.4.3 Real-Time RT-PCR Validation of IL-1α, IL-8, IL-12A, PTGIR, PTGFR, and CXCR4 
gene expression in response to SP in HeLa S3 Cells 
To validate the results obtained from TaqMan 96 array experiment, qRT-PCR was carried out on 
cDNA samples from HeLa cells treated with vehicle or SP (1:50) for a duration of 4, 8, 16, and 
24 hrs, respectively and the mRNA expression of IL-1α (Figure 3.1 A and B), IL-8 (Figure 3.1 
C), IL-12α (Figure 3.1 D), PTGIR (Figure 3.1 E), PTGFR (Figure 3.1 F), and CXCR4 (Figure 
3.1G) was determined.  
In keeping with the result obtained from the TaqMan 96 array, IL-1α mRNA was found to be 
significantly induced or up-regulated at all time points investigated in both SYBR Green and 
TaqMan reporter dye (Figure 3.1 A and B; P < 0.05). IL-8 mRNA expression was significantly 
induced at 4, 8, and 16 hrs (Figure 3.1C; P < 0.05, P < 0.01, P < 0.001), while IL-12α mRNA 
expression was significantly induced at all-time point investigated except for 16 hrs (Figure 3.1 
D; P < 0.05, P < 0.01). PTGIR mRNA expression displayed a time-dependent increase which 
peaked at 24 hrs treatment (Figure 3.1 E; P < 0.05). PTGFR mRNA expression was significantly 
up-regulated at 4, 8, and 16 hrs respectively (Figure 3.1 F; P < 0.05, P < 0.01). While CXCR4 
mRNA showed no significant increase in expression at all time point investigated (Figure 3.1 G), 
this also in keeping with the result obtained from the TaqMan array experiment.   
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Figure 3.1: Relative mRNA  expression of (A) IL-1α (SYBR Green reporter),  (B) IL-1α 
(TaqMan reporter),  (C)  IL-8, (D) IL-12α, (E) PTGIR, (F) PTGFR, and (G) CXCR4 in HeLa 
cells treated with PBS (control) or SP 1:50 dilution for 4, 8, 16, or 24 hrs as determined  by qRT-
PCR. Data are presented as mean ± SEM from five independent experiments. *, **, and *** 
represents significance at P < 0.05, P < 0.01, and P < 0.001. 
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3.5 Discussion 
Inflammation involves tissue remodeling events which acts across multiple cellular 
compartments in the face of infection or injury or insult in order to regulate homeostasis [350]. It 
has been estimated that chronic inflammation accounts for about more than 25% of all new 
cancer cases globally [75,351].   
Although persistent infection with high risk HPV has been identified as the single most 
important risk factor for cervical cancer, other factors including multiple sexual partners have 
been attributed to the etiology of this disease. Several studies have shown that seminal plasma 
can mount inflammatory response in the cervix [285,352]. Furthermore lipid components of 
seminal plasma can be reabsorbed into the vaginal fornix or local tissues [353], where they can 
regulate tissue remodeling processes in an autocrine or paracrine manner [285]. Few studies have 
reported on the role of seminal plasma in the regulation of inflammatory pathways in cervical 
cancer cells. Hence I investigated the role of seminal plasma in the regulation of arrays of 
inflammatory pathways and genes using the TaqMan-Array 96-well plate (human inflammation 
and human chemokines).  
As highlighted in table 3.1, the gene array analysis revealed 95 genes that are regulated by 
seminal plasma. Analysis of the gene list for Gene Ontology and PANTHER pathway 
annotations indicated functions in catalytic activity, receptor activity, cellular processes, immune 
system process and inflammatory pathway.  
 
 
 103 
 
Interestingly, inflammation mediated by chemokine and cytokine-cytokine receptor signaling 
pathway was identified as the major pathway significantly regulated by these genes. Further 
analysis thus reveals that components of this pathway can be grouped into 3 signaling cascades 
namely; eicosanoid signaling (cyclooxygenase and lipooxygenase), chemokine signaling, and 
cytokine-cytokine receptor signaling. Other pathways shown to be regulated by SP include toll 
receptor signaling pathway, kallikrien-kinin-bradykinin receptor signaling pathway, integrin 
signaling pathway, interferon-gamma signaling pathway, JAK/STAT signaling pathway. 
 
Regulation of eicosanoid signaling 
Eicosanoids, including prostaglandins and leukotrienes, are biologically active lipids that have 
extensively been implicated in inflammation and cancer [354]. It has been documented that 
altered metabolism of arachidonic acid by cyclooxygenase (COX) and lipoxygenase (LOX) 
enzymes is a common feature of several epithelial-derived malignancies and it plays a central 
role in cancer progression [354].  
COX exist in two isoforms; COX-1 (PTGS-1) and COX-2 (PTGS-2) and both catalyzes the 
oxygenation and reduction of arachidonic acid (AA) after its release from glycerophospholipids 
by phospholipase A2 (PLA2) or phospholipase C (PLC) to  the intermediate form prostaglandin 
H2 (PGH2). COX-2 is an immediate early response gene that is naturally absent in most cells in 
health but can be rapidly induced at site of inflammation [133]. COX-1 is considered to be a 
housekeeping gene responsible for the maintenance of basal prostanoid levels required for tissue 
homeostasis [355-357]. However, evidence show that both enzymes and their products are up-
regulated in numerous cancers including cervical cancer where they play vital roles in cervical 
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tumorigenesis [28,312,358]. Similarly, COX-1 expression is up-regulated in breast cancer [359], 
prostate cancer [360], ovarian cancer [361], and murine models of lung tumorigenesis [362]. In 
addition, COX-1 expression can be induced in vitro by tobacco carcinogens [363], VEGF [364], 
arachidonic acid and PGE2 [365]. As depicted schematically in figure 3.2, data obtained from 
this study shows that SP significantly induce the expression of COX enzyme (COX-1) (Figure 
3.2). 
 
Figure 3.2: Schematic diagram showing the regulation of eicosanoid biosynthesis pathway by 
SP in neoplastic cervical epithelial cell as means of mediating cervical cancer progression.  
↑; Up-regulated genes, ↓; down-regulated genes, ┬; direct inhibition, →; direct stimulation 
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This is in agreement with similar study by Sutherland et al. (2012) where it was shown that SP 
induces the expression of COX-1 in neoplastic cervical epithelial cells (HeLa) [287]. A major 
metabolite of COX-1 enzyme is PGs. PGs can modulate tumor cell proliferation, differentiation, 
and apoptosis through multiple signaling pathways in both autocrine and paracrine manner [354]. 
PGE2 biosynthesis and signaling are significantly elevated in cervical cancer [287,345,350], and 
in lung and colon cancer, PGE2-EP signaling has been shown to promote proliferation by 
activating the glycogen synthase kinase-3β (GSK3β)-β catenin and Ras-ERK pathways 
[157,366,367]. In ApcMin/+ mice, PGE2-EP signaling promote colon tumor cell survival by 
activating the PI3K-Akt-PPARδ cascade [368]. Furthermore, data from this study shows that SP 
induces FP receptor expression to potentiate PGF2α-FP signaling as shown schematically in 
figure 3.2. PGF2α-FP signaling has been shown to induce cell proliferation through an FP-ERK-
fibroblast growth factor 2(FGF-2)-FGF receptor 1(FGFR1)-ERK cascade in endometrial tumor 
cell lines [369]. Similarly, Wallace et al. (2009) demonstrated that PGF2α-FP signaling regulates 
the expression of the chemokine CXCL1 (GRO α) a potent tumor growth factor [370]. Hence in 
sexually active women with underlying cervical pathology, exposure to seminal plasma can lead 
to the activation of the COX-PGs signaling pathway consequent of COX-1 induction. Activated 
COX-PGs pathway can then promote both PGE2-EP and PGF2α-FP signaling which can act in 
similar manner to enhance cervical inflammation and tumorigenesis. 
In addition to regulating inflammatory and pro-tumorigenic pathways, SP can also potentially 
regulate inflammation and tumor progression by inhibiting negative feedback regulators or 
inhibitory/anti-inflammatory pathways. The release of AA by phospholipase A2 is negatively 
regulated by annexin (encoded by ANXA 1-5), a group of cellular proteins known to inhibit 
cPLA2 activity [371]. The gene array showed that SP inhibited annexin expression (Table 3.1). 
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By inhibiting annexin expression and up-regulating phospholipase A2 expression (Figure 3.2), 
SP ensures steady and continuous release of AA metabolite into the cascade for PGH2 synthesis, 
thereby driving inflammatory pathways and potentially enhancing tumor progression, by 
enhancing biosynthesis of PGE2, PGF2α, PGI2 [137,138,354].  
Furthermore in addition to production of PGs, prolongation of pathways that prevent their 
destruction or metabolism can also prolong inflammation by enhancing ligand receptor 
interaction. Prostanoids, such as PGE2, are metabolized through oxidation of their 15(S)-
hydroxyl group by NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH, encoded 
by HPGD) to inactive 15-keto products [372-374]. 15-PGDH is a cytosolic enzyme that has been 
reported to act as bladder, breast, gastric, lung and colorectal tumor suppressor [375-380]. In 
immunodeﬁcient mice, 15-PGDH inhibits the development of murine intestinal neoplasia 
[380,381]. These ﬁndings supported with the fact that 15-PGDH expression is abolished in 
various cancers [373,382], emphasize the oncogenic potential of the PG biosynthesis pathway. In 
the array, I found that SP suppressed HPGD expression. This can lead to reduction in PGE2 
degradation and enhanced oncogenic properties of the PGE2 in cervical tumorigenesis.  
Taken together, my data has highlighted that SP can potentially enhance cervical cancers by not 
only enhancing pro-inflammatory and pro-tumorigenic lipid signaling pathway, but also by 
concomitantly altering the expression of enzyme systems and pathways that inhibit production 
and metabolism of these pathways, thereby driving inflammation forward.  
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The gene array identified not only prostaglandins, but also leukotrienes as being regulated by SP. 
Leukotrienes are powerful lipid mediators of inflammation in various acute and chronic 
inflammatory diseases [383,384]. Compared with PGs, much less is known about the role of pro-
inflammatory leukotrienes in cancer [354]. However, emerging data suggest that leukotrienes 
can play vital roles in carcinogenesis [354]. Data from this present study shows that SP induces 
the expression of leukotriene C4 synthase (LTC4S), cysteinyl leukotriene receptor 1 (CysLT1), 
and leukotriene B4 receptor 1 (BLT1) (Table 3.1 and figure 3.2).   
LTC4S is a membrane protein that functions as a non-covalent homodimer of two 18-kDa 
polypeptides. LTC4S catalyzes the conjugation of leukotriene A4 (LTA4) with gluthathione 
(GSH) to form leukotriene C4 (LTC4), the parent compound of the cysteinyl leukotrienes 
(CysLTs) (LTC4, LTD4, LTE4) [385]. CysLTs exert their biological activity by binding to two 
distinct CysLTs receptor (CysLT1 or CysLT2), both belonging to the G-protein-coupled receptor 
(GPCR) superfamily [386,387]. Though, CysLT1 has been shown to have higher affinity to bind 
to CysLTs than CysLT2 [354].  
CysLTs-CysLT1 cascade has been confirmed to be involved in the pathophysiology of 
inflammatory disease such as bronchial asthma where it activate NF-κB to induce RANTES 
(Regulated on Activation, Normal T cell Expressed and Secreted) production, causing the 
migration of eosinophils and activated T lymphocytes into the airway [388]. CysLTs-CysLT1 
signaling has been suggested to play an important role in carcinogenesis. For example, in human 
colorectal and prostate cancer, CysLTs-CysLT1 signaling has been shown to mediate 
proliferation and inhibit apoptosis, thus conferring poor prognosis [389,390]. It is likely that 
CysLTs-CysLT1 signaling could regulate cervical cancer via similar mechanisms.  
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Similarly, in non-transformed human intestinal epithelial cell lines, LTD4-CysLT1 cascade was 
shown to promote cell proliferation and survival through multiple parallel pathways such as 
GSK3β-β catenin, PKC-Raf-ERK1, ERK2, BCL-2, and COX-2 pathways [391-393]. CysLTs 
(LTD4) induction of COX-2, as well as PGE2 production, do suggests that crosstalk exists 
between the LOX and COX pathways.  
Leukotriene B4 receptor 1 (BLT1); a G-protein coupled receptor (GPCR) is a high-affinity 
receptor specific for LTB4 [394]. LTB4 is a potent chemoattractant and pro-inflammatory 
mediator in several inflammatory diseases including atherosclerosis, where LTB4-BLT1 
signaling cascade has been shown to phosphorylate MAPKs and stimulate NF-κB dependent 
inflammation [395]. However, data from several studies have emerged to support the role of 
LTB4-BLT1 in tumorigenesis [396,397]. LTB4-BLT1 cascade has been shown to stimulate cell 
proliferation and promote cell survival through a LTB4-BLT1-Erk pathway in colonic tumor cell 
[398]. Similarly, by activating both Mek-Erk and PI3K-Akt pathways, LTB4-BLT1 signaling 
induces cell proliferation in pancreatic cancer cell lines [399]. Taken together, these data suggest 
that deposition of seminal plasma within the cervical cancer microenvironment can activate the 
CysLTs-CysLT1 and LTB4-BLT1 signaling pathways to induce inflammatory reactions which 
could promote cervical tumorigenesis via similar mechanisms.  
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Regulation of Kallikrien-kinin-bradykinin 
Additional data from this study shows that SP induces the expression of kallikrein-related 
peptidases (KLKs) which belong to a subgroup of secreted serine proteases [400]. KLKs 
catalyzes several physiological processes, including tissue remodeling, apoptosis, coagulation 
and immune responses within the human body [401]. To date, about 15 members KLKs (i.e. 
KLK 1-15) have been discovered, most of which have been labeled as potential biomarkers for 
cancer diagnosis and/or prognosis [401]. Despite the significant progress in understanding the 
biomarker efficacy of the KLKs, their pathophysiological role in inflammation and cancer 
pathogenesis remains poorly understood. Emerging evidences designate a possible role for KLKs 
in inflammation and various cancer processes [401].  
KLKs have been shown to participate in early neoplastic progression by regulating cancer cell 
proliferation [400]. KLKs mediate tumor growth mainly via insulin-like growth factors (IGFs) 
[400]. KLK 2 and KLK 3 can cleave a number of IGF binding proteins (IGFBPs) to indirectly 
induce tumor growth [402]. Similarly, KLK 14 is also suggested as a potential upstream 
regulator of IGFBPs thus also participating in tumor growth induction [403-405]. As highlighted 
in figure 3.3, KLKs can also facilitate tumor metastasis via the remodeling of extracellular 
matrix (ECM) (Figure 3.3).  
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Figure 3.3: Schematic diagram showing the regulation of Kallikrien-Kinin-Bradykinin and 
TLR2 signaling by SP in neoplastic cervical epithelial cells. ECM (extracellular matrix), LPS 
(lipopolysaccharide). 
 
In addition, there is compelling evidence that KLKs may stimulate tumor angiogenesis by 
facilitating blood vessel remodeling and modulating the balance between angiogenic activators 
and inhibitors [400]. KLKs indirectly facilitate endothelial cell invasion and migration by 
processing components of the extracellular matrix (ECM) via the matrix metalloproteinases 
(MMPs), urokinase plasminogen activator (uPA), and kinin signaling pathways [401]. Induction 
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of KLKs by SP does strongly suggest a role for KLKs in SP-mediated cervical tumorigenesis in 
sexually active women. 
 More so, activation of KLKs by tissue damage or inflammatory stimuli such as PGs in SP can 
result in the generation of biologically active kinins by limited proteolysis of kininogens 
[406,407] (Figure 3.3). Kinins (Bradykinins) are a group of pluripotent peptides implicated in 
various pathophysiological events [408]. Kinins exert their biological effects on target cells by 
activating their cognate receptors, BDKR1 and BDKR2 [409], which belongs to the superfamily 
of GPCRs [410]. BDKR2 is constitutively expressed in all tissues and is thought to mediate most 
physiological action of kinins [408]. BDKR1 is generally not expressed under physiological 
conditions, but can be rapidly up-regulated after cell injury and stress [411] or under several 
inflammatory stimuli [412,413] as orchestrated by SP in this study (Figure 3.3).  
The role of kinins-BDKR signaling in inflammation was first demonstrated by Lewis (1964) 
where kinins-BDKR cascade was shown to evoke cardinal inflammatory signs, such as oedema 
(tumor), increased in vascular permeability and pain (dolor) [414]. Thereafter, several studies 
have emerged supporting the role of both Kinins-BDKR1 and Kinins-BDKR2 cascades in the 
onset and maintenance of inflammatory and nociceptive functions [408,412,413,415]. Although, 
little is understood about the mechanism by which kinins mediates its inflammatory function, 
Pan et al. (1996) showed that kinins-BDKR signaling induces the expression of pro-
inflammatory cytokines via the activation of NF-κB in human WI-38 fibroblast cells [416]. 
Therefore, it is likely that kinins do exert similar mechanism to mediate inflammatory reactions 
in cervical carcinoma cells (Figure 3.3).  
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Furthermore, increasing body of evidence has emerged indicating that kinins-BDKR signaling 
appears to be involved in tumorigenesis [417,418]. Study by Taub et al. (2003) showed that 
stimulation of BDKR1 in prostatic cancer cells promotes tumor cell growth, migration, and 
invasion [419]. Though the exact mechanism by which activated BDKR1 mediated these actions 
was not investigated in that study, the mitogenic properties of kinins and their ability to activate 
tyrosine and MAP-kinase cascades can explain in part their role in tumor growth and metastasis 
[408,418,420]. Secondly, BDKR1 can promote tumor cell migration via the activation of focal 
adhesion kinase and MMPs [421,422]. These data suggests that continuous exposure of 
neoplastic cervical epithelial cells to SP can activate KLKs-kinin-BDKR1 signaling pathways to 
mediate chronic inflammatory reactions and augment tumor progression within the cervix.  
 
Regulation of TLR2 signaling 
Toll-like 2 receptor (TLRs) belongs to the family of type I transmembrane receptors which are 
structurally characterized by extracellular leucine rich repeats (LRRs) and an intracellular 
Toll/IL-1 receptor (TIR) signaling domain [423]. TLRs are activated by a wide range of 
pathogen-associated molecular patterns (PAMPs) including, lipoproteins, flagellins, and bacterial 
lipopolysaccharides (LPS) [424]. In addition to PAMPs, TLRs can also be activated by a variety 
of endogenous molecules released from damaged cells or tissue to initiate a sterile inflammatory 
process without detectable infection [425]. TLRs initiate series of downstream signaling events 
that induces the expression of inflammatory mediators such as cytokines, chemokines and 
adhesion molecules [426].  
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Upon activation with an appropriate agonist, TLRs recruit proximal cytoplasmic adaptor protein 
MyD88 (myeloid differentiating antigen 88), in the MyD88 dependent signaling pathway [423]. 
Recruitment of MyD88 leads to the activation of IRAK1 (IL-1R-associated kinase) by IRAK4, 
which facilitates the recruitment of TRAF6 (TNF receptor-associated kinase). TRAF6 then 
recruit MAP3Ks including TAK1, MEKK2/3, and ASK1. Activated TAK1 then activates IKK 
complex and subsequent IκB degradation and NF-κB translocation to the nucleus. Within the 
nucleus NF-κB mediate the transcription of pro-inflammatory cytokines and growth factor genes 
such as IL-1, TNF, IL-6, and EGF [427]; several antiapoptotic genes including bcl-2, bcl-XL, 
cIAP, xIAP, TRAF1, TRAF2, SOD and A20 [428]; angiogenic and metastatic genes such as 
COX-2 [429], iNOS [430], uPA [431], MMP-2 [432], IL-8 [287], VEGF [433]; and adhesion 
molecules (ICAM-1, VCAM-1, and ELAM-1) [434]. In addition to mediating inflammatory 
response, TLRs have been shown to also regulate cell proliferation and survival [435-437]. No 
doubt Xie et al. (2009) showed that the activation of TLR2 in breast cancer cells  significantly 
promote cellular invasion via the activation of NF-κB and induced phosphorylation of TAK1 and 
IκBα [438]. It was also shown that activation of the TLR2/NF-κB signaling induces the 
expression IL-6, TGF-β, VEGF, and MMP9 in these cells [438].  
As seen in this present study, SP significantly induces the expression of TLR2 in HeLa cells 
(Table 3.1). It is therefore very feasible that induced TLR2 can be activated by the lipoproteins 
that might be present within SP (Figure 3.3). Activated TLR2 can then recruit MyD88 (also 
regulated by SP in this study) to activate the TLR2-MyD88-NF-κB signaling pathway (Figure 
3.3). Translocated NF-κB can then mediate the release of pro-inflammatory and tumorigenic 
genes from the neoplastic cells themselves to augment cervical tumorigenesis. In sexually active 
women, STIs such as gonorrhea are known cause of chronic cervicitis, a persistent inflammation 
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of the cervix which has been linked to cervical cancer [75,439]. It is plausible that the bacterial 
LPS present within infective seminal plasma can bind to the induced TLR2 to activate the TLR2-
MyD88-NF-κB signaling pathway, releasing pro-inflammatory modulators to mediate cervical 
inflammation.  
 
Regulation of chemokine signaling 
Chemokines (chemotactic cytokines) represent a large family of protein (about 40-50) in man, 
with structural similarities based on a conserved cystein residues and capacities to bind to 
particular GPCR [107,440,441]. They are small proteins with molecular weight of about 8-10 
kDa [442]. Of the four different families (CC, CXC, XC, and CX3C) of chemokines that exist, 
the CC and CXC groups are by far the most common [443]. Chemokines were initially described 
as soluble factors able to selectively regulate directional migration of leukocytes during infection 
and inflammation [442,443]. However, their biological effects have been discovered to be far 
more complex and virtually all cells, including many tumor cell types, can express chemokines 
and their receptors [441]. In health, chemokines have been shown to be pleiotropic in their 
effects hence suggesting that in cancer microenvironment chemokines will also exert a wide 
range of molecular effects [442]. In addition, several chemokines can share same receptor and 
one chemokine can bind to several receptors, creating multiple combinations ultimately leading 
to multiple biological outcomes [443].   
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Most tumors express a broad network of chemokines and chemokine receptors [443,444] which 
have been extensively studied in cancers of the ovary, breast, cervix and hematological 
malignancies [442]. Within the tumor microenvironment, tumor-associated chemokines are 
believed to regulate leukocyte infiltration, angiogenesis, tumor cell metastasis, tumor immune 
response, and also act as autocrine or paracrine growth and survival factors [445]. Recently 
chemokines and their receptors have been identified as key mediators of chronic inflammation, 
which play an important role in the pathogenesis and progression of various human cancers 
including cancer of the cervix [446-449]. Induction of chemokines in disease state have been 
shown to be closely regulated by inflammatory cytokines, growth factors and pathogenic stimuli 
[450]. As seen in this study, SP regulated the expression of chemokines C5, CCL2, CCL5, 
CXCL1, CXCL2, CXCL3, CXCL8 (IL-8), CXCL11, and CXCR4 (Table 3.1) all of which play 
vital role in cervical cancer inflammation and tumorigenesis. The induction of tumor-associated 
chemokines mediated by SP in this present study can be consequent to the effect of the various 
inflammatory cytokines secreted from some or all of the earlier discussed inflammatory 
pathways (i.e. COX-1-PGE2-EP, PGF2α-FP, CysLTs-CysLT1, LTB4-BLT1, KLKs-kinin-
BDKR1, and TLR2-MyD88-NF-κB) activated by SP (Figure 3.4).  
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Figure 3.4: Schematic diagram showing the regulation of chemokine signaling by SP in 
neoplastic cervical epithelial cells. 
 
Alternatively, antigenically distinct signaling molecules including several cytokines and growth 
factors [280,343,451-453] found in SP can directly stimulate the tumor cells to secrete 
chemokines. 
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Chemokines expressed within specific tumor microenvironment can influence the extent and 
phenotypes of infiltrating leukocytes [442]. For example, the CC chemokines such as CCL2 
(MCP-1) are major determinants of macrophage and lymphocyte infiltration [454] expressed in  
variety of cancers where it modulates the recruitment of macrophages [442]. In a study carried 
out by Negus et al. (1997) expression of CCL2 by solid ovarian tumor cells correlated with the 
extent of lymphocyte and macrophage infiltration [87]. In addition CCL2 has been implicated in 
tumor metastasis [455]. Similarly, RANTES (CCL5) a C-C chemotactic chemokine is also 
known to promote recruitment and activation of inflammatory cells such as lymphocytes[456], 
monocytes [457], and mast cells [458]. RANTES has been shown to be a ligand for chemokine 
receptors CCR1, CCR3, and CCR5 [459], and elevated expression of RANTES has been 
observed in numerous inflammatory disease [460-462].  
Induction of CCL2 (MCP-1) and CCL5 (RANTES) expression by SP in this study suggests a 
role for both MCP-1 and RANTES in the characteristic post-coital inflammatory response 
described by Sharkey et al (2012). Furthermore, increased expression of RANTES has also been 
observed in several human cancers such as melanoma, lung, prostate, pancreatic, and breast 
cancer [463-465]. However, the most striking finding thus far is in breast cancer where 
expression of RANTES correlates with disease progression [466,467]. CCL5 has been shown to 
modulate cell migration and invasion in several cancer cells [468]. No known study have 
demonstrated the role of SP in the induction of CC-chemokines (CCL2 and CCL5) expression or 
their role in cervical cancer progression. It is likely that SP-induced CC-chemokines (CCL2 and 
CCL5) can act in similar manner to enhance cervical cancer cell migration and invasion.  
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 To maintain growth, tumor cells are dependent on angiogenesis [469]. CXC chemokines within 
tumor microenvironment can positively or negatively regulate angiogenesis depending on the 
presence or absence of the ELR motif in their amino acid terminus [470]. CXCL1, CXCL2, 
CXCL3 and CXCL8 (IL-8) are examples of angiogenic (ELR+) chemokines commonly 
associated with human cancers. CXCL1, CXCL2, and CXCL3 belong to the sub-family Growth-
regulated oncogene (GRO) which is a member of the CXC chemokine family that are crucial in 
recruitment of neutrophils to inflammatory sites [471]. All three ligands together with IL-8 exert 
their biological action by binding to the CXC chemokine receptor CXCR2, with CXCL1 having 
the highest affinity [472].  
Induction of CXCL1 and IL-8 by SP as seen in this present study is in accordance with similar 
study by Sales et al. (2012), where it was shown that SP induces the expression of CXCL1 and 
IL-8 in HeLa cells and regulates vascular function in vitro [350]. Furthermore, study by Wang et 
al. (2006) showed that PGE2 induces the expression of CXCL1 in human colorectal cancer cells 
and that expressed CXCL1 then induces microvascular endothelial cell migration and tube 
formation in vitro [471]. It is therefore very likely that the abundant PGE2 found in SP [310] and 
its ability to regulate the eicosanoid biosynthesis pathway might be responsible for CXCL1 
induction in neoplastic cervical cancer cells (Figure 3.4). These data therefore suggests that 
exposure of neoplastic cervical epithelium to SP can lead to increased tumor angiogenesis and 
invasiveness/metastasis consequent of CXCL1 and IL-8 expression (Figure 3.4). 
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Regulation of cytokines signaling 
Result obtained from this study showed that SP regulates the expression of inflammatory 
cytokines IL-1α, TNF, IL-6, IL-12, IL-18 and components of their respective signaling cascade 
(Table 3.1). 
 
 
Figure 3.5: Schematic diagram showing the regulation of cytokine signaling by SP in neoplastic 
cervical epithelial cells. 
↑; Up-regulated genes, ↓; down-regulated genes, ┬; direct inhibition, →, direct stimulation. 
 120 
 
IL-1α is a pleotropic pro-inflammatory cytokine belonging to the IL-1 family located in the long 
arm of chromosome 2 [473]. Studies have emerged demonstrating the role of IL-1α signaling in 
the pathogenesis of various human cancers including head and neck [474], breast [475], 
pancreatic [476], and cervical cancer [477] where it induce the activation of immediate-early 
transcription factors and genes that promote cell survival and proliferation and other cytokines 
that mediate inflammatory and angiogenic response [478,479]. In this study, SP significantly 
induces the expression of IL-1α and components of IL-1signaling including IL-1RI and 
intracellular adaptor molecules MyD88 while down regulating IL-1RII (IL-1 receptor type II), a 
decoy receptor that inhibits IL-1 signaling [473,479,480]. Hence, it is feasible that SP-mediated 
activation of IL-1α-IL-1RI signaling can exacerbate inflammatory response within the cervical 
cancer milieu and promote cervical cancer cell proliferation, growth, and survival via the 
activation of major transcription factor such as NF-κB (Figure 3.5).  
TNF is a potent pro-inflammatory cytokine that has been documented to be secreted by wide 
variety of tumor cells including cutaneous T cell lymphoma [481], adult T cell leukemia [482], 
breast cancer [480,483], ovarian carcinoma [484,485], and cervical epithelial cancer [486]. In 
most of these neoplastic cells, TNF can act as an autocrine growth factor or in some cases 
promote tumor growth/survival and invasion/metastasis via the activation of NF-κB–dependent 
genes [487]. It is therefore likely that SP activated TNF-TNFR signaling can act via similar 
mechanism to mediate cervical cancer progression.  
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CD40 ligand (CD40L) is a type II transmembrane protein with homology similar to TNF [488]. 
CD40 has been documented to be highly expressed on many in vitro transformed and carcinoma-
derived cell lines including cervical cancer cell lines [488-490]. In these cells, CD40L-CD40 
interaction initiates inflammatory responses leading to the synthesis of tumor associated 
chemokines [488,491,492] and cytokines [493] via the activation and translocation of NF-κB 
[494]. Hence persistence exposure of neoplastic cervical epithelium to SP can lead to poorer 
prognosis consequent of chronic inflammatory reactions initiated by SP induced CD40L.    
Induction of IL-6 by SP as obtained from this study in keeps with the result of previous study by 
Sutherland et al. (2012), where it was shown that SP acting via the COX signaling induces the 
expression of IL-6 in neoplastic cervical epithelial cell (HeLa) [287].  
Induction of IL-12α and IL-18 by SP in this study suggests a role for SP in the regulation of 
cervical immune response. IL-12α and IL-18 are pro-inflammatory cytokines [495,496] capable 
of inducing the production of interferon-γ (IFN-γ) [497] and cell mediated immunity which are 
important factors in determining the progression of HPV related cervical lesion including 
cervical cancer [498-500]. In addition, regulation of SLIT2, a ligand known for its anti-
inflammatory and tumor suppressor activity [501] suggest that SP can play a pivotal role in 
cervical cancer pathogenesis i.e. ability to promote or impede tumorigenesis. Furthermore, 
induction of cell adhesion molecules ICAM1 and ITGAM1suggest that SP can also play a role in 
cervical cancer cell metastasis [502].  
Finally, SP-regulated signaling cascades and expressed pro-inflammatory cytokines can all act 
synergistically to modulate disease pattern and outcome by promoting chronic inflammatory 
process and cervical tumorigenesis. 
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In conclusion, this study has highlighted that human seminal plasma (SP) can potentially 
enhance cervical cancer progression by regulating the induction of arrays of inflammatory 
pathways in neoplastic cervical epithelial cells. Regulation of these inflammatory pathways can 
play a crucial role in cancer cell angiogenesis, proliferation, invasion, metastasis, and survival. 
Constant exposure of dysplastic cervical epithelium to seminal plasma as occurs in sexually 
active women during the act of coitus can mediate early progression to invasive cancer 
consequent of its molecular effect on the already dysplastic epithelial cells. In view of the above 
it is of great importance to determine the molecular mechanism by which SP mediate the 
expression of some of these inflammatory genes/pathways, which form the basis of my next 
study. 
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CHAPTER 4 
SEMINAL PLASMA INDUCES THE EXPRESSION OF IL-1α IN NORMAL AND 
NEOPLASTIC CERVICAL CELLS VIA EP2/EGFR/PI3K/AKT PATHWAYS 
4.1 Introduction 
The inflammatory milieu of most cancer microenvironment has been shown to consist of tumor 
cells, surrounding stromal, immune and inflammatory cells which all interact intimately to 
produce cytokines/chemokines, growth factors, and adhesion molecules in a bid to promote 
tumorigenesis and metastasis [273]. Of special relevance within this milieu are pro-inflammatory 
cytokines which are important mediators of chronic inflammatory responses, and have cardinal 
effects on malignant processes. In the previous chapter, I have shown that SP regulates the 
expression of arrays of pro-inflammatory cytokines in neoplastic cervical epithelial cells. One of 
the most robustly regulated cytokines in the array was IL-1α.   
Interleukin 1α (IL-1α) is a pleotropic pro-inflammatory cytokine that belongs to the IL-1 family 
(IL-1α, IL-1β, and IL-1Ra) gene located on the long arm of chromosome 2 [473]. IL-1α 
possesses a wide range of inflammatory, immunologic and tumorigenic properties [101,503,504]. 
IL-1α is secreted by a variety of cells including monocytes, tissue macrophages, neutrophils, 
fibroblasts, smooth muscle cells, dendritic cells, and cervical epithelium [101,480,505]. 
Accumulative evidence suggests that IL-1α plays a crucial role in tumorigenesis. Within the 
tumor microenvironment, IL-1α has been shown to induce the expression of metastatic genes 
such as the matrix metalloproteinases (MMPs) and stimulate the production of angiogenic 
proteins and growth factors such as IL-8, IL-6, vascular endothelial growth factor (VEGF), 
tumor necrosis factor-α (TNF-α), and transforming growth factor-β (TGFβ) [503,506]. In 
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addition, IL-1α is capable of inducing enzymes (COX and iNOS) with carcinogenic properties 
within inflamed and malignant tissues [507]. Given the importance of IL-1α in regulating 
inflammation and cancer progression, it was of utmost interest to elucidate the molecular 
mechanism underlying the role of SP in regulating IL-1α and its potential role in cervical cancer.  
 
4.2 Aim of the study 
In the previous chapter, I have demonstrated that SP can induce pro-inflammatory pathways, 
chemokines and cytokines including IL-1α in neoplastic cervical epithelial cells (HeLa). Hence, 
this study was aimed at investigating the role of SP in the regulation of IL-1α expression in 
normal and neoplastic cervical tissue explants and epithelial cells, HeLa and the molecular 
mechanism underlying this regulation. 
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4.3 Materials and method 
4.3.1 Cervical tissue collection and processing 
Cervical cancer tissue (Ca.1-Ca.18) specimens obtained from previously diagnosed (pre or 
invasive carcinoma of the cervix) patients attending the Gynecologic Oncology Clinic at Groote 
Schuur Hospital (Cape Town) were processed and treated with SP as previously described in 
section 2.4.2. Patient age ranged between 29-62 years, with a median age of 41 years. The extent 
of invasiveness of carcinoma biopsies are presented in Appendix III. Similarly, histologically 
normal cervical tissues (N1-N12) were collected from women undergoing Wertheim’s 
hysterectomy for benign gynecological malignancies at Groote Schuur Hospital (Cape Town). 
Tissue explant were also processed and treated with SP as previously described in section 2.4.2.  
Patient age ranged between 37-73 years with a median age of 50.5 years.  
 
4.3.2 Cell culture, treatment with SP, RNA extraction and cDNA synthesis 
HeLa-S3 cells were routinely maintained as previously described in section 2.6. For experiments, 
HeLa-S3 cells were seeded in medium supplemented with 10% FBS at density of 2x105 cells in 3 
cm diameter tissue culture dishes and allowed to attach and grow overnight after which cells 
were serum starved by incubating in serum free medium for 24 hours. Cells were then treated 
with vehicle (PBS) or SP at a dilution of 1:50 or butaprost [5µM] or PGE2 [300nM] or EGF 
[10ng/ML] for 4, 8, 16, and 24 hours. For receptor blockade and inhibitor experiments, serum 
starved cells were treated with receptor antagonist/inhibitors alone or SP (1:50 dilution) alone or 
together for 4 or 16 hours. The antagonist and inhibitors used and their final concentrations were: 
EP2 receptor antagonist [AH-6809; 20µM], inhibitors of EGFR [AG-1478; 100nM], PI3 kinase 
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[LY-294002; 25μM], COX-1 [SC-560; 15μM], and COX-2 [NS-398 8μM]. The concentrations 
of chemical inhibitors used in this study were determined empirically by titration as described 
[325-327,508]. At the concentration and time used, the antagonist or inhibitors showed no 
adverse effects on cell viability when stained with 0.4% trypan blue dye. RNA was extracted 
individually from each set of experiment by using Trizol (Sigma) and concentrations and purity 
determined as described in section 2.8. cDNA was synthesized from total mRNA (200ng) by 
reverse transcription as described in section 2.9. Fold increases was calculated by dividing the 
values obtained from the SP/SP-inhibitor treatments by the vehicle/vehicle-inhibitor treatments.  
 
4.3.3 Quantitative real time PCR reaction. 
Quantitative real time-PCR was performed to determine the expression of IL-1α and IL-1RI in 
cervical carcinoma biopsies and normal cervical tissue and also to assess the effects of ligands or 
chemical inhibitors on SP mediated induction of IL-1α in HeLa S3 and normal cervical tissue 
explants. RNA was extracted from neoplastic cervical tissue (adenocarcinoma Ca.11 and 
squamous cell carcinoma Ca.1 - Ca.10 and Ca.12 - Ca. 18), normal cervix (N1-N12), and HeLa 
S3 cells using Trizol-reagent as per the manufacturers’ instruction and reversed transcribed as 
described in section 2.9 [312]. qRT-PCR reaction was carried out on an Illumina ECOTM 
quantitative RT-PCR machine and detected using SYBR green (Bioline,  Celtic Molecular, Cape 
Town, South Africa) incorporation during PCR reaction as described in section 2.10.3. All 
relative expressions were calculated using the comparative Ct (section 2.10.5) relative to an 
endogenous control of HeLa cell cDNA included in each experiment. Data are presented as fold 
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increase as determined by dividing the relative expression of SP treated group by that of the 
control. Data are presented as mean ± SEM. 
 
4.3.4 Enzyme linked immunosorbent assay 
Quantikine® Human IL-1α ELISA kit was used to assess IL-1α protein expression. The 
experiment was done on HeLa S3 cells seeded at a density of 5×105 in 3 cm tissue culture dishes 
and serum starved overnight. The cells were then treated with SP (1:50) or PBS (control) for 16 
and 24 hrs. Cells were lysed as described previously [312] and total protein quantified using 
Pierce® BCA Protein Assay Kit. Expressed cellular IL-1α protein was determined from the total 
protein in the lysate. Data are presented as fold change over control treated, which was 
calculated by dividing the amount of IL-1α measured in SP treated cells at the different time 
points by the amount measured in their respective controls. Data are presented as mean ± SEM 
of six independent experiments 
 
4.3.5 SDS-PAGE and Western blot analysis 
Immunoblot analysis was performed as described in section 2.13 and 2.14. Following 
immunblotting, membranes were incubated overnight with rabbit anti-PKB (AKT) and anti-P-
PKB (AKT) (1:1000 dilution) at 4 0C with gentle shaking. Thereafter, membranes were washed 
three times for 10 minutes each with 15mL of PBS, 0.1% Tween-20, incubated for 1 hour with 
anti-Rabbit HRP-conjugated secondary antibody (1:5000 dilution) at RT with gentle shaking and 
washed again three times with 15mL PBS, 0.1% Tween-20. Protein detection was done as 
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described in section 2.14. Densitometry on visualized protein bands was done using ImageJ 
version IJ 1.46r (www.imagej.nih.gov/ij/). Akt phosphorylation was calculated by dividing the 
value obtained from phosphorylated Akt channel by the value obtained from total Akt channel 
and expressed as fold above vehicle controls. Data are presented as mean ± SEM of three 
independent experiments. 
 
4.3.6 Immunohistochemistry 
 Immunohistochemistry was done on archival cervical blocks (Normal n=5, squamous cell 
carcinoma n=4 and adenocarcinoma n=4) obtained from the Department of Anatomical 
Pathology, University of Cape Town. Sections were deparaffinized, rehydrated and antigen 
retrieval done as described in section 2.16. Blocking for endogenous peroxidase was done as 
described earlier (section 2.16). Sections were blocked using 5% normal donkey/goat serum 
diluted in TBS after which tissue sections were incubated with polyclonal goat anti-IL-1α 
(1:200) antibodies at 4 0C for 18 hours. After incubation, tissue sections were then washed in 
TBS twice for 5 minutes each followed by incubation with biotinylated donkey anti-goat 
secondary IgG antibody at dilution of 1:500 at RT for 30 minutes. Tissue sections were then 
further incubated with streptavidin-biotin peroxidase complex (1:50) at RT for 30 minutes. 
Controls were incubated with biotinylated IgG secondary antibody only. Color reaction was 
developed by incubating with 3.3’-diaminobenzidine. Tissue sections were counterstained in 
aqueous hematoxylin, before mounting and coverslipping. Images were visualized and 
photographed using a Carl Zeiss laser scanning microscope LSM 510 (Jena, Germany).  
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4.3.7 Statistical Analysis   
All data in this study were analyzed by t-test or one-way ANOVA using Graph Pad Prism 5.0 
software (GraphPad Software Inc., San Diego, CA). Paired T-tests were conducted on the 
untransformed means of the replicates between SP and control. Unpaired T-tests were performed 
on SP versus SP and inhibitor after conversion to fold increases. One-way ANOVA was used as 
an additional tool to determine the significant difference between various time points for IL-1α 
by real-time PCR in response to SP.   
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4.4 Results 
4.4.1 SP induces expression of IL-1α in HeLa neoplastic cervical epithelial cells 
To investigate the potential role of IL-1α in cervical inflammation and tumorigenesis, I used a 
well-established HPV 18 positive HeLa (adenocarcinoma) cell line as a model system to 
investigate the regulation of IL-1α expression by SP in neoplastic cervical epithelium. HeLa S3 
cells were treated with vehicle or SP (1:50 dilution) for 4, 8, 16, and 24 hours and the expression 
of IL-1α mRNA assessed using qRT-PCR (Figure 4.1A). SP significantly induced the expression 
of IL-1α mRNA in HeLa S3 cells at all-time point investigated in keeping with result from the 
array study. Peak induction of IL-1α was observed after 4 hours of SP exposure and was 17.02 ± 
4.43 fold increase, while other inductions were 15.40 ± 4.26, 10.07 ± 5.03, and 8.22 ± 2.68 fold 
increase for 8, 16 and 24 hours, respectively.  
In addition, I investigated IL1-α protein expression in response to SP treatment. Protein lysates 
extracted from HeLa S3 cells treated with vehicle or SP (1:50) for 16 and 24 hours, respectively 
were subjected to ELISA. I found that SP treatment of HeLa S3 cells significantly induced the 
expression of IL-1α protein compared to the control (Figure 4.1 B; 10.91 ± 2.61 and 8.45 ± 2.36 
fold increase for 16 and 24 hours, respectively). The ELISA did not detect IL-1α expression in 
lysate of cells treated with SP at earlier time points (4 and 8 hours). 
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Figure 4.1:  Relative expression of IL-1α mRNA (A) and IL-1α protein (B) in HeLa cells treated 
with SP (1:50 dilution) relative to PBS (control) for 4, 8, 16, or 24 hrs as determined by qRT-
PCR and ELISA. Data are presented as mean ± SEM from 5 (A) and 6 (B) independent 
experiments (n = 5 and 6). Paired T-tests were conducted on the untransformed means of the 
replicates between SP and control. *, **, and *** indicates significance at P < 0.05, P < 0.01 and 
P < 0.001, respectively.  
 
4.4.2 SP regulation of IL-1α expression in HeLa cells is dependent on individual semen 
donor 
Induction of IL-1α (mRNA and protein) in HeLa cells seen in figure 4.1 above was mediated by 
pooled seminal plasma obtained from 10 healthy individual donors. To investigate whether the 
levels of IL-1α expression was donor dependent, individual ejaculates were assayed for their 
ability to induce IL-1α mRNA expression in HeLa cells. Result obtained showed that SP from all 
ejaculates (sperm cells removed by centrifugation, SP1-SP5; full ejaculate with sperm cell, 
SP6spr and SP7spr; and ejaculates from vasectomized men with no sperm cells present, SP8pv, 
SP9pv, and SP10pv) significantly induced IL-1α expression in HeLa cells after 4 and 24 hours 
incubation, albeit with different efficiency (Figure 4.2). Furthermore, I discovered that the 
presence or absence of sperm cells had no effect on IL-1α mRNA expression (Figure 4.2).  
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Similarly, the use of centrifugation step to remove spermatozoa had no effect on IL-1α 
regulation. This data suggests that individual variation in SP potency may also affect cervical 
inflammation. All subsequent experiments were conducted using pooled SP.     
 
Figure 4.2: Relative expression of IL-1α mRNA in HeLa cells treated with SP1-SP5, SP6spr, 
SP7spr, and SP8pv-SP10pv (1:50 dilution) relative to PBS (control) for 4 or 24 hrs as determined 
by qRT-PCR. Data are presented as fold above control. 
 
 
 
4.4.3 SP mediated IL-1α induction in HeLa neoplastic cervical epithelial cells via EP2 
receptor, EGFR and PI3 kinase pathways.  
Next I investigated the signal transduction pathways mediating SP induction of IL-1α mRNA 
expression, using PGE receptor 2 (EP2) antagonist and a panel of small molecule chemical 
inhibitors of signaling proteins. HeLa S3 cells were treated with vehicle or SP (1:50) alone or 
with EP2 receptor antagonist (AH-6809) or chemical inhibitors of EGFR (AG-1478), PI3 kinase 
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(LY-294002), COX-1 (SC-560), and COX-2 (NS-398) for either 4 hours or 16 hours. The 
expression of IL-1α in HeLa S3 cells following SP treatment in the presence of receptor 
antagonist or chemical inhibitors was determined by qRT-PCR after 4 hours (Figure 4.3A and B) 
and ELISA after 16 hours (Figure 4.3C). Figure 4.3A shows that EP2 receptor antagonist 
significantly reduced SP-mediated induction of IL-1α mRNA in HeLa S3 cells (P < 0.05). SP-
mediated induction of IL-1α was also found to be markedly reduced in the presence of chemical 
inhibitors of EGFR (AG-1478) and PI3 kinase (LY-294002), respectively (Figure 4.3B; P < 
0.001). Co-incubation of SP with selective COX-1 (SC-560) and COX-2 (NS-398) inhibitors had 
no inhibitory effect on SP-induced IL-1α mRNA expression (Figure 4.3B; P = 0.26 and 0.16). 
This indicates that SP-mediated induction of IL-1α mRNA expression is via EP2 and EGF 
receptors and not via the endogenous COX-PG pathway. In addition, co-treatment with EGTA 
[calcium chelator; 1.5mM] and PD-98059 [ERK inhibitor; 50µM] did not inhibit SP-mediated 
induction of IL-1α (Figure 4.3C).  
Similarly, data obtained from measuring IL-1α protein with ELISA (Figure 4.3D) revealed that 
AG-1478 and LY-294002 reduced the expression of SP-induced IL-1α protein in HeLa S3 cells 
from 20.42 ± 5.16 fold increase to 8.80 ± 1.89 and 2.00 ± 0.32 fold increases, respectively (P < 
0.05 and P < 0.001, respectively). However no significant decrease in IL-1α protein secretion 
was seen in the presence of NS-398 and SC-560 as compared to SP (1:50) (Figure 4.3D; P = 0.17 
and P = 0.11, respectively). These results together demonstrate that SP-mediated induction of IL-
1α transcript and protein expression is via EP2 and EGF receptors and PI3K and not via the 
endogenous COX-PG pathway.  
 
 
 
 134 
 
 
 
Figure 4.3: IL-1α mRNA and protein expression is regulated by seminal plasma via the EP2 
receptor, EGFR and PI3K pathways. IL-1α mRNA (A, B and C) and protein (D) as determined 
by qRT-PCR and ELISA analysis, respectively. HeLa cells were treated for 4 (A, B, C) and 16 
hours (D) with seminal plasma (1:50) or vehicle in the absence/presence of EP2 receptor 
antagonist [AH-6809; 20µM] and chemical inhibitors to EGFR kinase [AG-1478; 100nM], PI3 
kinase [LY-294002; 25µM], COX-1 [SC-560; 15µM] or COX-2 [NS-398; 8µM], EGTA 
[calcium chelator; 1.5mM] and PD-98059 [ERK inhibitor; 50µM]. Data are represented as mean 
± SEM from 5 independent experiments. Paired T-tests were conducted on the untransformed 
means of the replicates between SP and control and unpaired T-tests performed on SP versus SP 
and inhibitor after conversion to fold increases. *, **, and *** indicates significance at P < 0.05, 
P < 0.01, and P < 0.001, respectively. 
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4.4.4 PGE2 and EGF induces IL-1α expression in HeLa neoplastic cervical epithelial cells 
Since SP contains a variety of antigenically distinct molecules that include prostaglandins and 
growth factors [280,307]. I hypothesized that PGE2 and EGF, present in the SP, can induce IL-1α 
expression as these molecules have been shown to regulate inflammatory gene expression on 
their own. To investigate the role of PGE2 and EGF on IL-1α expression, I treated HeLa cells 
with vehicle or PGE2 [300nM] or human recombinant EGF [10ng/mL] alone or together for 4, 8, 
16, and 24 hours and determined IL-1α mRNA expression using qRT-PCR. Treatment of HeLa 
cells with PGE2 (Figure 4.4A) and EGF (Figure 4.4B) resulted in a 2.49 ± 0.66 and 5.76 ± 0.80 
maximum fold increase after 8 and 4 hours, respectively. Treatment of HeLa cells with both 
PGE2 and EGF together (Figure 4.4C) resulted in 2.39 ± 0.52, 6.60 ± 0.63, 16.31 ± 1.23 and 
10.88 ± 1.52 fold increase after 4, 8, 16, and 24 hours, respectively. With peak IL-1α mRNA 
induction observed after 16 hours treatment (16.31 ± 1.23 fold increase). Furthermore, the 
inductions of IL-1α mRNA at 8, 16, and 24 hours by both ligands together was greater than by 
each ligand on its own and suggesting that PGE2 and EGF act synergistically in inducing the 
increase of IL-1α production by HeLa cells. 
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Figure 4.4: Induction of IL-1α mRNA in HeLa cells treated with PGE2 (A), EGF (B), and PGE2 
plus EGF (C) as determined qRT-PCR. HeLa cells were treated for 4, 8, 16 and 24 hours with 
PGE2 [300nM] or human recombinant EGF [10ng/mL] or PGE2 together with EGF or vehicle as 
control. Data are represented as mean ± SEM from 5 independent experiments. Paired T-tests 
were conducted on the untransformed means of the replicates between PGE2 or EGF or PGE2 
and EGF treated cells and control. *, ** and *** indicates significance at P < 0.05, P < 0.01, and 
P < 0.001, respectively. 
 
 
 
 
 
 137 
 
4.4.5 Activation of EP2 and EGF receptors induces IL-1α expression in HeLa neoplastic 
cervical epithelial cells 
The marked inhibition of SP-mediated induction of IL-1α by the EP2 receptor antagonist AH-
6809 and EGFR kinase inhibitor AG-1478 indicated a role for EP2 receptor in combination with 
EGFR in this induction of IL-1α. I next investigated whether IL-1α regulation was mediated by 
the EP2 and EGF receptors.  In order to confirm that activation of the EP2 and EGF receptors can 
regulate IL-1α expression, I treated HeLa cells with vehicle or butaprost  which is a specific EP2 
receptor agonist or human recombinant EGF or both agonist together for 4, 8, 16 and 24 hours. 
Activation of EP2 (Figure 4.5A) and EGF (Figure 4.5B) receptors significantly induced IL-1α 
expression after 8 and 4 hours treatment, respectively (2.77 ± 0.23 and 5.76 ± 0.80 fold 
increases) as shown by qRT-PCR analysis. Co-treatment of HeLa cells with EP2 and EGF 
receptor agonists together (Figure 4.5C) significantly induced the expression of IL-1α mRNA at 
all-time points investigated (Figure 4.5C; 3.56 ± 1.48, 6.29 ± 1.28, 2.84± 0.34, and 2.36 ± 0.75 
fold increases). Moreover, the peak IL-1α induction observed after 8 hours of co-treatment was 
greater than either butaprost or EGF treatment alone suggesting that co-activation of EP2 and 
EGF receptors act synergistically in inducing the increase of IL-1α production by HeLa cells 
(Figure 4.5C). 
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Figure 4.5: Activation of EP2 receptor (A), EGF receptor (B) and co-activation of EGF and EP2 
receptors (C) induces the expression of IL-1α mRNA in HeLa cells as determined by qRT-PCR. 
HeLa cells were treated for 4, 8, 16 and 24 hours with butaprost [5µM] or EGF [10ng/mL] or 
butaprost and EGF or vehicle. Data represented as mean ± SEM from 5 independent 
experiments. Paired T-tests were conducted on the untransformed means of the replicates 
between butaprost or EGF or butaprost and EGF treated cells and control.* and ** indicates 
significance at P < 0.05 and P < 0.01, respectively. 
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4.4.6 EP2 receptor antagonist, EGFR and PI3 kinase inhibitors inhibit PGE2 and EGF 
mediated induction of IL-1α in HeLa neoplastic cervical epithelial cells. 
Having demonstrated that PGE2 and EGF induced the expression of IL-1α in HeLa S3 cells, I 
next investigated the transduction pathways by which PGE2 and EGF induce IL-1α expression in 
HeLa cells. SP was shown to induce IL-1α expression in HeLa S3 cell via the EP2/EGFR/PI3 
kinase pathways (Figure 4.3 A, B and C), thus I investigated whether PGE2 and EGF induces the 
expression of IL-1α in HeLa cells via similar pathways. HeLa S3 cells were treated with vehicle 
or PGE2 alone or in the presence of AH-6809 and chemical inhibitors, AG-1478 or LY-294002 
for 8 hours and IL-1α mRNA expression was assessed using qRT-PCR (Figure 4.6A). PGE2-
mediated induction of IL-1α (2.49 ± 0.66 fold increase) was significantly reduced in the presence 
of EP2 receptor antagonist (0.65 ± 0.38) and chemical inhibitors of EGFR and PI3 kinase (0.91 ± 
0.15, and 0.41 ± 0.35 fold increases, respectively; P < 0.05 in all cases). Subsequently, HeLa S3 
cells were treated with vehicle, or PGE2 and EGF alone or in the presence of AH-6809 or AG-
1478 separately or together or with LY-294002 for 16 hours (Figure 4.6B). Similarly, induction 
of IL-1α after treatment with PGE2 and EGF together was markedly reduced in the presence of 
EP2 receptor antagonist or EGFR kinase inhibitor, and almost abolished in the presence of EP2 
receptor antagonist together with EGFR inhibitor or in the presence of PI3 kinase inhibitor (P < 
0.01 in all cases). In addition, HeLa S3 cells were treated with vehicle or EGF alone or in the 
presence of LY-294002 for 4 hours (Figure 4.6C). The EGF-mediated IL-1α induction was 
reduced from 5.76 ± 0.80 fold increase to 1.88 ± 0.46 fold increase in the presence of PI3 kinase 
inhibitor (P < 0.01). These findings confirm that EGF regulates IL-1α expression via the 
activation of PI3 kinase pathways, while PGE2 regulates IL-1α expression via the activation of 
EP2/EGFR/PI3 kinase pathways.  
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Figure 4.6: EP2 antagonist, EGFR and PI3 kinase inhibitors inhibit PGE2 (A), PGE2 and EGF 
(B), and EGF (C) mediated induction of IL-1α in HeLa cells as determined by qRT-PCR. HeLa 
cells were treated for 4, 8 and 16 hours with EGF [10ng/mL], or PGE2 [300nM] or both or 
vehicle in the absence/presence of antagonist/inhibitors AH6809 [20µM], AG1478 [100nM], 
AH6809 together with AG1478, and LY294002 [25μM]. Data are represented as mean ± SEM 
from 5 independent experiments. Paired T-tests were conducted on the untransformed means of 
the replicates between ligand/ligands treated cells and control and unpaired T-tests performed on 
ligand/ligands versus ligand/ligands and inhibitor after conversion to fold increases. * and ** 
indicates significance at P < 0.05 and P < 0.01, respectively. 
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4.4.7 Seminal plasma phosphorylates AKT via EP2/EGFR/PI3 kinase signaling to induce 
IL-1α expression in HeLa neoplastic cervical epithelial cells. 
Protein kinase B (Akt) is known to be one of the major downstream targets of PI3 kinase and 
upon activation, Akt moves to the cytoplasm and nucleus where it phosphorylates numerous 
downstream targets involved in the regulation of various cellular functions [203]. Having shown 
that SP mediated the expression of IL-1α in HeLa cells via the activation of EP2/EGFR/PI3 
kinase pathways, next was to investigate the role of SP in the phosphorylation of Akt and the 
position of EP2, EGFR, and PI3 kinase pathways in relation to Akt signaling using immunoblot 
analysis. HeLa S3 cells were treated with vehicle or SP (1:50 dilution) for 0, 5, 10, 20, 40, 60, 
120 and 240 minutes and Akt phosphorylation was measured by immunoblot analysis. A 
significant Akt phosphorylation was observed after 40 minutes with a maximum phosphorylation 
at 60 minutes and remaining until 240 minutes post-stimulation with fold increases of 21.58 ± 
5.32, 44.64 ± 9.14 and 9.581 ± 2.475, respectively for these time points (Figure 4.7A) (P < 0.05). 
I next treated HeLa S3 cells with vehicle or SP (1:50 dilution) or in the presence or absence of 
chemical inhibitors of EGFR kinase (AG 1478), PI3 kinase (LY294002), and EP2 receptor 
antagonist (AH6809) for 60 min and measured Akt phosphorylation. SP-mediated 
phosphorylation of Akt was significantly reduced from fold increase of 8.08 ± 1.688 to fold 
increases of 1.70 ± 0.23, 3.62 ± 0.08, and 1.00 ± 0.16 in the presence of AH-6809, AG-1478, and 
LY-294002, respectively (P < 0.05) (Figure 4.7B). 
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Figure 4.7: Akt phosphorylation in HeLa cells by SP. (A) Akt phosphorylation in HeLa S3 cells 
treated with SP (1:50) or control for 0, 5, 10, 20, 40, 60, 120, and 240 min. (B) Akt 
phosphorylation in HeLa cells treated for 60 min with SP (1:50) or control in the 
presence/absence of chemical inhibitors/antagonist EGFR kinase [AG-1478;100nM], PI3 kinase 
[LY-294002; 25μM] and EP2 antagonist [AH-6809; 20μM]. Cell lysate were subjected to 
 143 
 
immunoblot analysis. Data are represented as mean ± SEM form 3 independent experiments. 
Paired T-tests were conducted on the untransformed means of the replicates between SP and 
control and unpaired T-tests performed on SP versus SP and inhibitor after conversion to fold 
increases. * indicates P < 0.05. 
 
4.4.8 IL-1α is up-regulated in cervical cancer 
Having elucidated the molecular pathways underlying SP-mediated induction of IL-1α in 
cervical epithelial cells using an in vitro HeLa cell line model system next was to investigate 
whether SP could act via similar pathway to induce IL-1α expression in cervical tissue. Here, I 
initially investigated the expression of IL-1α in normal and neoplastic cervical tissue explants 
using quantitative real time PCR (qRT-PCR) (Figure 4.8A I). Expression of IL-1α transcript was 
significantly elevated in all cancer tissue samples investigated compared with normal cervical 
tissue sample. IL-1α mean expression as assessed by qRT-PCR was 43.65 ± 13.21 fold greater in 
neoplastic cervical tissue than in normal cervical tissue (Figure 4.8A II). The site of IL-1α 
synthesis in the neoplastic tissue was then investigated by immunohistochemistry. IL-1α was 
localized to the neoplastically transformed squamous epithelium in squamous cell carcinoma 
(Figure 4.8B I) and to neoplastically transformed columnar epithelium lining the endocervical 
and the glandular epithelium of the endocervical glands in adenocarcinomas (Figure 4.8B II). In 
contrast to the high levels of immunoreactive IL-1α observed in cervical cancer tissue, little or 
no staining for IL-1α was observed in the normal cervical tissues (Figure 4.8B III). Incubation 
with biotinylated IgG in place of primary antibody as control did not show any immunostaining 
in carcinoma tissue sections (Figure 4.8B IV). Analysis/quantification of immunohistochemical 
stains revealed a significant expression of IL-1α in both adenocarcinoma and squamous cell 
carcinoma tissue compared to normal cervix (Figure 4.8 C and D; P < 0.05 in both cases). 
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Figure 4.8: A, Relative mRNA expression of IL-1α in (I) cervical squamous cell carcinoma 
(Ca.1-Ca.7, adenocarcinoma (Ca.11), and normal cervix (N1-N6). (II) Mean relative IL-1α 
mRNA expression in neoplastic and normal cervical tissue explant as determined by qRT-PCR 
and shown in (I). B, IL-1α expression by immunostaining in epithelial cells of squamous cell 
carcinoma (I), and columnar and glandular epithelium of adenocarcinoma (II). Minimal IL-1α 
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signal was detected in normal cervical tissue (III). IL-1α staining was abolished in sections 
incubated with the biotinylated secondary antibody alone (IV) (negative control). C, de-
convoluted images of squamous cell, adenocarcinoma and normal cervical immunohistochemical 
(IHC) stain. I-III, IV-VI, and VII-IX; immunohistochemical, hematoxylin (HE) and 
diaminobenzidine (DAB) stain of squamous cell, adenocarcinoma and normal cervix. D, % DAB 
stain in immumohistochemical slides. Scale bar, 50µm. Data represented as mean ± SEM. *, and 
**, indicates statistical significance at P < 0.05 and P < 0.01, respectively.  
 
 
4.4.9 IL-1RI is up-regulated in cervical cancer 
IL-1R type I (IL-1RI) (80 kD) is a signaling receptor responsible for the initiation of IL-1α signal 
transduction [509,510]. Overt expression of IL-1RI has been demonstrated in human cancers 
such as prostate cancer [510].  Having shown that IL-1α is up-regulated in cervical cancer, I next 
investigated the concurrent expression of IL-1RI in cervical cancer and normal cervix using 
qRT-PCR (Figure 4.9 A and B). IL-1RI transcript was found to be marginally elevated in all 
cancer tissue samples investigated compared with normal cervical tissue sample. IL-1RI mean 
expression as assessed by qRT-PCR was 19.70 ± 5.72 in neoplastic cervical tissue vs 15.33 ± 
4.19 in normal cervical tissue (Figure 4.9B), suggesting an enhanced IL-1α/IL-1RI signaling in 
cervical cancer.   
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Figure 4.9: A, Relative mRNA expression of IL-1RI in cervical squamous cell carcinoma (Ca.1-
Ca. 4) and normal cervix (N1-N3). B, Mean relative IL-1RI mRNA expression in neoplastic and 
normal cervical tissue explant as determined by qRT-PCR and shown in (A).  
 
 
4.4.10 SP induces the expression of IL-1α in the cervix via EP2/EGFR/PI3 kinase activation 
Finally I investigated the potential role of SP in the regulation of IL-1α expression in the cervix 
and determined whether SP induces IL-1α expression in the cervix via the same pathways as 
seen in the HeLa model cell line. Normal and neoplastic (squamous) cervical tissue explant were 
treated with vehicle or SP (1:50) for 24 hours and IL-1α mRNA expression was determined 
using qRT-PCR. SP significantly induced the expression of IL-1α in both neoplastic and normal 
cervical tissue with similar fold induction (1.959 ± 0.3226 and 2.124 ± 0.2673 fold increases) 
(Figure 4.10A and B). To investigate the signaling pathways by which SP induces IL-1α 
expression in the cervix, normal cervical tissue explants were incubated with vehicle or SP 
(1:50) in the presence or absence of AH-6809, AG-1478, and LY-290042. qRT-PCR assessment 
of IL-1α expression showed a marked reduction in SP-mediated induction of IL-1α in normal 
cervical tissue explants in the presence of EP2 receptor antagonist or the chemical inhibitors of 
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the EGFR (AG-1478) and PI3 kinase (LY-294002) pathways (P < 0.01 in all cases)  (Figure 
4.10C).  
 
Figure 4.10: SP induce IL-1α mRNA expression in neoplastic (A) and normal (B) cervical tissue 
explant. SP induces the expression of IL-1α in normal cervical tissue via the activation of 
EP2/EGFR/PI3 kinase inflammatory pathways as determined by qRT-PCR (C). Data represented 
as mean ± SEM of (n = 12 (A), n = 10 (B) and n = 7 (c), respectively). Paired T-tests were 
conducted on the untransformed means of the replicates between SP and control and unpaired T-
tests performed on SP versus SP and inhibitor after conversion to fold increases. *, **and *** 
represent significance at P < 0.05, P < 0.01 and P < 0.001, respectively. 
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4.5 Discussion 
Over the years, the role of inflammation as an etiological factor for cancer has been supported by 
findings that show that regular use of non-steroidal anti-inflammatory drugs (NSAIDs) is 
associated with reduced incidence of certain cancers [509]. Hence, inflammatory responses 
within tumor microenvironment are now recognized as a critical component for tumor 
progression and one of the major hall-marks of cancer [447,511]. Despite experimental and 
epidemiological evidence that supports the causal relationship between inflammation and cancer, 
the molecular mechanisms and pathways linking inflammation and cancer remain poorly 
understood [512]. The inflammatory milieu of most cancer microenvironments consist of tumor,  
surrounding stromal, immune and inflammatory cells which all interact intimately to produce 
cytokines/chemokines, growth factors, and adhesion molecules in a bid to promote inflammation, 
tumorigenesis and metastasis [273]. Of special relevance within this milieu are pro-inflammatory 
cytokines which are important mediators of chronic inflammatory responses, and have cardinal 
effects on malignant processes [509] as a result of their direct involvement in carcinogenesis, 
malignant transformation, tumor growth, invasion, and metastasis [473].  
Within the cancer microenvironment, pro-inflammatory cytokines can exert a direct effect on 
pre-malignant and/or malignant cells. By engaging their cognate receptors they activate 
downstream kinases to regulate an array of genes involved in cell proliferation, survival, 
metabolism, angiogenesis and metastasis [513], leading to enhanced tumor growth. Similarly, in 
epithelial cancer cells, pro-inflammatory cytokines can up-regulate the expression and augment 
the activity of epithelial NADPH oxidase (Nox) family proteins to increase ROS (reactive 
oxygen species) production in tumor microenvironment [513]. This leads to damage in genomic 
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DNA and may produce mutations that can enhance tumor formation in a chronic inflammatory 
background [513].  
Cervical cancer is a chronic inflammatory disease and one of the leading causes of cancer-related 
death worldwide with a higher incidence rate reported in underdeveloped countries [514]. It is 
well established that persistent infection with high-risk HPV is crucial to disease pathogenesis 
[15]. However, only a subset of women infected with high-risk HPV will proceed to develop 
invasive cervical cancer, thus suggesting that other co-factors must be present for the 
development of malignancy [515]. Studies have reported an association between the level of 
cervical inflammation and the development of high grade cervical neoplasia [20] or invasive 
cervical cancer [516]. It has been reported that cervical inflammation, but not the actual 
diagnosis of a specific sexually transmitted infection is associated with the development of 
squamous intraepithelial lesions within the cervix [517]. Direct links between increased pro-
inflammatory cytokine levels in patients and increasing grade of cervical intraepithelial neoplasia 
and invasive cervical cancer have been established [518]. Several in-vitro studies have 
demonstrated the expression of IL-1α in both normal and neoplastic cervical epithelial cell line 
[477]. However, few data exist on the expression of IL-1α and IL-1RI in normal and neoplastic 
cervical tissue. Using immunohistochemistry and qPCR, I investigated the expression of pro-
inflammatory cytokine IL-1α and its cognate receptor IL-1RI in normal and neoplastic cervical 
tissue. Data presented confirmed the elevated expression of IL-1α and IL-1RI in cervical cancer. 
This is in agreement with similar study by Pao et al. (1995) and Ricote et al. (2004), where it was 
reported that neoplastic cervical and prostate tissue overtly expresses IL-1α and IL-1RI 
[510,519]. In addition, these data suggests a similar pattern of IL-1α expression in cervical 
cancer as demonstrated in other malignancies [520-522]. 
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IL-1α is a pleiotropic pro-inflammatory cytokine and a member of the IL-1 family. Within the 
human body, IL-1α mediates normal physiological functions ranging from induction of vascular 
permeability and fever during sepsis to increased secretion of additional cytokines in 
autoimmune diseases [509]. The production and level of IL-1α and IL-1RI expression is elevated 
in numerous cancers including head and neck [474], breast [520,523], pancreatic [524], gastric 
[525] and prostatic cancer [510] and has been associated with virulent tumor phenotype and 
poorer prognosis via the regulation of inflammatory genes and growth factors to enhance tumor 
growth and differentiation [477,526,527] and metastatic potential of  cells [528]. Indeed Ricote 
and colleagues reported that high expression levels of IL-1α and IL-1RI in prostate cancer was 
involved in neoplastic cell proliferation [510]. Similarly, animal studies have further confirmed 
the role of IL-1α and IL-1RI in tumor development and blood vessel growth [529]. The 
expression/activation of IL-1α/IL-1RI cytokine family via autocrine and/or paracrine 
mechanisms leads to the activation of secondary pro-tumorigenic cytokines which can 
subsequently contribute to angiogenesis, tumor invasion and proliferation [523]. It is therefore 
probable that expression of IL-1α and IL-1RI in cervical cancers can act via similar manner to 
confer virulent tumor phenotype and poorer prognosis in these patients.  
IL-1α expression can be regulated by a host of inflammatory stimuli and recent studies have 
shown that seminal plasma can regulate IL-1α expression in the human cervix, post coitus 
[285,352]. Conventionally, human seminal plasma was regarded primarily as a transport and 
survival medium for the mammalian spermatozoa traversing the cervix and the uterus during and 
post coitus [280,451]. However, experimental studies using animal models shows that in addition 
to its role as a primary transport medium for the spermatozoa, seminal plasma also introduce to 
the female reproductive tract an array of signaling molecules including prostaglandins, several 
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cytokines and growth factors [280,343,451,452]. These molecules interact with cognate receptors 
on the epithelial lining of the female reproductive tract to initiate local cellular and molecular 
changes reminiscent of an inflammatory response [280]. These changes are required for maternal 
immune adaptation to pregnancy and for the generation of immune tolerance against fetal 
antigens [280,530]. However the molecular pathway by which seminal plasma mediates the 
expression of IL-1α and other cytokines is yet to be fully elucidated. Using HeLa 
(adenocarcinoma) cells, normal and neoplastic cervical tissue explants, I investigated the role of 
SP in the regulation of IL-1α expression in the cervix and transduction pathways by which SP 
induces the expression of IL-1α in neoplastic and normal cervical epithelium. In addition, I 
further investigated PGE2 and EGF as possible ligands mediating SP induction of IL-1α in 
neoplastic cervical cells.  
In the present study I have shown that exposure of HeLa neoplastic cervical epithelial cells to SP 
in vitro increases the expression of IL-1α in a donor dependent manner. The observation that IL-
1α is induced by SP as oppose to spermatozoa agrees with study by Robertson et al. (1996) 
where it was shown that SP from vasectomized mice elicit post-mating inflammatory response 
characterized by surge in pro-inflammatory cytokine synthesis [283]. In a similar manner, SP 
was found to increase the expression of IL-1α in both normal and neoplastic cervical tissue 
explants. This is in agreement with studies by Sutherland et al. (2012) and Sharkey et al. (2007 
and 2012) where it was reported that SP mediates pro-inflammatory cytokines expression in 
HeLa cells in vitro [287] and in the cervix  post coitus [285,352] to initiate an inflammatory 
response. Inflammatory response orchestrated by SP within the female genital tract can impact 
on both physiological and pathophysiological events within the cervix [285]. Because the 
epithelial microenvironment is a critical factor in cervical dysplasia and metaplasia [531], 
 153 
 
incessant exposure of dysplastic or metaplastic epithelial cells to SP in sexually active women 
with underlying pathology could inﬂuence the incidence and progression of cervical cancer [285] 
consequent of SP-mediated IL-1α expression. In addition, cytokines inﬂuencing the numbers and 
phenotypes of APCs (Antigen Presenting Cells) could interact with SP-induced expression of 
tumorigenic and angiogenic factors [345]  to favor tumor growth. Having shown that SP 
regulates IL-1α expression in normal and neoplastic cervical tissue and epithelial cells, I next 
investigated possible signal transduction pathways by which SP mediates this role.  
Employing HeLa cell line as a model, I showed that SP induces the expression of IL-1α via the 
EP2 receptor, EGFR and PI3 kinase pathways since EP2 receptor antagonist (AH6809) and the 
inhibitors of EGFR kinase (AG1478) and PI3 kinase (LY294002) inhibited SP mediated 
induction of IL-1α in these neoplastic cells. In contrast, COX-1 and COX-2 were not shown to 
have a role in the induction of IL-1α by SP, since addition of their inhibitors (SC-560 and NS-
398, respectively) did not reduce the induction of IL-1α. In addition, I found that SP-mediated 
induction of IL-1α in normal cervical tissue explant was also inhibited in the presence of the 
antagonist and these inhibitors.  Similar in vitro studies by Battersby et al. (2006),  Muller et al. 
(2006) and Sales et al. (2012) have shown that SP-mediated expression of pro-inflammatory and 
angiogenic genes in endometrial and cervical adenocarcinoma cells was significantly inhibited in 
the presence of AH6809 [344] and AG-1478 (EGFR kinase inhibitor) [345,350]. The inhibition 
of SP-mediated IL-1α by EP2 antagonist and EGFR kinase inhibitors suggested that the effects 
observed were mediated by PGE2 and EGF present in the SP.  
PGE2 has been established as the predominant  PG found in SP [310]. In the present study and as 
highlighted schematically in figure 4.11, I showed that PGE2-mediated activation of IL-1α 
occurs via activation of the EP2, EGFR and Akt pathways.  
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Figure 4.11: Schematic summary highlighting the role of SP and its constituents (PGE2 and 
EGF) in the regulation of signaling pathway mediating IL-1α (IL-1 alpha) expression in cervical 
epithelial cells. 
 
The role of the EP2 receptor in mediating these effects was further confirmed using the selective 
EP2 agonist butaprost. This is consistent with similar study by Shao et al. (2007) where it was 
shown that PGE2, acting via EP2 receptor activate cAMP/PKA pathway to mediate the 
expression of IL-1α in colon cancer cells in an autocrine/paracrine mechanism [505]. EP2 has 
been found to be up-regulated in cervical cancer [28] and its role in the induction of IL-1α in 
cervical cancer cells explains the greater induction in IL-1α in cervical cancer tissue relative to 
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normal cervical tissue. These data suggest that PGE2 in SP [280,532,533] can act via its E-series 
PGs receptor EP2 receptor to directly transactivate EGFR via an intracellular signaling 
mechanism, either by phosphorylation of cSRC or by the MMP-mediated release of heparin-
bound EGF tethered to the cell membrane, [344,345] leading to IL-1α induction. In addition to 
PGE2, SP has been shown to be rich in growth factors including epidermal growth factor (EGF) 
[534-536]. Data presented herein showed that EGF can induce IL-1α in neoplastic cervical HeLa 
cells. This in agreement with similar in vitro study by Hamilton et al. (2003) where it was shown 
that EGF induces the expression of pro-inflammatory cytokine in lung cancer cells, and the 
expression of this cytokine was suppressed in the presence of EGFR inhibitor (AG-1478) [537]. 
It is therefore very feasible that the EGFR expressed on the membrane of these neoplastic cells 
can be directly activated by EGF in SP to induce IL-1α expression. The evidence that IL-1α 
induction by SP is due to PGE2 and EGF present in SP is in agreement with findings of Sharkey 
et al. (2012) who demonstrated that SP-mediated IL-1α induction in Ect1 cells occurred 
independently of  TGF-β1, TGF-β2, and TGF-β3 which are abundant in SP [286].  
Furthermore, since my data show that concurrent treatment of HeLa S3 cells with PGE2 and EGF 
directed a sustained and elevated increase in IL-1α expression compared to either ligand alone, it 
is likely that the effects of SP on IL-1α induction may be mediated by a combination of PGE2 
and EGF working in synergy. Once released, IL-1α can act in an autocrine/paracrine manner 
within the site of production to regulate inflammation and tumorigenesis. Indeed, Shao and 
colleagues showed in their study that IL-1α stimulates the migration of colon cancer cells [505]. 
It is therefore plausible that in sexually active women with underlying pre-invasive or invasive 
cervical condition, repeated exposure of the elevated EP2 receptor expressed on the neoplastic 
cervical epithelial cells [28] to PGE2 present in seminal plasma could enhance tumorigenesis 
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following ligand-receptor binding and activation of similar intracellular signaling pathway to 
induce IL-1α expression. Expressed IL-1α can then stimulate cervical cancer cell migration to 
adjacent structures within the pelvis and perineum, hence conferring poor prognosis. 
Several studies have shown that PI3 kinase-Akt signaling is deregulated in many cancers 
including cervical cancer where amplification of the p110α catalytic subunit has been reported 
[217,218,220,538]. Interestingly in this present study, SP and its constituents (PGE2 and EGF) 
have been shown to mediate IL-1α expression in normal and neoplastic cervical epithelial cells 
via the activation of PGE2-EP2-EGFR-PI3 kinase pathways. Once activated Akt phosphorylates 
proteins on serine and threonine residues resulting in the modulation of multiplicity of 
downstream substrates, including NF-κB involved in the regulation of cell proliferation and 
survival [224,230,232]. The SP-mediated Akt phosphorylation seen in this study may act via 
similar mechanism to induce IL-1α expression. The SP-mediated induction of a pleotropic pro-
inflammatory cytokine IL-1α in neoplastic cervical epithelial cells suggests that SP may promote 
cervical inflammation as well as progression of cervical cancer in sexually active women [350]. 
This present study is the first to demonstrate that SP regulates pro-inflammatory cytokine IL-1α 
expression in normal and neoplastic cervical cells via the induction of the EP2-EGFR-PI3 kinase-
Akt pathways.  
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In conclusion, this study identifies PGE2 and EGF within SP as possible ligands responsible for 
SP-mediated induction and secretion of IL-1α in neoplastic cervical cells. Furthermore, this 
study provides evidence for pathways that are used by SP to induce the production of pleotropic 
pro-inflammatory cytokine IL-1α in normal and neoplastic cervical epithelial cells following 
coitus. The secreted IL-1α can in turn regulate in an autocrine or paracrine manner through its 
cognate receptor the surrounding cells and promote inflammation and tumorigenesis.  
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CHAPTER 5 
C-C CHEMOKINE RECEPTOR 5   IS UP-REGULATED IN CERVICAL CANCER AND 
IS REGULATED BY SEMINAL PLASMA: POTENTIAL ROLE IN INCREASED RISK 
OF HIV TRANSMISSION IN CERVICAL CANCER  
5.1 Introduction 
Human immunodeficiency virus (HIV) infection is a major public health problem in developing 
countries. In Southern Africa alone, there are more than 5 million people infected with 
HIV/AIDS, accounting for a staggering 34 % of the global HIV infection burden, with women 
more affected than men [539]. HIV infection is characterized by persistent immune activation 
and chronic inflammation which is beneficial for HIV replication but detrimental to the host 
[540]. Although two decades have now elapsed since the identification of HIV as the etiology of 
AIDS, knowledge about how pro-inflammatory mediators affect HIV pathogenesis is still 
unclear [256]. However, it has been established that a main feature of HIV infection is the 
expression of numerous pro-inflammatory mediators including cytokines and PGs [256,313]. 
These pro-inflammatory mediators have been shown to enhance HIV-1 transmission [313,541] 
and viral replication in vitro [313,542]. 
Mucosal inflammation of the female lower genital tract is regarded as an imperative factor 
favoring acquisition of HIV infection in receptive vaginal intercourse [543,544]. Cervical cancer, 
an AIDS-deﬁning illness [545,546] is a characterized chronic inflammation of the cervical 
epithelium with underlying neoplasia [547]. Histopathologic features of cervical cancer shows a 
predominance of tumor-infiltrating leukocytes [548] and neoplastic cells interacting to release 
inflammatory mediators including pro-inflammatory cytokines [519]  and PGs [28]. Hence, 
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women with cervical cancer, where there are already infiltrating leukocytes and elevated 
cytokines could be at greater risk of HIV infection.  
Here I show that CD4 and CCR5 receptors are up-regulated in neoplastic cervical tissue that has 
high levels of IL-1α [519], PGE2 and COX enzymes [28,312]. These (PGs and cytokines) have 
been shown to regulate chemokine receptors including CXCR4, in cervical cancer [276]. 
 
5.2 Aim of the study 
This study was aimed at investigating the expression and SP regulation of HIV receptors CD4 
and CCR5 in cervical cancer.    
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5.3 Materials and Methods 
5.3.1 Cervical cytobrush sample 
Cervical cytobrush specimens were collected from women (n=20) attending the Colposcopy 
Clinic at Groote Schuur Hospital, Cape Town. All women were of reproductive age (median age 
of 37 years) and reported normal menstrual cycles. Sampling was carried out mid-cycle and any 
patients that showed signs of bleeding were excluded from the study. Specimens were obtained 
by cytobrush according to the method described by Musey and colleagues [321] and treated with 
SP as described in section 2.4.1. After which, cells were pelleted by centrifugation at 15000rpm 
and RNA extracted using Trizol (Sigma) following the manufacture’s guidelines and reverse 
transcribed as previously described in section 2.9. Data are presented as mean ± SEM. 
 
5.3.2 Cervical tissue collection 
Cervical cancer tissue (Ca.1-Ca.7) specimens obtained from previously diagnosed (pre or 
invasive carcinoma of the cervix) patients attending the Gynecologic Oncology Clinic at Groote 
Schuur Hospital (Cape Town) were processed and treated with SP as previously described in 
section 2.4.2. Patient age ranged between 29-62 years, with a median age of 41 years. The extent 
of invasiveness of carcinoma biopsies are presented in Appendix III. Similarly, histologically 
normal cervical tissues (N1-N5) were collected from women undergoing Wertheim’s 
hysterectomy for benign gynecological malignancies at Groote Schuur Hospital (Cape Town). 
Tissue explant were also processed and treated with SP as previously described in section 2.4.2.  
Patient age ranged between 37-73 years with a median age of 50.5 years.  
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5.3.3 Construction of HeLa Tet-off cells 
HeLa Tet-off cells containing the tetracycline (doxycycline; DOX) transactivator/VP16 domain 
cloned upstream of the minimal CMV promoter [549,550] were purchased from Clontech. 
Construction and validation of the COX-1 Tet-Off system is described in Sales et al., 2002 [312]. 
Briefly, HeLa Tet-off cells were stably transfected with the full length COX-1 cDNA cloned 
upstream of the tetracycline (DOX) regulatory element fused to the minimal CMV promoter. In 
the presence of DOX, the TetR/VP16 transcativator protein is inhibited from transactivating the 
TRE and expression of the transgene is suppressed. Removal of DOX from the culture medium 
promotes COX-1 transgene expression [312]. 
 
5.3.4 Cell culture and treatment with SP  
HeLa S3 cells were routinely maintained as previously described in section 2.6. HeLa COX-1 
Tet-off cells were maintained under the same culture conditions as HeLa S3 cells, with the 
addition of 2µg/ml Doxycyline (DOX; Sigma) to maintain the suppression of the COX-1 
transgene as previously described by Sales et al. (2002) [312]. For the wild type HeLa cell 
experiments, HeLa cells were seeded at a density of 2 x 105 cells in 3cm dishes and allowed to 
attach and grow overnight. The following day cells were serum starved for 24 hours in serum-
free medium. Cells were then treated with vehicle or 1:50 dilution of SP for 4, 8, 16 and 24 
hours, respectively. For inhibitor experiments, cells were serum starved and treated with 
inhibitor alone or 1:50 dilution of SP and inhibitor of EGFR kinase [AG1478; 200nM], ERK1/2 
kinase [PD98059; 50µM], COX-1 [SC560; 10µM], COX-2 [NS398; 10µM] or nuclear factor 
kappa B [NFB, SN50; 100µg/ml] or EGTA [1.5mM] for 8 hours or 16  hours. The 
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concentrations of chemical inhibitors were determined empirically by titration as described 
previously [325-327]. At the concentrations and time used, the inhibitors showed no adverse 
effect on cell viability when stained with 0.4% trypan blue dye. For HeLa COX-1 Tet-off 
experiments, 2 x 105 HeLa COX-1 Tet-off cells were incubated in 3cm dishes in the absence (to 
allow for induction of COX-1 transgene expression) or presence (to switch off transgene 
expression) of 2µg/ml Doxycyline (DOX; Sigma) in serum free DMEM for 24, 48 and 72 hours. 
Cells were supplemented daily with DOX. RNA was extracted individually from each set of 
experiment by using Trizol (Sigma) following the manufacturer’s guidelines and concentrations 
and purity of the RNA determined as described in section 2.8. cDNA was synthesized from total 
mRNA (200ng) by reverse transcription as described in section 2.9. Fold increase was calculated 
by dividing the values obtained from the SP only/SP plus inhibitor treatments by the vehicle 
only/vehicle plus inhibitor treatments. All in vitro cell culture experiments were carried out in 
duplicate.  
 
5.3.5 Quantitative real time PCR reaction 
Quantitative real time PCR was performed to determine the expression of CD4 and CCR5 in 
normal and neoplastic cervical tissue explant, assess the expression of CD4, CCR5, CCR2b, 
CXCR4, CXCR6 and GPR1 on SP-treated HeLa cells, and determine the effects of chemical 
inhibitors on SP-mediated induction of CCR5 in HeLa cells. RNA was extracted from neoplastic 
cervical tissue (squamous cell carcinoma Ca.1 - Ca.7), normal cervix (N1-N5), and HeLa cells 
using Trizol reagent as per the manufacturers’ instruction and reversed transcribed as described 
in section 2.9. qRT-PCR reaction was carried out on an Illumina ECOTM quantitative RT-PCR 
 163 
 
machine and detected using SYBR green (Bioline,  Celtic Molecular, Cape Town, South Africa) 
incorporation during PCR reaction as described in section 2.10.3. All relative expressions were 
calculated using the comparative Ct (section 2.10.5) relative to an endogenous control of HeLa 
cell cDNA included in each experiment. Data are presented as fold increase as determined by 
dividing the relative expression of SP treated group by that of the control. Data are presented as 
mean ± SEM.  
 
5.3.6 SDS-PAGE and Western blot analysis 
Immunoblot analysis was performed as described in section 2.14. Immunoblots were incubated 
in 10mL of blocking buffer (PBS, 0.1% Tween-20 with 5% w/v nonfat dry milk) on a shaker for 
1 hour at room temperature (RT), after which membranes were washed three times for 10 
minutes each with 15mL PBS, 0.1% Tween-20 followed by an overnight incubation with 
specific β-actin, CCR5, CD4 or COX-1 primary antibody (1:400 dilution) in 5% BSA at 4 0C 
with gentle shaking. Thereafter, membranes were washed three times for 10 minutes each with 
15mL of PBS, 0.1% Tween-20, incubated for 1 hour with HRP-conjugated secondary antibody 
(1:5000 dilution) at RT with gentle shaking and washed again three times with 15mL PBS, 0.1% 
Tween-20. Protein detection was conducted as described in section 2.14. Densitometry on 
visualized protein bands was done using a UVP Biospectrum 500 Imaging system (UVP, 
Scientific Group, Cape Town, South Africa). Fold induction was determined in SP-treated cells 
or HeLa COX-1 Tet-off cells incubated without DOX relative to control-treated cells or HeLa 
COX-1 Tet-off cells incubated with DOX, after normalizing to β-actin, by dividing the 
expression in the treated group (HeLa COX-1 Tet-off minus DOX) by the expression in the 
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control group (HeLa COX-1 Tet-off plus DOX). Data are presented as mean ± SEM from four 
independent experiments. 
 
5.3.7 Immunohistochemistry 
Immunohistochemistry was done on archival cervical blocks (Normal n=4, squamous cell 
carcinoma n=5 and adenocarcinoma n=5) obtained from the Department of Anatomical 
Pathology, University of Cape Town. Sections were deparaffinized, rehydrated and antigen 
retrieval done as described in section 2.16. Blocking for endogenous peroxidase was done as 
described earlier (section 2.16). Sections were blocked using 5% normal donkey/goat serum 
diluted in TBS after which tissue sections were incubated with polyclonal goat anti-CCR5 
(1:200), mouse anti-CD4 (1:200) or rabbit anti-neutrophil elastase (1:400) antibodies at 4 0C for 
18 hours. After incubation, tissue sections were then washed in TBS twice for 5 minutes each 
followed by incubation with biotinylated donkey anti-goat or goat anti-mouse secondary IgG 
antibody at dilution of 1:500 at RT for 30 minutes or donkey anti-rabbit Cy3 at dilution of 
1:1000 for neutrophil elastase at RT for 60 minutes. Tissue sections with the CCR5 and CD4 
antibodies were then further incubated with streptavidin-biotin peroxidase complex (1:50) at RT 
for 30 minutes. Controls were incubated with biotinylated IgG secondary antibody only. Color 
reaction was developed by incubating with 3.3’-diaminobenzidine. Tissue sections were 
counterstained in aqueous hematoxylin, before mounting and coverslipping. For sections 
incubated with neutrophil elastase/Cy3, nuclei were counterstained with Dapi (Santa Cruz). 
Fluorescent images were visualized and photographed using a Carl Zeiss laser scanning 
microscope LSM 510 (Jena, Germany).  
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5.3.8 Statistical Analysis 
The data in this study was analyzed by t-test or one-way ANOVA using Graph Pad Prism 5.0c 
(Graph Pad, San Diego, CA). Paired T-Tests were conducted on the untransformed means of the 
replicates between SP and control or inhibitor and inhibitor and SP or HeLa COX-1 Tet-off cells 
incubated in the absence vs presence of DOX for each experiment. Unpaired T-Tests were 
conducted on SP versus SP and inhibitor after conversion to fold/percentage increase. One way 
ANOVA was used as an additional test to determine significant difference between the various 
time points for CD4, CCR5, CCR2b, CXCR4, CXCR6 and GPR1 by real-time PCR and/or 
Western blot analysis in response to SP treatment. 
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5.4 Results 
5.4.1 CD4 and CCR5 expression is elevated in cervical cancer tissue 
Quantitative RT-PCR analysis revealed elevated expression of CD4 (Fig. 5.1A) and CCR5 (Fig. 
5.1B) in all cervical cancer biopsies (Ca1-Ca7) compared with normal cervical tissues (N1-N3). 
Using serial sections, the site of CD4 (Figure 5.1C and 5.1D) and CCR5 (Figure 5.1F and 5.1G) 
expression was localized to the neoplastic epithelial cells in cervical adenocarcinomas (Figure 
5.1C and 5.1F) and squamous cell carcinomas (Figure 5.1D and 5.1G) with strong 
immunoreactivity in immune cells adjacent to the epithelium, in the stromal compartment. Using 
a specific antibody for leukocyte neutrophil elastase, I confirmed that the immune cells strongly 
expressing CD4 and CCR5 in the cervical adenocarcinoma (Figure 5.1I) and squamous cell 
carcinomas (Fig. 5.1J) were infiltrating leukocytes. In contrast to the strong immunoreactive 
staining for CD4 and CCR5 observed in the cancer tissues, I observed minimal immunoreactivity 
for CD4 and CCR5 in normal cervix (Figure 5.1E and 5.1H respectively). I also did not detect 
any infiltrating leukocytes in normal cervical tissues by immunohistochemistry and confocal 
microscopy. Analysis/quantification of immunohistochemical stains revealed a significant 
expression of CD4 and CCR5 in both adenocarcinoma and squamous cell carcinoma tissue 
compared to normal cervix (Figure 5.1L; P < 0.05, respectively). The high levels of CD4 and 
CCR5 expression in the cancer tissues in the same cellular compartment as elevated IL-1α, 
COX-1 and COX-2 reported in an earlier study conducted in our laboratory [312], suggest that 
they could be regulated by inflammatory pathways in cervical epithelial cells. 
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Figure 5.1: Expression and localization of CD4 and CCR5 in cervical tissues. CD4 (A) and 
CCR5 (B) mRNA expression in cervical cancer (Ca1-Ca7; n=7) and normal cervical tissues (N1-
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N3; n=3) as determined by quantitative real time PCR analysis. Localization of CD4 (C, D, E), 
CCR5 (F, G, H) and neutrophil elastase (I, J) expression was determined in cervical 
adenocarcinoma (C, F, I), squamous cell carcinoma (D, G, J) and normal cervix (E, H) by 
immunohistochemistry. A representative section of de-convoluted (HE and DAB) IHC stain is 
shown for each. Controls incubated with IgG from host species (K; representative section shown) 
were negative for immunoreactivity. % DAB stain for CD4 and CCR5 in normal, squamous and 
adenocarcinoma tissues (L). Scale bar, 100µm. Data represented as mean ± SEM. *, represent 
significance at P < 0.05. 
 
5.4.2 SP regulates expression of CD4 and CCR5 in the cervix  
SP has been shown to induce inflammatory and tumorigenic pathways in the vagina [315] and 
cervix [287,346,350]. I investigated whether SP could regulate expression of CD4 and CCR5, 
the main receptor-co-receptor pair involved in HIV infection, in the cervical mucosa using 
heterogeneous cervical epithelial cells (cytobrush samples), neoplastic and normal cervical tissue 
explants. Samples were treated for 24 hours with vehicle or 1:50 dilution of SP and expression of 
CD4 and CCR5 determined by qRT-PCR. SP was found to significantly elevate the expression 
of CD4 (Figure 5.2A; 5.2C and 5.2E; P < 0.05) and CCR5 (Figure 5.2B; P<0.01, 5.2D; P < 0.01, 
and 5.2F; P < 0.05) in the cervical specimens obtained from the cervical mucosa by cytobrush 
sampling (Figure 5.2A and 5.2B), normal cervical biopsy (Figure 5.2C and 5.2D), and cervical 
cancer biopsies (Figure 5.2E and 5.2F) compared with vehicle treated controls.  
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Figure 5.2: Seminal plasma induces expression of CD4 and CCR5 in the cervix. CD4 (A, C, E) 
and CCR5 (B, D, F) mRNA expression was determined by qRT-PCR analysis of cervical tissues 
obtained from the cervix with a cervical cytobrush (A and B), normal cervical biopsy from the 
ectocervix-transformational zone (C and D), cervical cancer biopsy (E and F). Cervical 
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cytobrush samples (n=20) and biopsies (n=5) were treated with control (PBS) or 1:50 dilution of 
seminal plasma for 24 hours. Data are presented as mean ± SEM. *, ** indicate significance at 
P<0.05 and P<0.01 respectively. 
 
 
5.4.3 SP regulates the expression of HIV chemokine co-receptors in HeLa neoplastic 
cervical epithelial cells 
 The role of SP in the regulation of pro-inflammatory chemokines and their receptors within the 
epithelial and stroma compartments of the cervix after coitus has been demonstrated in vivo 
[285]. Here, I hypothesized that SP can regulate HIV chemokine co-receptors expression in 
neoplastic cervical epithelial cells in vitro, using a well-established HeLa (adenocarcinoma) cell 
line as a model system. HeLa cells were treated with vehicle or SP (1:50 dilution) for 4, 8, 16, 
and 24 hours and the expression of CD4, CCR5, CCR2b, CXCR4, CXCR6 and GPR1 mRNA 
expression assessed using qRT-PCR (Figure 5.3A, 5.3B, 5.3C, 5.3D, 5.3E, and 5.3F). SP 
significantly induces the expression of CD4, CCR5, and CCR2b mRNA at all-time points 
investigated (Figure 5.3A, B, and C, respectively; P < 0.01). SP treatment of HeLa cells 
significantly induce CXCR4 expression after 24 hours, indicating that longer exposure of 
neoplastic epithelial cells is required to induce CXCR4 ( Figure 5.3D; P < 0.01). This is in 
agreement with prior result from the Taqman array, where no significant expression of CXCR4 
was observed after 8 hours treatment with SP. CXCR6 expression was found to be increased 
significantly in a biphasic manner at 4 hours (P < 0.01) and 24 hours (P < 0.05), with minimal 
expression observed at 8 and 16 hours after SP treatment (Figure 5.3E). I found no increase in 
GPR1 mRNA expression in response to SP treatment (Figure 5.3F). These results suggest that 
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SP-mediated inflammation can regulate the expression of HIV chemokine co-receptors in 
neoplastic cervical epithelial cells. 
 
 
 
Figure 5.3: Seminal plasma induces expression of HIV chemokine co-receptors in HeLa cells. 
(A) CD4, (B) CCR5, (C) CCR2b, (D) CXCR4, (E) CXCR6 and (F) GPR1 mRNA expression as 
determined by qRT-PCR analysis. HeLa cells were treated with control (PBS) or 1:50 dilution of 
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seminal plasma for 4, 8, 16 or 24 hours. Data are presented as mean ± SEM from 8 individual 
experiments. ** indicates significance at P < 0.01. 
 
5.4.4 SP regulation of CD4 and CCR5 expression in the cervix is dependent on individual 
semen donor. 
In the present study, prior experiments describing SP regulation of CD4 and CCR5 in HeLa 
cells, neoplastic and normal cervical tissue (Figure 5.2 and 5.3) was conducted with pooled SP 
obtained from 10 healthy individual donors. To assess whether SP-mediated regulation of CD4 
and CCR5 in the cervix was donor-dependent, I analyzed the effect of SP from individual donors 
on CD4 and CCR5 mRNA expression in HeLa cells. Results as shown in figure 5.4 A and B 
revealed that SP from all ejaculates (SP1-SP5; spermatozoa removed by centrifugation, SP6spr 
and SP7spr; full ejaculates containing spermatozoa, SP8pv-SP10pv; ejaculates from 
vasectomized men i.e. no spermatozoa present) all increased CD4 and CCR5 expression in HeLa 
cells after 4 and 24 hours incubation, respectively with different efficacies (Figure 5.4 A and B). 
Thus suggesting that individual variation in SP potency can affect HIV susceptibility and 
transmission in sexually active women. All subsequent experiments were conducted using 
pooled SP.     
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Figure 5.4: Relative expression of CD4 (A) and CCR5 (B) mRNA in HeLa cells treated with 
SP1-SP5, SP6spr, SP7spr, and SP8pv-SP10pv (1:50 dilution) relative to PBS (control) for 4 or 
24 hrs as determined by qRT-PCR. Data are presented as fold above control 
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5.4.5 SP induces CCR5 protein expression of in HeLa cells 
To further investigate protein expression of CD4 and CCR5 in response to SP treatment, Western 
blot analysis was carried out on HeLa cell lysates treated with SP for 8, 16, and 24 hours. I found 
no significant change in HeLa CD4 protein levels in response to SP treatment in contrast to 
observed fold increase (2.5, 2.2, and 3.5 fold increase at 8, 16, and 24 hours, respectively) in 
mRNA level expression (Figure 5.5A). CCR5 protein on the other hand was robustly induced at 
8, 16 and 24 hours in HeLa cells treated with 1:50 dilution of SP, compared with control treated 
cells (Fig. 5.5B; P < 0.05), similar to my observations for mRNA.  
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Figure 5.5: Seminal plasma induces expression of CCR5 protein in HeLa cells. (A) CD4 and (B) 
CCR5 protein expression as determined by Western blot analysis. HeLa cells were treated with 
control (PBS) or 1:50 dilution of seminal plasma for 8, 16 or 24 hours. Immunoblots were 
revealed and quantified as described above. A representative immunoblot is shown for each with 
quantification from 4 individual experiments shown beneath. Data are presented as mean ± 
SEM.* indicates significance at P < 0.05. 
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5.4.6 Seminal plasma regulates CCR5 expression in HeLa cells via the EGFR and COX-1 
pathways 
Having shown that SP regulates CCR5 expression next was to investigate the signal transduction 
pathways underlying SP-mediated induction of CCR5 expression, using a panel of small 
molecule chemical inhibitors of cell signaling. HeLa cells were treated with vehicle or chemical 
inhibitor or 1:50 dilution of SP or SP and inhibitor for 8 hours (mRNA) (Fig. 5.6A) or 16 hours 
(protein) (Fig. 5.6B). SP treatment of HeLa cells induced a 6.5 ± 0.8 fold increase in CCR5 
mRNA (Fig. 5.6A; P < 0.01) and a 1.8 ± 0.5 fold increase in CCR5 protein (Fig. 5.6B; P < 0.05) 
expression respectively compared with control treated cells. Co-treatment of cells with SP and 
inhibitor of epidermal growth factor (EGF) receptor tyrosine kinase (AG1478) and COX-1 
(SC560) significantly inhibited SP-mediated increase in CCR5 mRNA expression (Fig.5.6A; P < 
0.001) and protein (Fig. 5.6B; P < 0.001) respectively. However, co-treatment of cells with SP 
and inhibitors of NFB (SN50), extracellular signal-regulated kinase (PD98059), COX-2 
(NS398) or calcium (EGTA) had no significant effect on SP-induced CCR5 mRNA or protein 
expression. 
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Figure 5.6: SP induces CCR5 expression in HeLa cells via the activation of EGFR and COX-1 
pathways. (A) CCR5 mRNA and (B) CCR5 protein expression as determined by qRT-PCR and 
Western blot analysis respectively. HeLa cells were treated for 8 hours (A) or 16 hours (B)  with 
SP (1:50) or vehicle (PBS) in the absence/presence of inhibitors of EGFR kinase [AG1478; 
200nM], COX-1 [SC560; 10µM], NFB [SN50; 100µg/ml], calcium [EGTA; 1.5mM], ERK1/2 
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kinase [PD98059; 50µM] or COX-2 [NS398; 10µM].  Data are represented as mean  SEM from 
4 independent experiments. *, **, *** indicate significance at P < 0.05, P < 0.01 and P < 0.001, 
respectively. 
 
 
5.4.7 EGF and PGE2 induces the expression of CCR5 in HeLa cells 
PGE2 is abundant in SP [315,533]. Prior studies have shown a role for PGE2 and the E-series 
prostaglandin receptors (EP2 and EP4 receptors) in mediating the effects of SP in cervical and 
endometrial cancer cells via transactivation of the EGFR [344,345]. Here I sought to determine 
whether EGF or PGE2 could be the active fraction in SP which was responsible for mediating the 
elevation of CCR5 in HeLa cells. HeLa cells were treated with 10ng/mL human recombinant 
EGF (Figure 5.7A) or 300nM PGE2 (Figure 5.7B) for 4, 8, 16 and 24 hours and subjected the 
cDNA to quantitative RT-PCR analysis. EGF treatment of HeLa cells was found to marginally 
increase CCR5 expression only at 16 hours of stimulation (Figure 5.7A; P < 0.05), however 
PGE2 treatment rapidly and significantly elevated expression of CCR5 at 4 and 8 hours of 
stimulation (Figure 5.7B; P < 0.05). Furthermore, I found that PGE2-mediated CCR5 increase 
occurred via the transactivation of the EGFR, since treatment of HeLa cells with the EGFR 
tyrosine kinase inhibitor AG1478 inhibited the PGE2-induction of CCR5 (Figure 5.7C; P < 0.05). 
These data suggest that the SP-mediated induction of HIV chemokine co-receptors in the cervix 
is mediated via the inflammatory PGE2-E-series PG receptor axis. 
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Figure 5.7: Regulation of CCR5 mRNA expression by EGF and PGE2 in HeLa cells. CCR5 
mRNA expression in HeLa cells treated for 4, 8, 16 or 24 hours with vehicle or 10ng/mL 
recombinant EGF (A) or 300nM PGE2 (B). CCR5 mRNA expression in HeLa cells treated for 8 
hours with vehicle or 300nM PGE2 in the absence or presence of the EGFR tyrosine kinase 
inhibitor AG1478 (C). mRNA expression was determined by qRT-PCR analysis. Data are 
presented as mean ± SEM from 4 independent experiments done in duplicate. 
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5.4.8 Expression of CCR5 in HeLa cells can be regulated by an inducible COX-1 enzyme 
Having shown that PGE2 could induce CCR5 expression to similar levels observed for SP. Next 
was to confirm that the COX-1-PGE2 axis can regulate expression of CCR5, using a doxycycline 
(DOX)-inducible expression system in HeLa cells (COX-1 Tet-off system) [312]. In HeLaCOX-
1 Tet-off cells, the COX-1 transgene is under the control of a DOX-inducible promoter, which 
contains a tetracycline (DOX) response element (TRE) upstream of the immediate early 
promoter of cytomegalovirus (as outlined schematically in Figure 5.8A). When HeLa COX-1 
Tet-off cells are maintained in culture medium containing 2µg/mL DOX, the tetracycline 
transactivator protein (TetR/VP16) is prevented from binding to the TRE. Under these 
conditions, induction of the COX-1 transgene is prevented. Removal of DOX from the culture 
medium results in activation of the COX-1 transgene and biosynthesis of PGE2 [312]. HeLa 
COX-1 Tet-off cells were cultured in serum free medium with or without DOX for 24, 48 or 72 
hours. Removal of DOX from the culture medium induced a time dependent increase in COX-1 
mRNA and protein levels (Figure 5.8B) reaching a maximum after 72 hours (3.8 ± 0.7 and 4.5 ± 
0.8 fold increase in COX-1 mRNA and protein expression, respectively; Figure 5.8B; P < 0.001), 
consistent with  previous study [312]. Coincident with the induction of COX-1 expression in 
HeLa cells, I observed a 3.8 ± 0.9 and 2.9 ± 0.8 fold increase in expression of CCR5 mRNA and 
protein respectively (Fig. 5.8C) in HeLa COX-1 Tet-off cells cultured in the absence of DOX for 
72 hours, compared with control HeLa COX-1 Tet-off cells cultured in the presence of DOX for 
72 hours, which had the COX-1 transgene switched off (Fig. 5.8C; P < 0.01). 
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Figure 5.8: CCR5 expression is regulated by COX-1. (A) A schematic overview of the HeLa 
COX-1 Tet-off system. (B) COX-1 mRNA and protein expression in HeLa COX-1 Tet-off cells 
incubated in the presence or absence of DOX for 24, 48 or 72 hours. (C) CCR5 mRNA and 
protein expression in HeLa COX-1 Tet-off cells incubated in the presence or absence of DOX 
for 72 Hours. Data are represented as mean  SEM from 4 independent experiments. *** 
indicates significance at P < 0.001 respectively. 
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5.5 Discussion 
Cervical cancer displays all the hallmarks of a chronic inflammatory disease and over the past 
two decades, the COX-PG pathway has emerged as a central regulator of inflammatory and 
tumorigenic events [80,129]. In cervical cancers, the expression both COX enzymes (COX-1 and 
COX-2) is elevated [340,551], and they have been shown to mediate the induction of 
inflammatory chemokines, cytokines and angiogenic genes via the autocrine/paracrine regulation 
of PGE2 and the E-series prostaglandin receptors [312] within the cancer microenvironment. 
Moreover COX-1 and COX 2 can be regulated by SP and inflammatory cytokines and PGs in a 
positive feedback manner [346,552]. In this study, the high levels of CD4 and CCR5 detected in 
cervical cancer tissues was found to be localized in the same cellular compartment in which high 
levels of IL-1α and COX-1 had previously been detected [312], raising the possibility that CD4 
and CCR5 could be regulated by inflammatory pathways. In addition, these pro-inflammatory 
mediators COX-1 [313] and IL-1α have been shown to enhance HIV-1 transmission [541] and 
viral replication in vitro [542].  
Recent studies have shown that in addition to endogenous regulation of inflammatory pathways 
by the COX-PG axis, SP and SP prostaglandins can directly regulate inflammatory and 
tumorigenic pathways in cervical [287,346,350] and vaginal cells [315]. Inflammation of the 
cervical mucosa is considered a significant risk factor for HIV infection, however the role of 
inflammatory mediators and SP on pathways involved in HIV infection in the cervix have yet to 
be fully elucidated. I hypothesized that SP and inflammatory pathways could regulate chemokine 
receptors and pathways with known roles in HIV infection, in cervical epithelial cells and 
cervical cancer.  
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I found that SP significantly elevated the expression of the HIV receptor CD4 and chemokine co-
receptor CCR5 in heterogeneous cervical epithelial cells obtained by cytobrush sampling of the 
cervical os and both normal and neoplastic cervical tissue explants. Similarly, SP also elevated 
the expression of CD4, CCR5 and other chemokine receptors that have been shown in vitro, to 
mediate HIV infection such as CCR2b, CXCR4 and CXCR6 [253,254,553] in neoplastic cervical 
epithelial cells HeLa. Although pooled SP was used in the present study, I show that though the 
potency in CD4 and CCR5 induction varies between individual semen samples, all samples 
irrespective of whether they were whole ejaculates, centrifuged to remove sperm cells or 
ejaculate from vasectomized patients, with no detectable sperm cells, all had ability to induce 
CD4 and CCR5 expression in the cervix.  
 The epithelial compartment of several tissues in the human body, including the gastrointestinal 
tract, prostate and cervix have all been implicated in the uptake and transport of HIV to 
submucosal leukocytes [554,555]. Cervical epithelial cells can behave as viral reservoirs, to 
sequester and transfer virus to activated peripheral blood mononuclear cells in the submucosa 
[555-557]. Furthermore, several studies have shown that levels of CCR5 expression in cells 
positively correlate with HIV infectivity and levels of cellular activation in vivo [558-560]. It is 
therefore plausible that any mechanism that enhances CCR5 expression, or expression of other 
HIV co-receptors, could enhance HIV susceptibility. In sexually active women, this could be 
enhanced by exposure of the cervix to SP.  
The SP-mediated regulation of CCR5 was further explored in more detail. In accordance with 
my observation for SP regulation of CCR5 mRNA expression, I found a similar robust increase 
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in CCR5 protein in HeLa cells in response to SP, indicating a good correlation between SP-
mediated CCR5 mRNA and protein expression. I explored the molecular mechanism whereby 
SP regulates CCR5 expression using a panel of small molecule chemical inhibitors. I found that 
SP regulated CCR5 expression via the EGFR and COX-1 pathways. These pathways have been 
shown to regulate inflammatory and angiogenic genes in cervical and endometrial cancers and 
are regulated by SP and SP prostaglandins [344,345]. SP is rich in a variety of cytokines and 
inflammatory mediators, including epidermal growth factor (EGF), transforming growth factor 
beta (TGFβ) and PGE2 [280,532,533,536,561]. In this study, I found that although EGF could 
modestly induce CCR5 expression, PGE2 which is present at high concentrations in SP [315,533] 
robustly enhanced CCR5 expression to similar levels observed for SP. Recently the PGE2 
fraction of SP has been shown to be the main fraction responsible for inducing inflammatory 
gene expression in vaginal cells [315]. Furthermore, in this study, I confirmed the importance of 
the EGFR in mediating CCR5 expression, since both SP and PGE2 induction of CCR5 could be 
abolished with the EGFR tyrosine kinase inhibitor AG1478. It is likely that SP and PGE2 induces 
intracellular second messenger scaffolds to transactivate the EGFR in HeLa cells in a similar 
manner reported previously, via ligand-receptor activation of the E-series PG receptors (EP2 and 
EP4 receptors) [344,345].  
To confirm the role of COX-1 in regulating CCR5 expression, I used an inducible COX-1 model 
system in HeLa COX-1 Tet-off cells [312]. I show here that induction of COX-1 induces 
expression of CCR5 in HeLa cells to a similar level observed for SP, indicating that activation of 
this inflammatory pathway can regulate CCR5 expression directly, and further confirms that it is 
an intermediate step in the SP-mediated induction of CCR5 in HeLa cells. Furthermore, 
inhibition of COX-1 with the COX-1 inhibitor SC560 or maintaining HeLa COX-1 Tet-off cells 
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in DOX, to maintain the transgene in its inactive state, abolished induction of CCR5 expression 
in HeLa cells. Inhibition of the inflammatory COX enzyme pathway over the past 2 decades has 
elicited significant attention in terms of therapeutic intervention strategy for a host of 
inflammatory diseases. My observations for the role of COX-1 in regulating HIV receptor 
expression, suggests that administration of non-steroidal anti-inflammatory drugs (NSAIDs) to 
suppress COX-enzyme expression in sexually active women might also suppress inflammatory 
pathways that regulate HIV receptor expression and susceptibility to HIV infection.  
In conclusion, these data show for the first time a potential role for seminal plasma in regulating 
HIV chemokine co-receptors in cervical epithelial cells, via the inflammatory cyclooxygenase 
pathway. These findings implicate seminal plasma in the regulation of the mucosal epithelium in 
sexually active women and may enhance susceptibility to HIV infection.  
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CHAPTER 6 
GENERAL DISCUSSION AND CONCLUSION 
 
6.1 General discussion 
In sub-Saharan Africa, cervical cancer is the most common cancer among women, and also the 
leading cause of cancer related deaths in this region [3]. Disease prevalence is gradually having a 
decline trend in the developed countries due to prophylactic vaccination and regular screening 
programs. However, in many countries in sub-Saharan Africa the incidence rate is on the rise 
because of inadequate screening programs and inaccessibility to medical intervention and 
vaccination [4]. As highlighted in section 1.2 the main causal factor for cervical cancer is 
infection of the cervix with HPV, present in seminal fluid [562] or infected skin during 
intercourse. HPV triggers the development of cervical neoplasia by its direct effects on epithelial 
cell DNA and subsequent dysregulation of intracellular signal transduction pathways [27,563]. 
However, the finding that only a subset of women infected with high-risk HPV will proceed to 
develop invasive cervical cancer pose the likelihood that other factors are involved in the 
development of malignant transformation. It has been reported that cervical inflammation, but 
not the actual diagnosis of a specific sexually transmitted infection is associated with the 
development of squamous intraepithelial lesions within the cervix [517]. 
Inflammation is a normal host response to tissue damage caused by infectious agents or other 
stimuli [513]. Most pathogenic infection are known to incite an acute inflammatory response that 
results in complete clearance of the irritants in suitable host, however inadequate resolution of 
inflammation and unabated inflammatory reactions can evoke chronic inflammation 
predisposing the host to various diseases including cancer. Chronic inflammation enhance tumor 
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initiation and progression by inducing DNA damage, enhancing neoplastic cell proliferation, and 
stimulating angiogenesis and tissue remodeling to mediate cell invasion and metastasis 
[104,564,565]. A main feature of chronic inflammation includes the predominance of 
inflammatory mediators or cytokines that amplify immune reactivity and presence of immune 
cells in the tissue. Cervical cancer is regarded as a chronic inflammatory disease [514] and 
exhibit all the hallmark of chronic inflammation. One of the major cytokines responsible for 
regulating inflammation is IL-1α [507], which I have found to be up-regulated in cervical 
cancers in the current study.  
The association of HIV infection and cervical cancer has long been established [566,567]. It has 
been shown that in many areas with high incidence of cervical cancer, large numbers of women 
are also likely to be HIV infected, raising a theoretical possibility that HIV infection may 
increase the incidence of cervical cancer. Moreover, cervical cancer and premalignant cervical 
lesions may increase transmission and acquisition of HIV infection [5]. Mucosal inflammation of 
the female lower genital tract is regarded as an imperative factor favoring acquisition of HIV 
infection in receptive vaginal intercourse [543,544]. It has been demonstrated that chronic 
inflammation of the cervical mucosa as seen in cervical cancer increases the risk of HIV 
transmission [568]. The site of inflammation are enriched with HIV target immune cells and may 
have breaches in mucosal epithelium both of which facilitate HIV acquisition [293].  
HIV infects cells by binding to receptors on the host cell surface. Initially, the viral cell surface 
glycoprotein gp120 attaches to host cells. This can occur via heparin sulphate proteoglycans 
[569]. The initial step in membrane fusion begins with binding of the viral envelope protein 
(Env, consisting of a trimer of gp120-gp41 heterodimers) to the CD4 cell surface protein and a 
chemokine co-receptor present on the host cell [570]. Most HIV-1 variants use CCR5 and 
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CXCR4 as the main co-receptor in vivo, however up to 12 other chemokine co-receptors for HIV 
infection have been identified in vitro [252,253].  
Findings generated in this study confirm the up-regulation of CD4 and CCR5 in cervical cancer. 
Cells expressing this receptor-co-receptor complex CD4/CCR5 in cervical cancer were 
confirmed to be infiltrating immune cells. Hence, in women with cervical cancer, breach in 
cervical mucosal epithelium and chronic inflammation characterized by infiltration with HIV 
target immune cells would predispose them to greater risk of HIV infection. This in keeping with 
findings by Gichangi et al. (2003) where higher incidence of HIV infection was reported in 
women with cervical cancer  as compared to women of the same age group with uterine fibroids 
[5]. This was associated with younger age at presentation, poor histological differentiation of the 
tumor, accelerated clinical progression of premalignant cervical lesions and poorer prognosis.  
Little is known about the association between HIV and HPV-mediated cervical neoplasia. 
However, the natural course of HPV is altered in the presence of HIV infection [571]. For 
example, HIV mediated immunosuppression can facilitate inadequate clearance of HPV in 
infected individuals, enhancing HPV persistence or re-infection, and increases the likelihood that 
premalignant lesions will develop into cancer. Furthermore, HIV may modify HPV related 
carcinogenesis by altering the expression of inflammatory components (cytokines) in the cervix 
and diminution of local cervical cellular immunity, thus altering HPV regulation [249]. In 
addition, HIV Tat gene has been shown to activate the early and late HPV genes leading to 
increased virulence of HPV [27]. Taken together, this suggests that in women with cervical 
cancer co-infected with HIV, HIV could act via similar manner to mediate HPV virulence 
leading to advanced disease and poor prognosis.  
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Cervical inflammation can be mediated by a variety of effectors, including exposure to SP [572]. 
In addition to being the primary means of transport and survival medium for the mammalian 
spermatozoa [280,451] or the major dissemination vector of HIV [294,573], seminal plasma 
contains arrays of antigenically distinct signaling molecules [343]. When these signaling 
molecules are introduced in to the female reproductive tracts, they initiate local cellular and 
molecular changes typical of an inflammatory response [280]. During inflammation, a wide array 
of intracellular signaling pathways are often activated leading to the expression of cell surface 
receptors, kinases, transcription factors and pro-inflammatory genes involved in malignant 
transformation [513].  
Using TaqMan-Array 96-well plate, this study initially confirmed the role of SP in the regulation 
of arrays of inflammatory pathways, cytokines and chemokines in neoplastic cervical epithelial 
cells. SP was found to significantly regulate COX-1-PGs, LTC4S-CysLTs-CysLT1 and LTB4-
BLT1 signaling pathways in HeLa cells. It is well documented that altered expression/activation 
of cyclooxygenase (COX) and lipooxygenase (LOX) enzymes is a common feature of several 
epithelial-derived malignancies where they mediate the induction of inflammatory chemokines, 
cytokines and angiogenic genes leading to cell proliferation, inhibition of apoptosis, and poor 
prognosis [389,390]. Hence, this study suggests that in sexually active women with cervical 
pathology, incessant exposure to SP can confer poorer prognosis consequent of SP-mediated 
activation of eicosanoid signaling pathways. In addition, SP-mediated activation of TLR-
MyD88-NFκB signaling suggests that SP can transcriptionally regulate the expression of pro-
inflammatory mediators within the cervical milieu [513]. Upon nuclear localization, NFκB 
encodes genes such as pro-inflammatory chemokines/cytokines [574] that are involved in 
inflammation associated carcinogenesis. 
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More so, I show that SP activated EP2-EGFR-PI3K-Akt and EGFR-COX-1 signaling pathways 
up-regulate in particular the expression of pleotropic pro-inflammatory cytokine IL-1α and HIV 
chemokine co-receptor CCR5, respectively in neoplastic cervical cells exacerbating the already 
up-regulated levels of these inflammatory mediators within the cancer microenvironment. 
Furthermore, this study suggests that PGE2 and EGF could be the active component in SP 
mediating inflammatory cytokines and chemokines expression in the cervix.  
Interleukin 1α is a pro-inflammatory cytokine that possess a wide range of inflammatory and 
tumorigenic properties [101,503,504]. In addition to its tumorigenic effects, IL-1α-mediated 
NFκB activation has been shown to enhance HIV transmission [541] and viral replication in vitro 
[542]. Similarly, studies have shown that levels of CCR5 expression in cells positively correlate 
with HIV infectivity and levels of cellular activation in vivo [558-560]. Taken together, these 
findings suggest that in women with pre-invasive or invasive cervical cancer, repeated exposure 
to SP can exacerbate the overall inflammatory process within the cancer microenvironment 
consequent of IL-1α expression. In these women, IL-1α-mediated inflammatory response can 
alter local tissue remodeling to facilitate immune cell extravasation and trafficking. This can lead 
to increase in inflammatory and/or immune cell infiltrates and can alter receptor expression of 
epithelial cells, including CD4 and CCR5 to further increase their risk of HIV acquisition. 
Aggravated inflammatory process in the presence of HIV can then further augment the course of 
cervical neoplasia conferring poorer prognosis (Figure 6.1).  
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Figure 6.1: Schematic diagram showing the role of seminal plasma in the regulation of IL-1α 
and CCR5 in neoplastic cervical epithelial cells and their role in cervical cancer progression. 
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6.2 Conclusion 
From the findings generated in this study, it can be concluded that SP regulates the activation of 
arrays of inflammatory pathways in neoplastic cervical epithelial cells. Induction of these 
inflammatory pathways plays a crucial role in cervical inflammation and cancer progression by 
regulating the expression of a pleiotropic cancer associated pro-inflammatory cytokine IL-1α. 
Moreover, this study demonstrates that SP-mediated inflammatory response could enhance HIV 
transmission in women with cervical cancer by inducing the expression of HIV chemokine co-
receptor CCR5 in the cervix. 
Taken together, this study suggests that repeated exposure of neoplastic cervical epithelium to 
seminal plasma as seen in sexually active women with cervical cancer could mediate advanced 
disease and poorer patient outlook consequent of its molecular effect on inflammatory pathway 
activation, pro-inflammatory cytokine expression, and promotion of HIV infection in the cervical 
cancer milieu. 
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APPENDIX I 
 
Inflammatory pathways and genes regulated by seminal plasma in HeLa cells. 
Accession 
number 
Gene Gene description Fold 
change 
NM_000014 A2M Alpha-2-macroglobulin ND 
NM_000684 ADRB1 Adrenergic, beta-1-, receptor 1.50 
NM_000024 ADRB2 Adrenergic, beta-2-, receptor, surface 0.64 
NM_000697 ALOX12 Arachidonate 12-lipoxygenase ND 
NM_000698 ALOX5 Arachidonate 5-lipoxygenase 0.88 
NM_000700 ANXA1 Annexin A1 0.15 
NM_005139 ANXA3 Annexin A3 0.29 
NM_001154 ANXA5 Annexin A5 0.00031 
NM_001030047 KLK3 Kallikrein-related peptidase 3 34.58* 
NM_000710 BDKRB1 Bradykinin receptor B1 22.39* 
 NM_000623 BDKRB2 Bradykinin receptor B2 1.63 
NM_000719 CACNA1C Calcium channel, voltage-dependent, L type, alpha 1C subunit ND 
NM_000720 CACNA1D Calcium channel, voltage-dependent, L type, alpha 1D subunit ND 
NM_000722 CACNA2D1 Calcium channel, voltage-dependent, alpha 2/delta subunit 1 0.73 
NM_000724 CACNB2 Calcium channel, voltage-dependent, beta 2 subunit 0.28 
NM_000726 CACNB4 Calcium channel, voltage-dependent, beta 4 subunit 0.51 
NM_033292 CASP1 Caspase 1, apoptosis-related cysteine peptidase  0.66 
NM_001250 CD40 CD40 molecule, TNF receptor superfamily member 5 ND 
NM_000074 CD40LG CD40 ligand (TNF superfamily, member 5, hyper-IgM syndrome) 18.69* 
NM_001266 CES1 Carboxylesterase 1 (monocyte/macrophage serine esterase 1) 3.97* 
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NM_001143919 LTB4R Leukotriene B4 receptor 4.27* 
NM_001315   MAPK14 Mitogen-activated protein kinase 14 0.67 
NM_000176 NR3C1 Nuclear receptor subfamily 3, group C, member 1  0.84 
NM_000860 HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD) 0.32 
NM_000861 HRH1 Histamine receptor H1 1.39 
NM_001131055 HRH2 Histamine receptor H2 0.32 
NM_000869 HTR3A 5-hydroxytryptamine (serotonin) receptor 3A 1.82 
NM_000201 ICAM1 Intercellular adhesion molecule 1 (CD54) 3.82* 
NM_000877 IL1R1 Interleukin 1 receptor, type I 1.24 
NM_000417 IL2RA Interleukin 2 receptor, alpha ND 
NM_000878 IL2RB Interleukin 2 receptor, beta ND 
NM_000206 IL2RG Interleukin 2 receptor, gamma  0.018 
NM_002188 IL13 Interleukin 13 1.39 
NM_001114380 ITGAL Integrin, alpha L (antigen CD11A (p180) ND 
NM_000632 ITGAM Integrin, alpha M (complement component 3 receptor 3 subunit) 4.78* 
NM_002211 ITGB1 Integrin, beta 1 (fibronectin receptor, beta polypeptide) 1.02 
NM_000211 ITGB2 Integrin, beta 2 (complement component 3) 0.61 
NM_002257 KLK1 Kallikrein 1 0.64 
NM_001002231 KLK2 Kallikrein-related peptidase 2 19.59* 
NM_000892 KLKB1 Kallikrein B, plasma (Fletcher factor) 1 1.73 
NM_001102416 KNG1 Kininogen 1 ND 
NM_000895 LTA4H Leukotriene A4 hydrolase ND 
NM_000897 LTC4S Leukotriene C4 synthase 10.03* 
NM_000529 MC2R Melanocortin 2 receptor (adrenocorticotropic hormone) 6.52* 
NM_001165412 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 2.32* 
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(p105) 
NM_000625 NOS2A Nitric oxide synthase 2A (inducible, hepatocytes) ND 
NM_001111307 PDE4A Phosphodiesterase 4A 0.52 
NM_002600 PDE4B Phosphodiesterase 4B 0.42 
NM_000923 PDE4C Phosphodiesterase 4C ND 
NM_001165899 PDE4D Phosphodiesterase 4D 0.52 
NM_000928 PLA2G1B Phospholipase A2, group IB (pancreas) 0.89 
NM_000300 PLA2G2A Phospholipase A2, group IIA 3.00* 
NM_000929 PLA2G5 Phospholipase A2, group V ND 
NM_004573 PLCB2 Phospholipase C, beta 2 ND 
NM_000932 PLCB3 Phospholipase C, beta 3 (phosphatidylinositol-specific) 0.40 
NM_000933 PLCB4 Phospholipase C, beta 4 2.82* 
NM_001130964 PLCD1 Phospholipase C, delta 1 0.21 
NM_182811 PLCG1 Phospholipase C, gamma 1 29.05* 
NM_002661 PLCG2 Phospholipase C, gamma 2 (phosphatidylinositol-specific) 0.85 
NM_002745 MAPK1 Mitogen-activated protein kinase 1 0.72 
NM_001040056 MAPK3 Mitogen-activated protein kinase 3 0.52 
NM_002750 MAPK8 Mitogen-activated protein kinase 8 0.83 
NM_000952 PTAFR Platelet-activating factor receptor 0.09 
NM_000953 PTGDR Prostaglandin D2 receptor (DP) ND 
NM_000956 PTGER2 Prostaglandin E receptor 2 (subtype EP2), 53kDa 0.80 
NM_000957 PTGER3 Prostaglandin E receptor 3 (subtype EP3) ND 
NM_000959 PTGFR Prostaglandin F receptor (FP) 20.21* 
NM_000960 PTGIR Prostaglandin I2 (prostacyclin) receptor (IP) 7.22* 
NM_000961 PTGIS Prostaglandin I2 (prostacyclin) synthase ND 
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NM_000962 PTGS1 Prostaglandin-endoperoxide synthase 1  2.43* 
NM_000963 PTGS2 Prostaglandin-endoperoxide synthase 2  0.53 
NM_001060 TBXA2R Thromboxane A2 receptor 0.96 
NM_001061 TBXAS1 Thromboxane A synthase 1  0.63 
NM_001066 TNFRSF1B Tumor necrosis factor receptor superfamily, member 1B 2.70* 
NM_001078 VCAM1 Vascular cell adhesion molecule 1 ND 
NM_004633 IL1R2 Interleukin 1 receptor, type II 0.20 
NM_001168357 PLA2G7 Phospholipase A2, group VII  0.005 
NM_003561 PLA2G10 Phospholipase A2, group X 46.32* 
NM_001159322 PLA2G4C Phospholipase A2, group IVC (cytosolic, calcium-independent) 0.42 
 NM_016232 IL1RL1 Interleukin 1 receptor-like 1 22.65* 
NM_006028 HTR3B 5-hydroxytryptamine (serotonin) receptor 3B ND 
NM_001145645 TNFSF13B Tumor necrosis factor (ligand) superfamily, member 13b 4.83* 
NM_006639 CYSLTR1 Cysteinyl leukotriene receptor 1 150.14* 
NM_007232 HRH3 Histamine receptor H3 ND 
NM_001271814 PLA2G2D Phospholipase A2, group IID ND 
NM_017416 IL1RAPL2 Interleukin 1 receptor accessory protein-like 2 5.67* 
NM_022046 KLK14 Kallikrein-related peptidase 14 2.53* 
NM_016341 PLCE1 Phospholipase C, epsilon 1 6.71* 
NM_017509 KLK15 Kallikrein-related peptidase 15 ND 
NM_001164693 LTB4R2 Leukotriene B4 receptor 2 ND 
NM_005161 AGTRL1 Angiotensin II receptor-like 1  ND 
NM_001716 CXCR5 Chemokine (C-X-C motif) receptor 5  ND 
NM_001735  C5 Complement component 5  2.14* 
NM_002981 CCL1 Chemokine (C-C motif) ligand 1  ND 
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NM_002986 CCL11 Chemokine (C-C motif) ligand 11  ND 
NM_005408 CCL13 Chemokine (C-C motif) ligand 13  ND 
NM_004590 CCL16 Chemokine (C-C motif) ligand 16  ND 
NM_002987 CCL17 Chemokine (C-C motif) ligand 17  ND 
NM_002988 CCL18 Chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated)  ND 
NM_006274 CCL19 Chemokine (C-C motif) ligand 19  ND 
NM_002982 CCL2 Chemokine (C-C motif) ligand 2  4.43* 
NM_004591 CCL20 Chemokine (C-C motif) ligand 20  ND 
NM_002989 CCL21 Chemokine (C-C motif) ligand 21  ND 
NM_002990 CCL22 Chemokine (C-C motif) ligand 22  ND 
NM_005064 CCL23 Chemokine (C-C motif) ligand 23  ND 
NM_002991 CCL24 Chemokine (C-C motif) ligand 24  ND 
NM_005624 CCL25 Chemokine (C-C motif) ligand 25  ND 
NM_006072 CCL26 Chemokine (C-C motif) ligand 26  ND 
NM_006664 CCL27 Chemokine (C-C motif) ligand 27  ND 
NM_148672 CCL28 Chemokine (C-C motif) ligand 28  ND 
NM_002983 CCL3 Chemokine (C-C motif) ligand 3  ND 
NM_002984  CCL4 Chemokine (C-C motif) ligand 4  ND 
NM_002985 CCL5 Chemokine (C-C motif) ligand 5  5.24* 
NM_006273  CCL7 Chemokine (C-C motif) ligand 7  ND 
NM_005623 CCL8 Chemokine (C-C motif) ligand 8  ND 
NM_016602 CCR10 Chemokine (C-C motif) receptor 10  ND 
NM_001123041 CCR2 Chemokine (C-C motif) receptor 2  ND 
NM_001164680 CCR3 Chemokine (C-C motif) receptor 3  ND 
NM_005508 CCR4 Chemokine (C-C motif) receptor 4  ND 
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NM_016557 CCRL1 Chemokine (C-C motif) receptor-like 1  ND 
NM_001130910 CCRL2 Chemokine (C-C motif) receptor-like 2  ND 
NM_016326 CKLF Chemokine-like factor  ND 
NM_013246 CLCF1 Cardiotrophin-like cytokine factor 1  1.46 
NM_052999 CMTM1 CKLF-like MARVEL transmembrane domain containing 1  3.15* 
NM_000758 CSF2 Colony stimulating factor 2 (granulocyte-macrophage)  ND 
NM_172220 CSF3 Colony stimulating factor 3 (granulocyte)  ND 
NM_002996  CX3CL1 Chemokine (C-X3-C motif) ligand 1  ND 
NM_001511 CXCL1 Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating 
activity, alpha)  
12.37* 
NM_001565 CXCL10 Chemokine (C-X-C motif) ligand 10  ND 
NM_005409 CXCL11 Chemokine (C-X-C motif) ligand 11  2.47* 
NM_000609 CXCL12 Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1)  ND 
NM_006419 CXCL13 Chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant)  ND 
NM_004887 CXCL14 Chemokine (C-X-C motif) ligand 14  ND 
NM_022059 CXCL16 Chemokine (C-X-C motif) ligand 16  ND 
NM_002089 CXCL2 Chemokine (C-X-C motif) ligand 2  0.49 
NM_002090 CXCL3 Chemokine (C-X-C motif) ligand 3  8.19* 
NM_002994 CXCL5 Chemokine (C-X-C motif) ligand 5  ND 
NM_002993  CXCL6 Chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2)  ND 
NM_002416 CXCL9 Chemokine (C-X-C motif) ligand 9  ND 
NM_001008540 CXCR4 Chemokine (C-X-C motif) receptor 4  1.67 
NM_002036 DARC Duffy blood group, chemokine receptor  ND 
NM_001953 TYMP Thymidine phosphorylase  3.22* 
NM_000557 GDF5 Growth differentiation factor 5  ND 
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NM_032554 GPR81 G protein-coupled receptor 81  ND 
NM_002086 GRB2 Growth factor receptor-bound protein 2  ND 
NM_001530 HIF1A Hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix 
transcription factor)  
ND 
NM_000619 IFNG Interferon, gamma  ND 
NM_000416 IFNGR1 Interferon gamma receptor 1  1.03 
NM_020124 IFNK Interferon, kappa  ND 
NM_000572 IL10 Interleukin 10  ND 
NM_000882 IL12A Interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic 
lymphocyte maturation factor 1, p35)  
2.36* 
NM_002187 IL12B Interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic 
lymphocyte maturation factor 2, p40)  
ND 
NM_002188 IL13 Interleukin 13  ND 
NM_172217 IL16 Interleukin 16 (lymphocyte chemoattractant factor)  ND 
NM_001562 IL18 Interleukin 18 (interferon-gamma-inducing factor)  17.84* 
NM_000575 IL1A Interleukin 1, alpha  68.56* 
NM_000576 IL1B Interleukin 1, beta  ND 
NM_001167928 IL1RAP Interleukin 1 receptor accessory protein  ND 
NM_000586  IL2 Interleukin 2  ND 
NM_000589 IL4 Interleukin 4  ND 
NM_000879 IL5 Interleukin 5 (colony-stimulating factor, eosinophil)  ND 
NM_000600 IL6 Interleukin 6 (interferon, beta 2)  4.19* 
NM_000584 IL8 Interleukin 8  38.93* 
NM_000590 IL9 Interleukin 9  ND 
NM_004972 JAK2 Janus kinase 2 (a protein tyrosine kinase)  1.72 
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NM_002468 MYD88 Myeloid differentiation primary response gene (88)  9.41* 
NM_002619 PF4 Platelet factor 4 (chemokine (C-X-C motif) ligand 4)  ND 
NM_002704 PPBP Pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)  ND 
NM_004757 SCYE1 Small inducible cytokine subfamily E, member 1 (endothelial 
monocyte-activating)  
ND 
NM_004787 SLIT2 Slit homolog 2 (Drosophila)  3.63* 
NM_014011 SOCS5 Suppressor of cytokine signaling 5  0.00047 
NM_139276 STAT3 Signal transducer and activator of transcription 3 (acute-phase response 
factor)  
0.86 
NM_003151  STAT4 Signal transducer and activator of transcription 4  ND 
NM_003264 TLR2 Toll-like receptor 2  88.47* 
NM_138554 TLR4 Toll-like receptor 4  1.66 
NM_000594 TNF Tumor necrosis factor (TNF superfamily, member 2)  26.55* 
NM_001065 TNFRSF1A Tumor necrosis factor receptor superfamily, member 1A  3.16* 
NM_001190942 TNFSF10 Tumor necrosis factor (ligand) superfamily, member 10  1.91* 
NM_003807 TNFSF14 Tumor necrosis factor (ligand) superfamily, member 14  ND 
NM_002995 XCL1 Chemokine (C motif) ligand 1,chemokine (C motif) ligand 2  ND 
NM_001024644 XCR1 Chemokine (C motif) receptor 1 ND 
 
*, Fold change ≥ 2. 
ND, Not detected. 
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APPENDIX II 
Gene ontology and PANTHER classification of genes regulated by seminal plasma in to (A) 
molecular function, (B) biological processes, (C) protein class, and (D) pathways regulated by 
the genes. 
 
 
 
 (a) Binding, (b) Catalytic activity, (C) Enzyme regulator activity, (d) Ion channel activity, (e) 
Receptor activity, (f) Structural molecule activity, (g) Transcription regulator activity, (h) 
Transporter activity. 
(A) 
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(a) Apoptosis, (b) Cell adhesion, (c) Cell communication, (d) Cell cycle, (e) Cellular component 
organization, (f) Cellular process, (g) Developmental process, (h) Generation of precursor 
metabolites and energy, (i) Homeostatic process, (j) Immune system process, (k) Metabolic 
process, (l) Regulation of biological process, (m) Reproduction, (n) Response to stimulus, (o) 
System process, (p) Transport.  
 
 
 
 
 
 
 
 
(B) 
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(a) Calcium-binding protein, (b) Cell adhesion molecule, (c) Cytoskeletal protein, (d) 
Defense/immunity protein, (e) Enzyme modulator, (f) Extracellular matrix protein, (g) 
Hydrolase, (h) Isomerase, (i) Kinase, (j) Nucleic acid binding, (k) Oxidoreductase, (l) Protease, 
(m) Receptor, (n) Signaling molecule, (o) Transcription factor, (p) Transfer/carrier protein, (q) 
Transferase, (r) Transporter.  
 
 
 
 
 
 
 
(c) 
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(a) 2-arachidonoylglycerol biosynthesis, (b) 5HT2 type receptor mediated signaling pathway, (c) 
5HT3 type receptor mediated signaling pathway, (d) Alpha adrenergic receptor signaling 
pathway, (e) Alzheimer disease-amyloid secretase pathway, (f) Angiogenesis, (g) Angiotensin II-
stimulated signaling through G proteins and beta-arrestin, (h) Apoptosis signaling pathway, (i) 
Axon guidance mediated by Slit/Robo, (j) Axon guidance mediated by netrin, (k) B cell 
(D) 
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activation, (l) Beta1 adrenergic receptor signaling pathway, (m) Beta2 adrenergic receptor 
signaling pathway, (n) Blood coagulation, (o) EGF receptor signaling pathway, (p) Endogenous 
cannabinoid signaling, (q) Endothelin signaling pathway, (r) FAS signaling pathway, (s) FGF 
signaling pathway, (t) Gonadotropin releasing hormone receptor pathway, (u) Heterotrimeric G-
protein signaling pathway-Gi alpha and Gs alpha mediated pathway, (v) Heterotrimeric G-
protein signaling pathway-Gq alpha and Go alpha mediated pathway, (w) Histamine H1 receptor 
mediated signaling pathway, (x) Histamine H2 receptor mediated signaling pathway, (y) 
Huntington disease, (z) Inflammation mediated by chemokine and cytokine signaling pathway, 
(a1) Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade, (b1) 
Integrin signalling pathway, (c1) Interferon-gamma signaling pathway, (d1) Interleukin signaling 
pathway, (e1) JAK/STAT signaling pathway, (f1) Metabotropic glutamate receptor group I 
pathway, (g1) Muscarinic acetylcholine receptor 1 and 3 signaling pathway, (h1) Muscarinic 
acetylcholine receptor 2 and 4 signaling pathway, (i1) Nicotinic acetylcholine receptor signaling 
pathway, (j1) Oxidative stress response, (k1) Oxytocin receptor mediated signaling pathway, (l1) 
PDGF signaling pathway, (m1) PI3 kinase pathway, (n1) Parkinson disease, (o1) Pyrimidine 
Metabolism, (p1) Ras Pathway, (q1) Salvage pyrimidine deoxyribonucleotides, (r1) T cell 
activation, (s1) TGF-beta signaling pathway, (t1) Thyrotropin-releasing hormone receptor 
signaling pathway, (u1) Toll receptor signaling pathway, (v1) Toll_pathway_drosophila, (w1) 
VEGF signaling pathway, (x1) Wnt signaling pathway, (y1) p38 MAPK pathway, (z1) p53 
pathway feedback loops 2. 
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APPENDIX III 
 
Histological typing, extent of invasiveness, and FIGO staging of carcinoma biopsies 
 
Sample identification Histological type FIGO staging 
Ca.2-Ca.10, Ca.12-Ca.15  Squamous carcinoma 0; carcinoma in-situ 
Ca.5,Ca.16 Squamous carcinoma IA; moderately differentiated 
Ca.1,Ca.17 Squamous carcinoma IA1; moderately differentiated  
Ca.11 Adenocarcinoma IB1; well differentiated 
Ca.18 Squamous carcinoma IB1; moderately differentiated 
Ca.4 Squamous carcinoma IIIB; moderately differentiated 
 
